VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 11 (1-15 mayo / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

COVID-19: El fin de la emergencia sanitaria internacional

El 30 de enero de 2020, la Organización Mundial de la Salud (OMS) decidió que el brote de neumonía causada por un nuevo virus (inicialmente 2019-nCoV, ahora SARS-CoV-2) originado en Wuhan (China) un mes antes y ya extendido a otros países, constituía una "emergencia de salud pública de interés internacional" (PHEIC, *Public Health Emergency of International Concern*).

Después, el 11 de marzo de 2020, el doctor Tedros Adhanom Gebreyesus director general de la OMS, ante la rápida extensión y la gravedad de la infección, afirmó que el mundo se encontraba amenazado por la nueva enfermedad y declaró el estado de **PANDEMIA**.

Vacunas

A raíz de esta situación mundial, diversas instituciones científicas y compañías farmacéuticas se dieron a la tarea de desarrollar vacunas contra la enfermedad. Fueron utilizadas diferentes plataformas tales como, virus inactivado, vector viral (replicativo y no replicativo), subunidad proteica, ARNm, ADN, partículas similares a virus y virus vivo atenuado.

Las primeras vacunaciones a gran escala comenzaron el 8 de diciembre de 2020, menos de un año después de que se notificara a la OMS el primer caso de la enfermedad, un extraordinario triunfo de la ciencia. Pero al proceso colaborativo de desarrollo de las vacunas le siguió un periodo sombrío de acaparamiento y nacionalismo; un año entero después, cuando la población de los países industrializados estaba recibiendo la segunda y tercera dosis de las vacunas, solo el cinco por ciento de la población del África subsahariana había sido vacunada, por ejemplo.

Cuba no estuvo ajena a la situación y en aras de obtener su soberanía tecnológica, creó sus propias vacunas contra la enfermedad, basadas en la plataforma de subunidad proteica. Estas fueron Soberana 01, Soberana 02 y Soberana Plus, desarrolladas por el Instituto Finlay de Vacunas y Abdala y Mambisa, desarrolladas por el Centro de Ingeniería Genética y Biotecnología, ambos centros pertenecientes al Grupo de las Industrias Biotecnológica y Farmacéutica de Cuba (BioCubaFarma).

Gracias a la alta cobertura de vacunación lograda tanto en población adulta como pediátrica, el país caribeño se posicionó en un lugar privilegiado a nivel internacional. Según el sitio *Our World in Data*, hasta el 13 de mayo de 2023 Cuba se encuentra en la primera posición en cuanto a dosis totales de vacuna contra la COVID-19 administradas por cada 100 personas, lo cual se muestra en el siguiente gráfico.



Seguimiento del desarrollo de vacunas contra COVID-19

Para dar información detallada del desarrollo de estas vacunas, a la comunidad científica y población mundial en general, la OMS implementó el reporte *COVID-19 vaccine tracker and landscape* que incluye:

- Tablas de resumen de candidatos vacunales contra la COVID-19 tanto en desarrollo clínico como preclínico;
- Análisis y visualización para varias categorías de candidatos vacunales contra la COVID-19;
- Seguimiento del progreso de cada vacuna desde los estudios de eficacia preclínicos, de fase 1, fase 2 hasta la fase 3 e incluye la fase 4 registrada como estudios de intervención;
- Enlaces a informes publicados sobre datos de seguridad, inmunogenicidad y eficacia de los candidatos vacunales;
- Incluye información sobre los atributos clave de cada vacuna candidata; y
- Permite a los usuarios buscar vacunas contra la COVID-19 a través de varios criterios, como la plataforma de vacunas, el programa de vacunación, la vía de administración, el desarrollador, la fase de prueba y los criterios de valoración clínicos.

Este reporte está actualizado hasta el 30 de marzo de 2023.

La fase de emergencia ha terminado, pero la COVID-19 no

Ahora, el pasado 5 de mayo, el Comité de Emergencias de la COVID-19 declaró el fin de la emergencia sanitaria internacional por dicha enfermedad. No obstante, el director general de la OMS advirtió que eso no significa que la COVID-19 haya dejado de ser una amenaza para la salud mundial, aún sigue siendo una prioridad de salud pública global.

La declaración de que la COVID-19 ya no constituye una emergencia de salud pública de importancia internacional (ESPII) implica que es el momento que los países transiten del modo de emergencia al manejo y control de la COVID-19 de conjunto con otras enfermedades infecciosas, es decir, que la COVID-19 es ahora un problema de salud establecido y persistente.

Es por ello que plantean cuatro aspectos fundamentales a tener cuenta a partir de este momento y son:

- Mantener y reforzar la vigilancia epidemiológica y virológica para anticipar la evolución de la pandemia.
- Volver la mirada a objetivos desatendidos por la presión de la pandemia (con la correspondiente reasignación de recursos) y hacer los preparativos reales para dotarse de herramientas de protección ante nuevas crisis sanitarias.

- Revisar en profundidad las estrategias de control del nuevo coronavirus y las medidas para paliar sus consecuencias. En línea con esta propuesta se sitúa la reevaluación de las prioridades de la investigación, marcando los efectos a largo plazo sobre la salud mental como una de ellas, entre otras.
- Revisar las respuestas dadas para evitar la vergonzosa e inadmisible falta de equidad en el acceso a las medidas de control, la vacunación, por ejemplo, de las poblaciones y lugares del planeta con menos recursos.

El 3 de mayo, la OMS publicó un plan actualizado de gestión de la COVID-19, cuyo objetivo es orientar a los países sobre cómo lidiar con la enfermedad en los próximos dos años, en la transición de la respuesta de emergencia a la prevención y el control de la COVID-19 a largo plazo.

Mucho más que una crisis sanitaria

El doctor Tedros explicó que la pandemia ha causado graves trastornos económicos, borrando billones de dólares del PIB, perturbando los viajes, el turismo, y el comercio, cerrando empresas y sumiendo a millones de personas en la pobreza.

Otros graves trastornos sociales se produjeron con el cierre de fronteras, la restricción de movimientos, el cierre de escuelas y otros muchos continúan, como los millones de personas que sufren soledad, aislamiento, ansiedad y depresión, además de la COVID persistente.

También agregó que, la COVID-19 ha dejado al descubierto y ha exacerbado las divisiones políticas dentro de las naciones y entre ellas. Ha erosionado la confianza entre las personas, los gobiernos y las instituciones, alimentado por un torrente de desinformación. Y ha dejado al descubierto las desigualdades más acuciantes de nuestro mundo, siendo las comunidades más pobres y vulnerables las más afectadas, y las últimas en recibir acceso a vacunas y otras herramientas.

La pandemia ha seguido una tendencia descendente, con un aumento de la inmunidad de la población gracias a la vacunación y la infección, una disminución de la mortalidad y una reducción de la presión sobre los sistemas sanitarios. Esto ha permitido a la mayoría de los países volver a la “normalidad”.

Estado actual de la COVID-19 a nivel mundial

Hasta finales de abril de 2023 han sido más de 765 millones de casos y más de 6,9 millones de muertes registradas, aunque se acepta que las cifras reales deben ser al menos 3 veces más. En el mes de abril de 2023 se registraron 2,8 millones de casos nuevos y cerca de 17·000 muertes, un 17 % y 30 % menos, respectivamente, que en las cuatro semanas anteriores.





Estado mundial de la COVID-19 hasta el 3 de mayo de 2023.

La vacunación de la COVID-19 ha jugado, sin lugar a dudas, un papel muy importante en la evolución de la pandemia y la mejor situación actual.

En cuanto a las coberturas de vacunación:

- El 70 % de la población mundial ha recibido al menos una dosis de una vacuna contra la COVID-19.
- Se han administrado 13.380 millones de dosis en todo el mundo y ahora se administran 117.952 cada día.
- El 29,9 % de las personas en países de bajos ingresos han recibido al menos una dosis.

Anticipándose al paso dado ahora por la OMS, en el pasado mes de febrero, la propia OMS perfilaba las consideraciones prácticas, aunque provisionales, que debían orientar las siguientes fases de la vacunación de la COVID-19, y que son, básicamente: la integración de la vacunación de la COVID-19 en los programas de vacunación nacionales y en el núcleo estructural de los sistemas sanitarios, en particular, la Atención Primaria.

En la nueva situación que ahora se abre, la vacunación frente a la COVID-19 aún seguirá jugando un papel primordial. La inmunidad híbrida proporcionada por las infecciones naturales y la vacunación brinda una oportunidad inmejorable para investigar y evaluar sin urgencias el papel que pueden jugar las distintas vacunas disponibles y las que, previsiblemente, vendrán en el futuro.

Referencias

[1] WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Disponible en https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)

[2] WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Disponible en https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

[3] OPS. Se acaba la emergencia por la pandemia, pero la COVID-19 continúa. Disponible en https://www.paho.org/es/noticias/6-5-2023-se-acaba-emergencia-por-pandemia-pero-covid-19-continua

[4] The New York Times. La OMS declara el fin de la COVID-19 como emergencia internacional de salud. Disponible en https://www.nytimes.com/es/2023/05/05/espanol/covid-emergencia-oms.html

[5] WHO. Disponible en https://www.nytimes.com/es/2023/05/05/espanol/covid-emergencia-oms.html

[6] Twitter. Noticias ONU. Disponible en https://twitter.com/NoticiasONU/status/1654476605127884807

[7] Watson OJ, Barnsley G. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. The Lancet Infectious Diseases 22(9), P1293-1302, Sep 2022. Disponible en https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00320-6/fulltext

[8] Bobrovitz N, Ware H. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases 23(5), P556-567, May 2023. Disponible en https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00801-5/fulltext

[9] Our World in Data. Coronavirus (COVID-19) Vaccinations. Disponible en https://ourworldindata.org/covid-vaccinations?country=~OWID_WRL

[10] WHO. COVID-19 vaccine tracker and landscape. Disponible en https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

[11] Noticias ONU. Se acaba la emergencia por la pandemia, pero el COVID continua. Disponible en https://news.un.org/es/story/2023/05/1520732

Noticias en la Web

Continuará en Cuba campaña de vacunación antipoliomielítica oral

1 may. Cuba continúa del 2 al 6 de mayo la segunda etapa de la 62 Campaña Nacional de Vacunación Antipoliomielítica Oral, un periodo de recuperación para niños que no recibieron la dosis la semana anterior.

En esta ocasión se inmunizará a los infantes desde un mes de nacidos hasta menores de tres años de edad con la primera dosis en la etapa del 27 de febrero al 4 de marzo y que por enfermedad u otra causa no hayan podido vacunarse en la semana de la campaña (del 26 al 29 de abril), informó el Ministerio de Salud Pública (Minsap).

Se incorporan en esta fase los niños de nueve años que van a recibir su reactivación como parte de la estrategia nacional, regional y mundial de mantener erradicada la poliomielitis.

La poliomielitis es una enfermedad infecto-contagiosa que afecta el sistema nervioso central, principalmente en niños, y puede provocar atrofia muscular, parálisis, deformidad y en algunos casos la muerte.

Cuba es el primer país de Latinoamérica en lograr la eliminación de esta enfermedad y en 1995 recibió de la Organización Panamericana de la Salud (OPS) la Certificación de Erradicación de la Poliomielitis.

La jefa nacional del Programa de Inmunización del Minsap, Lena López, recientemente comunicó que en Cuba se administran como promedio anual unos cuatro millones 800 mil dosis de 13 tipos diferentes de vacunas simples o combinadas, dirigidas a la prevención de igual número de enfermedades.

De los inmunobiológicos, precisó, ocho son de producción nacional, cuatro importados: BCG, OVP, Influenza estacional y PRS (los dos últimos con apoyo del Fondo de las Naciones Unidas para la Infancia) y una donación (IPV, por la Alianza Global de Vacunas).

Además, se administran en el país otras vacunas preventivas dirigidas a grupos de riesgo, como la Influenza estacional de adulto, la Hepatitis B de adulto, la Antiamarílica (contra la fiebre amarilla) y la Antileptospirósica.

Resaltó que, fruto de la ciencia cubana durante la proliferación de la pandemia, tres vacunas de producción nacional contra la Covid-19 (Soberana 02, Soberana Plus y Abdala) permitieron, junto a otras medidas, el control de la enfermedad en la isla.

López exaltó el impacto del Programa Nacional de Inmunización, tras seis décadas de implementado, periodo en el cual posibilitó la eliminación de seis enfermedades (Poliomielitis, Difteria, Sarampión, Tosferina, Rubéola y Parotiditis).

También permitió erradicar dos formas clínicas severas en menores de un año (tétanos neonatal y meningitis tuberculosa) y dos complicaciones clínicas graves (síndrome de rubéola congénita y meningitis posparotiditis).

Asimismo, agregó, se controlaron cinco enfermedades, con tasa de incidencia menor de 0,1 por cada 100 mil habitantes: Tétanos, Fiebre Tifoidea, Enfermedad Meningocócica, Meningitis por Haemophilus Influenzae tipo b y Hepatitis B.

Actualmente, subrayó, Cuba mantiene coberturas de inmunización por encima del 95 por ciento para todas las vacunas del esquema.

Fuente: Sierra Maestra. Disponible en https://bit.ly/3nXMqm0

Los virus propagados por mosquitos, los principales candidatos a originar la próxima pandemia

1 may. La pandemia de COVID-19 ha puesto de manifiesto la vulnerabilidad de la humanidad ante un brote a gran escala de patógenos emergentes. El cambio climático global y la naturaleza en continua evolución del genoma del ARN, entre otros factores, dan pistas a los científicos y profesionales implicados en la vigilancia de enfermedades con potencial epidémico de que la proxima pandemia podría ser ocasionada por los arbovirus- virus propagados por artrópodos como los mosquitos- como el virus Chikungunya (CHIKV), el virus del dengue, el virus del Nilo Occidental y el virus Zika.

"Dado su potencial epidémico ya demostrado, encontrar tratamientos eficaces de amplio espectro contra estos virus es de suma importancia, ya que se convierten en agentes potenciales de pandemias", señaló Gustavo García, del Departamento de Farmacología Molecular y Médica de la Universidad de California Los Ángeles (UCLA), en Estados Unidos, según informa Europa Press.

Este investigador ha liderado un nuevo estudio que ha logrado identificar posibles agentes antivirales de amplio espectro que inhiben estos arbovirus en distintos grados. El trabajo, publicado en la revista Cell Reports Medicine, probó una biblioteca de agonistas inmunitarios innatos que actúan dirigiéndose a receptores de reconocimiento de patógenos, y halló varios agentes prometedores, entre ellos uno que mostraba una potente actividad antivírica contra miembros de familias virales de ARN.

El estudio concluye que los agonistas STING -una proteína esencial para la respuesta inmunitaria contra las infecciones y el cáncer- mostraron una actividad antiviral de amplio espectro contra virus transmitidos por artrópodos y respiratorios, incluidos el SARS-CoV-2 y el enterovirus D68- es uno de más de 100 tipos de enterovirus que causa resfriados comunes- en modelos de cultivo celular.

"Una sólida respuesta antivírica del huésped inducida por una dosis única del agonista STING es eficaz para prevenir y mitigar la artritis vírica debilitante causada por el virus Chikungunya (CHIKV) en un modelo de ratón. Se trata de una modalidad de tratamiento muy prometedora, ya que las personas afectadas por el virus Chikungunya sufren artritis vírica años y décadas después de la infección inicial", indicó el autor principal Vaithi Arumugaswami, profesor asociado del Departamento de Farmacología Molecular y Médica de la UCLA.

"A nivel molecular, el CHIKV contribuye a fuertes desequilibrios transcripcionales (y químicos) en las células cutáneas infectadas (fibroblastos) en comparación con el virus del Nilo Occidental y el virus ZIKA, lo que refleja una posible diferencia en los mecanismos de lesión mediada por parte de virus que pertenecen a familias diferentes, a pesar de ser todos ellos virus transmitidos por mosquitos", destacó por su parte Arunachalam Ramaiah, científico principal del Departamento de Salud de la ciudad de Milwaukee.

García avanzó que "el siguiente paso es desarrollar estos antivirales de amplio espectro en combinación con otros antivirales existentes y que estén disponibles en caso de futuros brotes de enfermedades respiratorias y arbovirales".

La bacteria "salvadora"

Dada la gravedad de la amenaza que suponen para la salud las enfermedades transmitidas por mosquitos- una sola especie de este tipo de insecto, el Aedes aegypti, es capaz de transmitir el dengue, el Zika y el Chikungunya- hay muchas vías de investigación abiertas para ofrecer soluciones (vacunas en distinto punto de desarrollo, fármacos para tratar los síntomas, etc).

Pero una de ellas merece ser reseñada porque supone un acercamiento distinto y revolucionario frente a esta amenaza. "Resulta que una bacteria completamente inocua para el ser humano, la Wolbachia pipientis, es capaz de infectar una gran variedad de insectos. Unos investigadores se dieron cuenta de que los mosquitos A. aegypti normalmente no presentan esta bacteria dentro de su cuerpo. Al examinarlo con detenimiento, observaron que la bacteria compite con los distintos virus por infectar al mosquito. Como consecuencia, un mosquito con Wolbachia es menos probable que pueda transmitir dengue o Zika", señalaba el virólogo Javier Cantón en su perfil de Twitter hace unos días.

Basándose en esta premisa, se han liberado mosquitos portadores de la bacteria en distintas ciudades de Brasil e Indonesia y se ha visto una disminución de infecciones por virus."Una de las ventajas de este sistema es que los mosquitos liberados transmiten Wolbachia a mosquitos de la ciudad, expandiendo 'la cura' a la población salvaje de estos insectos", añadía el experto. La iniciativa se llama World Mosquito Program (WMP) y va a liberar grandes cantidades de mosquitos portadores de la bacteria Wolbachia en Australia, Brasil, Colombia, Indonesia y Vietnam durante los próximos 10 años.

Fuente: La Razón. Disponible en https://bit.ly/3MsVN6p

Pneumonia vaccine delays kill thousands needlessly in Africa

May 2. Delays in rolling out a vaccine against childhood pneumonia in four of the world's poorest countries have been blamed for thousands of unnecessary deaths.

South Sudan, Somalia, Guinea and Chad are four of the last African nations without the pneumococcal conjugate vaccine (PCV), one of the most powerful tools against pneumonia in children.

Estimates from the Global Burden of Disease suggest 40,000 children died from the illness in the four countries in 2019, which are all off track to meet UN targets to reduce deaths of children under five by 2030.



A chest x-ray of a child with pneumonia, which is the world's biggest infectious killer of children worldwide. The PCV vaccine targets the leading bacterial cause of pneumonia. Photograph: BSIP/ Universal Images/Getty

Childhood pneumonia is the biggest infectious killer of children worldwide, claiming 700,000 lives annually. It is a disease of poverty, with almost all deaths occurring in low- and middle-income countries, and most of them are preventable.

"It's unfair that this vaccine is not yet available because every child has a right to survive and thrive," said Dr Ubah Farah, an adviser to Somalia's health ministry.



She said pneumonia was a "big killer" in the country, and noted that the Covid vaccine had been rolled out quickly by comparison. "Why can't we do the same for children?" she said. "It's double standards."

Prof Fiona Russell, a vaccinologist from the University of Melbourne and the Murdoch Children's Research Institute, called the delays "a failure".

"How many thousands of children have died while waiting to get this vaccine?" she asked.

The PCV targets the leading bacterial cause of pneumonia and was introduced in the US in 2000 and to South Africa in 2009. Most African states now have the vaccine, and studies show that hospitalisations and deaths fall significantly after rollout, including in Rwanda, South Africa and Kenya.

At the second Global Forum on Childhood Pneumonia, held in Madrid last week, delegates from South Sudan, Somalia, Guinea and Chad announced plans to roll out the vaccine in 2024 with the help of Gavi, a global health alliance that shares the cost that countries pay for vaccines.

The four countries first planned to introduce the vaccine three years ago but struggled to meet Gavi's co-financing requirements. Gavi pays for most of the initial rollout, but countries must make a contribution, with a plan to eventually meet all the costs.

Last year, Gavi was urged to be more flexible with how much it expects countries to pay.

The rollouts were also delayed by Covid, and Guinea faced two outbreaks of Ebola, which hit the country and its health system hard, while South Sudan and Somalia are in the grip of a humanitarian crises caused by conflict and drought.

Gavi announced at the forum that South Sudan and Somalia, as fragile states facing massive humanitarian crises, would now not have to pay for the vaccine introduction.

"This is a revolution. Up until now, we never waived [the cost] for new [vaccine] programmes," said Veronica Denti, a senior programme manager at Gavi. "The principle of Gavi is that we want [governments] to find a way to pay for it because that's how you build sustainability."

Chad and Guinea still have to find $200,000 t $300,000 (£160,000-£240,000) a year to receive Gavi support, added Denti.

Russell said: "In these countries that are so troubled and so poor, the desire is there from the government but they can't find that extra bit of money. That means they don't have the vaccine, under-five mortality will still be huge, and it will be much more challenging for them to meet their Sustainable Development Goal target [to reduce child mortality by 2030]."

Fuente: The Guardian. Disponible en https://bit.ly/3Og34Ic

La vacuna Patria mexicana contra el Covid-19 está lista y comenzará a producirse en diciembre

3 may. Tras más de dos años en proceso de desarrollo, el Consejo Nacional de Ciencia y Tecnología (Conacyt) anunció que la vacuna Patria contra el Covid-19 consiguió la aprobación para utilizarse como refuerzo contra el coronavirus que cobró la vida de millones de personas en el mundo.

María Elena Álvarez-Buylla Roces, directora general del Conacyt, aseguró en conferencia de prensa que la vacuna Patria superó la fase 3 de estudios clínicos y cumplió con los requisitos establecidos por la Organización Mundial de la Salud (OMS) para utilizarse como refuerzo en el esquema de vacunación.

"Contar con esta plataforma nos abre el camino para la recuperación en la soberanía de vacunas que es tan importante para la prevención de enfermedades. Esto se dio gracias a la conjunción de capacidades de varias universidades públicas, el IMSS y también en alianza con una empresa mexicana, honesta", comentó la directora del Conacyt.

La vacuna Patria fue desarrollada por el laboratorio Avimex con fondos gubernamentales y tuvo un costo de producción cercano a los 973 millones de pesos. A decir de las autoridades de gobierno, esta cifra es considerablemente menor a los recursos invertidos por otros laboratorios para el desarrollo de fármacos similares.

Según datos compartidos por el gobierno federal, la vacuna Moderna tuvo un costo de desarrollo de 19,000 millones de pesos. Esta opción de inmunización estuvo disponible en el mercado un año después del inicio de la pandemia y fue utilizada en México para acelerar el proceso de vacunación en el país.

En septiembre de este año, la vacuna Patria comenzará el proceso de autorización de emergencia frente a la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris), mientras que será a finales de 2023 cuando comience su producción en masa.

Fue en 2021, cuando el presidente de México, Andrés Manuel López Obrador, delegó al Conacyt la tarea de desarrollar una vacuna mexicana contra el Covid-19 para reducir la dependencia del país alrededor de inmunizadores extranjeros.

¿La vacuna Patria llega a tiempo?

A finales del año pasado, estimaciones de la Secretaría de Salud indicaban que el 84% de la población en México tenía al menos una vacuna contra Covid-19. De este total, la mayoría de las personas tenía el esquema completo de tres aplicaciones.

Por grupo de edad, las autoridades de salud estimaron que 91% de la población mayor de edad, el 64% de los adolescentes entre 12 y 17 años, así como el 60% de los infantes entre 5 y 11 años fueron inmunizados al menos una vez.

Las marcas que se han usado con autorización por la Cofepris para su uso de emergencia son Pfizer/ Biontech (en su presentación para adultos y pediátrica), Sputnik V, AstraZeneca, Sinovac, Cansino, Moderna y Abdala.

Si la ruta de aprobación y producción presentada por el Conacyt se cumple sin retrasos, la vacuna Patria estaría disponible en el mercado a más tardar a principios de 2024, momento en el que estas cifras seguramente habrán crecido.

El cumplimiento de los requisitos de la OMS por parte de la vacuna Patria llegan justo en un momento en el que el organismo internacional de salud recomendó ajustar los esquemas de vacunación para aplicar refuerzos, únicamente, a los grupos de alto riesgo entre los que se encuentran la personas de la tercera edad, adultos jóvenes con comorbilidades significativas, personas con condiciones inmunocomprometidas, personas embarazadas y trabajadores sanitarios.

A finales de marzo, la doctora Hanna Nohynek, presidenta del Grupo de Expertos en Asesoramiento Estratégico (SAGE) sobre inmunización de la OMS , aseguró que “los países deben tener en cuenta su contexto particular cuando decidan si siguen vacunando a los grupos de riesgo bajo, como los niños y adolescentes sanos, sin que ello suponga comprometer la administración de las vacunas rutinarias, que tan importantes son para la salud y el bienestar de este grupo de edad”.

Fuente: Wired. Disponible en https://bit.ly/42ZlrFp

Se acaba la emergencia por la pandemia, pero la COVID-19 continúa

6 may. La Organización Mundial de la Salud acogió la recomendación del Comité de Emergencia de declarar el fin de la emergencia de salud pública de emergencia internacional por la COVID-19.

El anuncio fue hecho por el doctor Tedros Adhanom Gebreyesus, director general de la Organización Mundial de la Salud, OMS. “Ayer, el Comité de Emergencias se reunió por decimoquinta vez y me recomendó que declarara el fin de la emergencia de salud pública de importancia internacional. He aceptado ese consejo. Por lo tanto, declaro con gran esperanza el fin de COVID-19 como emergencia sanitaria internacional”, declaró este 5 de mayo de 2023.

Sin embargo, el máximo responsable de velar por la salud pública mundial advirtió que “esto no significa que COVID-19 haya dejado de ser una amenaza para la salud mundial”. La COVID-19 sigue siendo una prioridad de salud pública global.

La declaración de que la COVID-19 ya no constituye una emergencia de salud pública de importancia internacional (ESPII) implica que es el momento que los países pasen del modo de emergencia al manejo y control de la COVID-19 con otras enfermedades infecciosas. La COVID-19 no ha terminado. El riesgo continúa. Por esa razón, los países, ni sus sistemas de salud, al igual que sus poblaciones, pueden bajar la guardia.

El final de una ESPII significa que la COVID-19 es ahora un problema de salud establecido y persistente, y

ya no constituye una emergencia de salud pública de importancia internacional (ESPII).

Sin embargo, el virus llegó para quedarse, y los países deben integrar las actividades de vigilancia y respuesta a la COVID-19 en los programas de salud regulares.

La OMS aconseja a los países que continúen siguiendo las recomendaciones emitidas:

• Conservar lo ganado en términos de capacidad nacional y prepararse para eventos futuros, a fin de evitar un ciclo de pánico y descuido.
• Integrar la vacunación contra la COVID-19 en los programas de vacunación a lo largo del curso de vida, y mantener las medidas para aumentar la cobertura de la vacunación contra la COVID-19 para todas las personas de los grupos de alta prioridad.
• Integrar la vigilancia de los agentes patógenos respiratorios y continuar la notificación de los datos a la OMS.
• Prepararse para que se autoricen las vacunas, los medios de diagnóstico y los tratamientos dentro de los marcos regulatorios nacionales, con objeto de garantizar la disponibilidad y el suministro a largo plazo.
• Seguir trabajando con las comunidades para lograr programas sólidos, resilientes e inclusivos en materia de comunicación de riesgos y participación de la comunidad y de gestión de la infodemia.
• Seguir eliminando las medidas de salud relacionadas con las COVID-19 aplicables a los viajes internacionales, en función de las evaluaciones de riesgos.
• Seguir apoyando la investigación para mejorar las vacunas y comprender mejor la afección posterior a la COVID-19.

Fuente: Organización Panamericana de la Salud OPS. Disponible en https://bit.ly/3OcQvgz

En Cuba no se han detectado casos de la nueva variante de coronavirus Ómicron xbb.1.16

6 may. Según confirmó Francisco Durán García, director nacional de Epidemiología del Ministerio de Salud Pública, en Cuba no se han detectado casos de la nueva variante de coronavirus Ómicron xbb.1.16 (llamada también Arcturus), la cual circula en más de 30 países, con una mayoría de casos en la India.

El experto precisó que el país mantiene la vigilancia en fronteras para detectar, de manera oportuna, todo caso sospechoso y sigue con atención el comportamiento de la xbb.1.16 en el mundo.

Ómicron xbb.1.16 (llamada también Arcturus) circula en más de 30 países, con una mayoría de casos en la India. Foto: EFE

La Organización Mundial de la Salud (OMS) la calificó recientemente como una nueva variante de interés, al tener en consideración su rápida propagación a nivel internacional, al superar a la variante xbb.1, 5, que era la dominante en muchas regiones.

Identificada por primera vez en enero último, esta variante tiene una mutación adicional en la proteína de espiga y muestra un alto grado de evidencia de mayor riesgo de transmisión y un moderado grado de escape

inmunológico, es decir, parece ser más contagiosa que las anteriores y moderadamente resistente al sistema inmunitario.

A pesar de expandirse más rápido que las anteriores, la OMS considera que no parece estar causando una enfermedad más grave, por lo que el riesgo es bajo.

Entre los síntomas más comunes están la fiebre muy alta, tos, decaimiento y conjuntivitis, aunque aún no existe total consenso en que la provoque.

Un informe de la OMS advierte que, por sus características, la xbb.1.16 puede propagarse globalmente y provocar un aumento en la incidencia de casos, pero la evidencia disponible no sugiere la adopción de medidas sanitarias adicionales.

Fuente: Cubadebate. Disponible en https://bit.ly/42ySwIp

Canada And PAHO Collaborate to Strengthen Vaccine Manufacturing in Latin America And the Caribbean

May 9. The Government of Canada and the Pan American Health Organization (PAHO) are collaborating to strengthen manufacturing capacities to increase the safe and timely access to vaccines in countries of Latin America and the Caribbean.

Through C$ 15 million (US$ 11.1 million) funding provided by Global Affairs Canada (GAC), PAHO will reinforce its current work to enhance the existing regional vaccine production capacities, including the manufacturing of messenger RNA (mRNA) vaccines against COVID-19 and other diseases.

“The COVID-19 pandemic underscored the severe impact of unequal access to vaccines and other health technologies,” PAHO Director, Dr. Jarbas Barbosa, said. “We thank Canada for supporting PAHO in this effort to expand and develop regional production capacities for medical products – an objective that is at the heart of our strategy to end the acute phase of the COVID-19 pandemic and a key step towards achieving universal access to health.”

Dr. Barbosa discussed the collaboration during a visit to PAHO headquarters by Mr. Jason Tolland, Director General for South America and Inter-American Affairs at GAC.

“Canada is looking forward to the implementation of its $15M support to PAHO’s COVID-19 Vaccine Manufacturing Platform to strengthen vaccine production capacities in Latin America and the Caribbean,” Mr. Tolland said. “Canada is committed to addressing barriers to equitable access of vaccines by supporting regional manufacturing initiatives in low- and middle-income countries. We recognize the enormous potential of initiatives that promote local ownership and enable regions to address their own needs, not only for COVID-19 but also for other diseases.”

The Latin American and Caribbean region imports six times more pharmaceuticals than it exports, leaving it vulnerable to fluctuations in global supply, particularly during emergencies. During the first years of the pandemic, severe shortages of COVID-19 vaccines heightened the need to rapidly increase regional production.

The new initiative supported by the Government of Canada will promote activities to foster an enabling environment for regional vaccine production, including the promotion of greater coordination across countries and public and private partners, and the strengthening of national regulatory systems and policies.

The project will support PAHO's Regional Platform for Advancing the Production of Vaccines and Other Health Technologies for COVID-19 in the Americas, including ongoing work with the mRNA Vaccine Technology Transfer Program. This multilateral collaboration by the World Health Organization, the Medicines Patent Pool and other partners aims to facilitate mRNA vaccine manufacturing technology transfer to low- and middle-income countries. Currently, it includes two institutions in the region, Sinergium Biotech of Argentina and the Institute of Technology in Immunobiological Bio-Manguinhos of Brazil.

In the next two years, PAHO will assist Bio-Manguinhos in planning and implementing clinical trials for vaccine development and will support Sinergium Biotech in technology transfer and the acquisition of necessary equipment for vaccine production.

The organization will produce a guide for the establishment of vaccine manufacturing pilot facilities, including key inputs for the development of business plans, technical brochures, and equipment and supply needs.

PAHO is also working on the selection of a regional training center and is developing a tool to assess country readiness for vaccine development, as well as conducting several studies on topics such as COVID-19 mRNA vaccine patents in the region, and health technology production value chain.

Canada's overall support to boosting manufacturing capacities for vaccines and medicines in low- and middle-income countries was announced last year by Prime Minister Justin Trudeau during the G20 Summit. It adds to the wider support provided by Canada since 2021 to increase access to COVID-19 vaccines for populations in situations of vulnerability in the Americas through two contributions of C$ 50 million and C$ 45 million, delivered to PAHO in 2021 and 2023, respectively.

In the past years, PAHO has assisted 37 countries and territories in increasing access to COVID-19 vaccines, including in the development and implementation of national plans for their deployment and use. PAHO has also supported 32 countries and territories in expanding cold chain storage and transportation capacities, mainstreaming gender equality in all its work.

As part of these efforts, 13 countries have implemented activities with a specific focus on gender and ethnicity, including actions to bring vaccines to remote communities. These included workshops and knowledge dialogues to identify local perceptions about vaccines, explain the benefits of vaccines to communities, and empower women, girls, Indigenous and Afro-descendant people and LGBT groups to communicate effectively about this issue through science-based and culturally appropriate content.

Fuente: Periódico Digital Centroamericano y del Caribe. Disponible en https://bit.ly/3oamoM8

Fin de emergencia internacional por viruela símica, declara OMS

9 may. La Organización Mundial de la Salud (OMS) anunció este jueves el fin de la emergencia internacional por la viruela del mono, denominada oficialmente como "mpox", y que ha afectado a alrededor de 87 000 personas en el mundo.

El director general del organismo sanitario internacional, Tedros Adhanom Ghebreyesus, comunicó la decisión en rueda de prensa luego de que en la víspera se reuniera el comité de emergencia que analizaba trimestralmente el brote de la enfermedad.

"Ayer, el comité de emergencia para el mpox se reunió y me recomendó que el brote multinacional de mpox ya no representa una emergencia de salud pública de importancia internacional", señaló el titular.

"Me complace declarar que la mpox ya no es una emergencia internacional, pero como ocurre con la COVID-19, eso no significa que haya dejado de ser un desafío para la salud pública", añadió.

De acuerdo con las autoridades sanitarias, los casos positivos a la viruela, que ha dejado un saldo de 140 fallecidos, se han reducido en un 90 % en los últimos tres meses.

"En particular, la labor de las organizaciones comunitarias, junto con las autoridades de salud pública, ha sido fundamental para informar a la población de los riesgos de la viruela símica, fomentar y apoyar el cambio de comportamiento y abogar por que el acceso a las pruebas, las vacunas y los tratamientos esté al alcance de los más necesitados", resaltó Tedros.

Durante los diez meses del brote, el continente americano resultó ser el de mayor cantidad de contagios con más de 59 000 casos, seguido por Europa con 25 000 y África con 1 500.

En julio del año pasado, la OMS decidió declarar a la enfermedad como una "emergencia de salud pública de interés internacional" (PHEIC, por sus siglas en inglés).

Fuente: Cubadebate. Disponible en https://bit.ly/3IjozEe

Comité de Cofepris emite opinión favorable sobre la vacuna Abdala

13 may. El Comité de Moléculas Nuevas (CMN) de la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) emitió una opinión favorable sobre la vacuna de proteína recombinante del dominio de unión al receptor del virus SARS-CoV-2, conocida como Abdala.

La vacuna, desarrollada por el Centro de Ingeniería Genética y Biotecnología (CIGB) de la República de Cuba, está indicada para la inmunización activa específica contra la infección por covid-19 en niños y niñas a partir de los cinco años, con eficacia a las formas clínicas leves, moderadas y graves de 92.13, 88.99 y 92.33 por ciento, respectivamente.

Indicó que la opinión emitida por el CMN forma parte del proceso para obtener la autorización de uso de emergencia que expide la Comisión de Autorización Sanitaria de Cofepris, una vez que se haya evaluado la información presentada.

En un comunicado, recordó que el 3 de abril el Comité Nacional de Ciencia, Tecnología e Innovación en Salud Pública, del Consejo Nacional de Humanidades, Ciencias y Tecnologías, recomendó ampliar el uso por emergencia de la vacuna Abdala para población pediátrica de cinco a 17 años.

Fuente: La Jornada. Disponible en https://bit.ly/3WcAtoQ

Cuánto tiempo tomó desarrollar estas 13 importantes vacunas

14 may. En todo el mundo, los científicos trabajaron a una velocidad récord para desarrollar una vacuna exitosa para el covid-19, que ha infectado a más de 670 millones de personas y ha matado a más de 6.8 millones.

En Estados Unidos, el desarrollo de vacunas se somete a un conjunto específico de pasos que incluyen fases exploratorias, ensayos preclínicos, aplicación de nuevos medicamentos, cuatro fases de ensayos de vacunas y una investigación exhaustiva de los Centros de Control y Prevención de Enfermedades y la Administración de Alimentos y Medicamentos.

Todo eso combinado podría tomar varios años por lo que podría no ser tan efectiva como se esperaba. Pero debido a la gravedad de la pandemia, los fabricantes y los principales científicos pudieron acelerar el proceso para obtener resultados lo más rápido posible.

Para obtener una perspectiva de las complejidades del desarrollo de vacunas, a continuación se muestra cuánto tiempo llevó desarrollarlas para otras enfermedades infecciosas a lo largo de la historia.

Viruela

La erradicación de la viruela a través de una vacuna se considera uno de los mayores logros en la historia de la salud pública, pero llevó varios siglos llegar allí.

Se desconocen los orígenes de la viruela, aunque los científicos creen que se remonta al Imperio egipcio del siglo III a. C. En el siglo XVIII, la colonización propagó la enfermedad por todo el mundo. Tenía una tasa de mortalidad devastadora de hasta 30%.

En 1796, Edward Jenner en el Reino Unido creó la primera vacuna exitosa contra la viruela, pero no fue hasta la década de 1950 que los tratamientos con vacunas comenzaron a erradicar la enfermedad de manera efectiva en algunas partes del mundo.

Luego, en 1967, un esfuerzo global que proporcionó un mayor nivel de producción de vacunas y el avance en la tecnología de las agujas finalmente condujo a la erradicación de la enfermedad en 1980.

Un adolescente es vacunado contra la viruela por un médico escolar y una enfermera de salud del condado, Gasport, Nueva York, 15 de marzo de 1938 | Harry Chamberlain/FPG/ Hulton Archive/Getty Images

Hasta la fecha, la viruela sigue siendo la única enfermedad que se ha eliminado por completo en todo el mundo gracias a los esfuerzos de vacunación.

Peste

La peste es una de las enfermedades más antiguas y letales del mundo; culminó con casi 200 millones de muertes a lo largo de la historia humana. Pero hasta la fecha, no hay ninguna vacuna autorizada disponible.

La peste es quizás más notoria por matar a millones de personas durante la Edad Media, pero la enfermedad

todavía está activa en áreas de todo el mundo. En 2017, un brote de peste en Madagascar atrajo la atención y el pánico generalizados.

Sin embargo, dado que la peste es una enfermedad propagada por bacterias, la llegada de los antibióticos modernos se usan como tratamiento. Aun así, los investigadores creen que el desarrollo de vacunas es la opción más viable para prevenir la propagación de enfermedades a largo plazo.

Se han hecho muchos intentos fallidos para crear una vacuna contra la peste en el pasado, incluido uno que se hizo en Estados Unidos para inocular a los soldados durante la guerra de Vietnam.

Pero en 2018, la OMS creó un Perfil de producto objetivo de la vacuna contra la peste, que enumera 17 posibles candidatos para la aprobación de la vacuna; se están sometiendo a ensayos clínicos y avanzando hacia la aprobación de la FDA.

Fiebre tifoidea

La fiebre tifoidea es una enfermedad mortal que se puede propagar ampliamente a través de los alimentos y el agua. Aunque es relativamente poco común en las áreas industrializadas, aún es una amenaza importante en los países en desarrollo del sudeste asiático, África y Latinoamérica.



Mary Mallon (1870?-1938), conocida como «Typhoid Mary», en Nueva York. Fue la primera persona identificada como portadora del bacilo de la fiebre tifoidea en Estados Unidos|Getty Images

Hay dos vacunas disponibles comercialmente para prevenir la fiebre tifoidea. Después de que se descubriera la bacteria responsable de la enfermedad en 1880, los científicos alemanes comenzaron a investigar estos esfuerzos por primera vez en 1896.

En 1909, el médico del ejército estadounidense Frederick F. Russell, desarrolló la primera vacuna contra la fiebre tifoidea en ese país. Durante los siguientes años, la vacuna se usaría con fines militares hasta que, en 1914, estuvo disponible para su población en general.

Fiebre amarilla

En 1951, Max Theiler se convirtió en el primer y único científico en recibir un Premio Nobel por el desarrollo de una vacuna. Sus esfuerzos para controlar la fiebre amarilla son ampliamente elogiados por la comunidad científica. Además, ayudó a corregir años de investigación equivocada.

La fiebre amarilla ha causado epidemias mortales a lo largo de la historia de la humanidad durante más de 500 años y, a fines del siglo XIX, era bien sabido que era una amenaza en todo el mundo. Sin embargo se sabía poco sobre la enfermedad en sí, y los primeros esfuerzos de vacunación a finales de siglo se centraron erróneamente en la transmisión bacteriana cuando en realidad es causada por un virus.

En 1918, los investigadores que trabajaban para el Instituto Rockefeller desarrollaron lo que pensaron que era la primera vacuna exitosa contra la fiebre amarilla, pero en 1926 Theiler demostró lo contrario y la

vacuna defectuosa dejó de producirse.

Más de una década después, en 1937, Theiler creó la primera vacuna segura y eficaz contra la fiebre amarilla, que desde entonces se convirtió en el estándar universal.

Influenza

La influenza tiene una larga y trágica historia de matar a millones de personas en todo el mundo. Durante la pandemia de influenza de 1918, no se conocían curas ni vacunas para el virus.



Enfermeras voluntarias de la Cruz Roja atienden a personas con gripe en el Auditorio de Oakland en Oakland, California, durante la pandemia de influenza de 1918|Edward A. «Doc» Rogers

A partir de la década de 1930, se necesitaron décadas de investigación para comprender las complejidades del virus de la influenza. No fue hasta 1945 que se aprobó la primera vacuna para su uso en Estados Unidos.

Pero solo dos años después, en 1947, los investigadores concluyeron que los cambios estacionales en la composición del virus hacían que las vacunas existentes fueran ineficaces.

Los investigadores se dieron cuenta de que ocurren dos tipos principales de virus de la influenza: la influenza A y la influenza B, junto con múltiples cepas nuevas del virus cada año. Debido a esto, los científicos tienen que modificar la vacuna contra la influenza todos los años.

Hoy en día, la OMS diseña las vacunas contra la gripe estacional utilizando los datos recopilados de los centros de vigilancia de la gripe para desarrollar una nueva vacuna basada en las tres cepas que tienen más probabilidades de circular en la próxima temporada.

Polio

Si bien es probable que la poliomielitis haya afectado a las poblaciones humanas durante miles de años, no fue sino hasta fines del siglo XIX que la enfermedad alcanzó proporciones epidémicas. A principios de siglo, la poliomielitis se extendió por Estados Unidos y dejó a muchos pacientes infectados paralizados o discapacitados de por vida.

La investigación para comprender la poliomielitis fue gradual durante las primeras décadas del siglo XX. En 1935 se intentó una vacunación, primero en monos y luego en niños en California. Aunque esta vacuna arrojó malos resultados, dos décadas más de investigación allanaron el camino para el desarrollo de vacunas por parte de Jonas Salk en 1953 y Albert Sabin en 1956.

Después de un ensayo de más de 1.6 millones de niños, la vacuna de Salk se adoptó en México en 1956. La investigación continua durante la década de 1980 dio paso a una producción de vacunas aún más eficaz y eficiente, y en 1994 se eliminó la poliomielitis en América.

Recientemente, en 1988, 350,000 personas tenían la enfermedad debilitante; la mayoría eran niños. Para 2018, solo había 33 casos de polio en todo el mundo.

Un estudio estimó que la vacuna contra la poliomielitis evitó que 24 millones de personas contrajeran la

enfermedad entre 1988 y 2021.

La poliomielitis podría convertirse en la segunda enfermedad humana que eliminamos del planeta.

Ántrax

Se cree que el ántrax existió desde el año 700 a. C., pero el primer informe clínico de la enfermedad se registró en el siglo XVIII.

A lo largo de la década de 1800, una serie de estudios para determinar de dónde se originó la enfermedad, cuánto tiempo podría sobrevivir la bacteria y cómo se transmitía la enfermedad a través de los animales allanaron el camino para los primeros intentos de una vacuna en 1881.

En 1937, el científico Max Sterne creó una exitosa vacuna contra el ántrax para ser utilizada en el ganado, una versión de la que todavía se usa actualmente, con el fin de reducir la transmisión de animales a humanos. 13 años después, se creó la primera vacuna humana y se puso a disposición de las personas que trabajaban en plantas procesadoras de animales.

En 1970 se desarrolló una vacuna actualizada contra el ántrax, que es en gran medida lo que se usa para prevenir la enfermedad en los humanos en la actualidad.

Sarampión, paperas y rubéola (MMR)

El sarampión, las paperas y la rubéola son infecciones virales que han causado brotes de enfermedades mortales y generalizadas. A lo largo de la década de 1960, se desarrollaron vacunas individuales para cada uno de ellos, pero una década más tarde, se combinaron en una sola.

El sarampión fue el primero de los tres en recibir su propia vacuna en 1963, seguido de las paperas en 1967 y la rubéola en 1969. Dos años después, en 1971, Maurice Hilleman del Instituto Merck de Investigación Terapéutica desarrolló una vacuna combinada que proporcionaría inmunidad para los tres virus.

Una enfermera muestra ampollas de la vacuna contra el sarampión en el Departamento de Salud del Condado de Orange el 6 de mayo de 2019 en Orlando, Florida|NurPhoto/Paul Hennessy via Getty Images

A Hilleman se le atribuyó la creación de la primera vacuna contra el sarampión y las paperas y comenzó a investigar formas de incorporar un sistema de inmunidad para cada virus. Usando su investigación anterior y una vacuna contra la rubéola desarrollada por Stanley Plotkin en 1969, creó la primera vacuna MMR exitosa en solo dos años.

Según los CDC, «una dosis de la vacuna MMR tiene una eficacia de 93% contra el sarampión, de 78% contra las paperas y de 97% contra la rubeóla».

«Dos dosis de la vacuna MMR tienen una eficacia de 97% contra el sarampión y 88% contra las paperas».

Varicela (Chicken Pox)

La infección primaria por varicela fue mal diagnosticada como viruela hasta finales del siglo XIX.

En la década de 1950, los científicos distinguieron la varicela del herpes zóster (culebrilla), y las investigaciones posteriores condujeron al desarrollo de la primera vacuna contra la varicela en Japón en la década de 1970.

Herpes (herpes zoster)

La culebrilla, o herpes zóster, proviene del mismo virus que causa la varicela. Las únicas dos formas en que se puede desarrollar el herpes zóster es después de una infección inicial de varicela o (poco común) la exposición a una vacuna contra la varicela.

La conexión entre el herpes zóster y la varicela se observó por primera vez en 1953 y, a lo largo de la década de 1960, los estudios indicaron que el herpes zóster era mucho más común en las poblaciones de mayor edad.

Frank Bienewald/LightRocket via Getty Images

Hepatitis B

El equipo de HEP proporcionó vacunas para ayudar a prevenir la hepatitis A y B a los interesados sin costo alguno |Carlos Chavez/Los Angeles Times via Getty Images

La hepatitis B es un virus más reciente y fue descubierto por el doctor Baruch Blumberg en 1965. Solo cuatro años después, creó la primera vacuna contra la hepatitis B utilizando una forma del virus tratada térmicamente.

Doce años más tarde, en 1981, la FDA aprobó la primera vacuna comercial contra la hepatitis B, que incluía muestras de sangre de donantes infectados.

Luego, en 1986, una nueva vacuna preparada sintéticamente que no utiliza productos sanguíneos reemplazó al modelo original.

Dado que la hepatitis B puede causar cáncer de hígado, la vacuna también se consideró la primera vacuna contra el cáncer.

Virus del papiloma humano (VPH)

Los estudios muestran que más del 80% de las mujeres habrán contraído el Virus del Papiloma Humano (VPH) en algún momento de sus vidas.

Se cree que dos cepas del VPH causan hasta 70% de los casos de cáncer de cuello uterino, lo que puede provocar cientos de miles de muertes cada año. El vínculo entre el VPH y el cáncer de cuello uterino se estableció por primera vez en 1981, y siguieron más de dos décadas de investigación antes de que una vacuna viable llegara al mercado.

La primera vacuna contra el VPH se desarrolló en Estados Unidos en 2006 y, desde entonces, la investigación posterior ha llevado al desarrollo de dos vacunas más.

Hoy en día, las recomendaciones sobre qué tipo de vacuna recibir dependen en gran medida de la edad.

COVID-19

Pfizer, junto con BioNTech, utilizó tecnología revolucionaria de ARNm para crear su vacuna contra el covid-19. El potencial de esta nueva tecnología podría transformar la ciencia, dijeron los líderes de la compañía.

Pfizer, junto con BioNTech, utilizó tecnología revolucionaria de ARNm para crear su vacuna contra la COVID-19. El potencial de esta nueva tecnología podría transformar la ciencia, dijeron los líderes de la compañía.

El brote de COVID-19 provocó que miles de millones de personas en todo el mundo se encerraran, cuestionando la vida cotidiana, para frenar la propagación del virus altamente contagioso.

El coronavirus resultó en hospitales superpoblados, trabajadores de la salud estresados y presión sobre los funcionarios que fueron presionados para crear una vacuna para acabar con la pandemia.

Durante las primeras etapas de la pandemia, el doctor Anthony Fauci, el principal experto en enfermedades del país, dijo frente al Congreso que se podría desarrollar una vacuna para fines de 2020 o que estaría disponible para su uso en 2021.

En diciembre de 2020, Sandra Lindsay, enfermera de cuidados intensivos, se convirtió en la primera persona en recibir la inyección fuera de los ensayos clínicos.

«Como minoría, quería infundir confianza en mi gente que se parece a mí para decir que es seguro, guiarse por la ciencia, no tener miedo», dijo Lindsay a Insider en ese momento.

Según los Centros para el Control y la Prevención de Enfermedades , se ha dado luz verde a cuatro vacunas incluidas Pfizer-BioNTech, Moderna, Johnson & Johnson y Novavax .

Fuente: Business Insider. Disponible en https://bit.ly/430Rp42

China comienza a utilizar la primera vacuna de ARN mensajero de producción propia

15 may. La primera vacuna contra la covid-19 basada en ARN mensajero desarrollada por China comenzó a emplearse este domingo en la provincia norteña de Hebei, recogen hoy medios estatales.

El primer lugar donde comenzó a administrarse la fórmula fue en Shijiazhuang, donde la población puede recibir la vacuna creada por el grupo CSPC Pharmaceutical, informa el diario oficialista Global Times.

Las autoridades sanitarias chinas aprobaron el uso de emergencia de este fármaco a finales de marzo y recomendaron su uso como refuerzo de inmunizaciones previas, en especial frente a las variantes ómicron del virus.

Según la compañía farmacéutica, su vacuna de ARN mensajero induce una buena protección cruzada contra las citadas variantes, responsables en el pasado invierno del mayor brote de coronavirus vivido en China desde que comenzó la pandemia y que llevó al rápido contagio de un alto porcentaje de la población.

El Grupo Central para la Prevención y Control del Nuevo Coronavirus también recomendó el uso alternativo como refuerzo de otra vacuna desarrollada en plataforma tradicional, la SCTV01E, de la empresa Sino Cell Tech, que acaba de finalizar la tercera y última fase de ensayos clínicos.

De acuerdo al rotativo, un número creciente de personas ha asegurado en las redes sociales chinas que se ha contagiado por segunda vez de COVID-19 en los últimos días, aunque en general con síntomas más suaves que en la primera ocasión.

El Centro para el Control de Enfermedades de China informó a finales de abril pasado de que las variantes predominantes del virus en el país asiático son las de ómicron, que suponían en ese momento un 74,4 % de los casos locales y un 97,5 % de los importados.

La campaña de vacunación en China continental se había basado hasta ahora en vacunas producidas por las empresas nacionales Sinovac, Sinopharm y CanSino, que emplean vectores inactivados del adenovirus, una de las plataformas vacunales más tradicionales y seguras que existen pero cuya eficacia es menor que la de las basadas en ARN mensajero.

China ha rechazado usar vacunas de ARN mensajero procedentes del extranjero, decisión que le ha valido al país asiático críticas por parte de expertos internacionales.

El pasado 8 de enero, las autoridades redujeron de la categoría A -nivel de máximo peligro- a la B la gestión de la covid-19, marcando así en la práctica el final de la política de 'cero covid'.

A la retirada de las restricciones le siguió una oleada de infecciones en todo el país, durante la cual se registraron momentos de gran presión hospitalaria.

En aquellas fechas, algunas voces criticaron una posible falta de preparación por parte de las autoridades antes de relajar las medidas.

Entre el 8 de diciembre y el pasado 9 de febrero, período que cubre la retirada de las medidas de prevención más estrictas y la posterior ola de contagios, se registraron oficialmente en China 83.150 muertes en hospitales relacionadas con la COVID-19.

Fuente: SWI swissinfo. Disponible en https://bit.ly/3Mz9ZuJ

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/05/01 to 2023/05/15. "COVID-19 vaccine" (Title/Abstract) 635 records.

Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, Cheng B, Abu Raddad LJ, Buckeridge DL, Van Kerkhove MD, Piechotta V, Higdon MM, Wilder-Smith A, Bergeri I, Feikin DR, Arora RK, Patel MK, Subissi L. Lancet Infect Dis. 2023 May;23(5):556-567. doi: 10.1016/S1473-3099(22)00801-5. Epub 2023 Jan 18. PMID: 36681084

Immunological imprinting: Understanding COVID-19.
Koutsakos M, Ellebedy AH. Immunity. 2023 May 9;56(5):909-913. doi: 10.1016/j.immuni.2023.04.012. Epub 2023 Apr 19. PMID: 37105169

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023.
Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, Halpert G, Watad A, Amital H, Shoenfeld Y. Autoimmun Rev. 2023 May;22(5):103287. doi: 10.1016/j.autrev.2023.103287. Epub 2023 Feb 3. PMID: 36738954

Drug treatment of COVID-19 infection.
Lui G, Guaraldi G. Curr Opin Pulm Med. 2023 May 1;29(3):174-183. doi: 10.1097/MCP.0000000000000953. Epub 2023 Mar 14. PMID: 36917228

Vaccines and therapeutics for immunocompromised patients with COVID-19.
Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, Kang G, Kim JH, Lall B, Larson HJ, Naniche D, Sheahan T, Strub-Wourgaft N, Sow SO, Wilder-Smith A, Yadav P, Bottazzi ME; Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force. EClinicalMedicine. 2023 May; 59:101965. doi: 10.1016/j.eclinm.2023.101965. Epub 2023 Apr 12. PMID: 37070102

Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV.
Krause KD, Pérez-Figueroa RE, Halkitis PN. Curr Opin HIV AIDS. 2023 May 1;18(3):142-147. doi: 10.1097/COH.0000000000000788. Epub 2023 Mar 17. PMID: 36943471

COVID-19 infection and vaccines: potential triggers of Herpesviridae reactivation.
Navarro-Bielsa A, Gracia-Cazaña T, Aldea-Manrique B, Abadías-Granado I, Ballano A, Bernad I, Gilaberte Y. An Bras Dermatol. 2023 May-Jun;98(3):347-354. doi: 10.1016/j.abd.2022.09.004. Epub 2023 Feb 10. PMID: 36803914

COVID-19 Vaccine Safety First Year Findings in Adolescents.
Hesse EM, Hause A, Myers T, Su JR, Marquez P, Zhang B, Cortese MM, Thames-Allen A, Curtis CR, Maloney SA, Thompson D, Nair N, Alimchandani M, Niu M, Gee J, Shay DK, Shimabukuro TT; MIS-C REVIEW GROUP. Pediatrics. 2023 May 1;151(5):e2022060295. doi: 10.1542/peds.2022-060295. PMID: 37082919

The effect of HIV on COVID-19 vaccine responses.
Levy I, Rahav G. Curr Opin HIV AIDS. 2023 May 1;18(3):135-141. doi: 10.1097/COH.0000000000000790. Epub 2023 Mar 14. PMID: 36943427

Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.
Meulewaeter S, Nuytten G, Cheng MHY, De Smedt SC, Cullis PR, De Beer T, Lentacker I, Verbeke R. J Control Release. 2023 May;357:149-160. doi: 10.1016/j.jconrel.2023.03.039. Epub 2023 Mar 30. PMID: 36958400

COVID-19 vaccination and menstrual disorders among women: Findings from a meta-analysis study.
Al Kadri HM, Al Sudairy AA, Alangari AS, Al Khateeb BF, El-Metwally AA. J Infect Public Health. 2023 May;16(5):697-704. doi: 10.1016/j.jiph.2023.02.019. Epub 2023 Mar 2. PMID: 36934644

Therapeutics for COVID-19.
Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Nat Microbiol. 2023 May;8(5):771-786. doi: 10.1038/s41564-023-01356-4. Epub 2023 May 4. PMID: 37142688

Rapid Development and Testing of a COVID-19 Vaccine Curriculum for Pediatricians.
Zaveri PP, Clark S, Kan K, Lee BR, Naik V, Opel DJ, Popovsky E, Ren D, Simpson J, Watts J, White ML, Myers AL. Acad Pediatr. 2023 May-Jun;23(4):790-799. doi: 10.1016/j.acap.2022.09.010. Epub 2022 Sep 16. PMID: 36122826

Pregnant Women's Concerns Regarding COVID-19 and Their Willingness to Be Vaccinated.
Mitchell SL, Strassberg E, Rhoades C, Jones A, Wagner JCP, Schulkin J, Power ML. J Womens Health (Larchmt). 2023 May;32(5):513-520. doi: 10.1089/jwh.2022.0427. Epub 2023 Mar 10. PMID: 36897317

Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis.
Hameed I, Khan MO, Nusrat K, Mahmood S, Nashit M, Malik S, Siddiqui OM, Samad SA, Marsia S, Usman MS, Siddiqi TJ. Am J Infect Control. 2023 May;51(5):582-593. doi: 10.1016/j.ajic.2022.08.014. Epub 2022 Aug 22. PMID: 36007670

Impact of social media news on COVID-19 vaccine hesitancy and vaccination behavior.
Zhang Q, Zhang R, Wu W, Liu Y, Zhou Y. Telemat Inform. 2023 May;80:101983. doi: 10.1016/j.tele.2023.101983. Epub 2023 Apr 23. PMID: 37122766

Co-administration of COVID-19 and influenza vaccines.
Didierlaurent AM, Lambert PH. Clin Microbiol Infect. 2023 May;29(5):558-559. doi: 10.1016/j.cmi.2023.02.003. Epub 2023 Feb 10. PMID: 36773770

Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.
Raghav PK, Mann Z, Ahluwalia SK, Rajalingam R. J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15. PMID: 37059487

Evaluating COVID-19 vaccination intentions and vaccine hesitancy among parents of children with autism spectrum disorder.

Khoodoruth MAS, Khoodoruth WNC, Ramadan AAM, Johnson B, Gulistan S, Deluvio RBC, Alamri MN, Al-Abdulla M, Ouanes S, Khan YS. Sci Rep. 2023 May 5;13(1):7353. doi: 10.1038/s41598-023-34191-y. PMID: 37147338

Acceptance, hesitancy and refusal towards COVID-19 vaccination.
Raut A, Samad A, Verma J, Kshirsagar P. Clin Epidemiol Glob Health. 2023 May-Jun;21:101283. doi: 10.1016/j.cegh.2023.101283. Epub 2023 Apr 4. PMID: 37033719

COVID-19 vaccination: public preference and intention in Vietnam.
Tran VD, Huynh TMD, Pham DT, Le MH, Dorofeeva VV, Dewey RS. Ann Ig. 2023 May-Jun;35(3):331-343. doi: 10.7416/ai.2022.2544. Epub 2022 Oct 12. PMID: 36222608

Protection Motivation Theory and Intentions to Receive the COVID-19 Vaccine.
Kowalski RM, Deas N, Britt N, Richardson E, Finnell S, Evans K, Carroll H, Cook A, Radovic E, Huyck T, Parise I, Robbins C, Chitty H, Catanzaro S. Health Promot Pract. 2023 May;24(3):465-470. doi: 10.1177/15248399211070807. Epub 2022 Feb 8. PMID: 35130748

All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic.
AlNuaimi AA, Chemaitelly H, Semaan S, AlMukdad S, Al-Kanaani Z, Kaleeckal AH, Latif AN, Al-Romaihi HE, Butt AA, Al-Thani MH, Bertollini R, AbdulMalik M, Al-Khal A, Abu-Raddad LJ. BMJ Glob Health. 2023 May;8(5):e012291. doi: 10.1136/bmjgh-2023-012291. PMID: 37142299

Attitudes toward COVID-19 vaccine mandate: The role of psychological characteristics and partisan self-identification.
Viskupič F, Wiltse DL, Kayaalp A. Pers Individ Dif. 2023 May;206:112119. doi: 10.1016/j.paid.2023.112119. Epub 2023 Feb 9. PMID: 36785728

Key factors influencing paediatric COVID-19 vaccine hesitancy: a brief overview and Decision-making Trial and Evaluation Laboratory analysis.
Wang Y, Zhang X. Public Health. 2023 May;218:97-105. doi: 10.1016/j.puhe.2022.11.015. Epub 2022 Nov 28. PMID: 37003124

The ethics of COVID-19 vaccine mandates for healthcare workers: Public health and clinical perspectives.
Gur-Arie R, Hutler B, Bernstein J. Bioethics. 2023 May;37(4):331-342. doi: 10.1111/bioe.13141. Epub 2023 Jan 29. PMID: 36710589

Automatic Identification of Self-Reported COVID-19 Vaccine Information from Vaccine Adverse Events Reporting System.
Patel JS, Zhan S, Siddiqui Z, Dzomba B, Wu H. Methods Inf Med. 2023 May;62(1-02):49-59. doi: 10.1055/s-0042-1760248. Epub 2023 Jan 9. PMID: 36623831

Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines.
Matsumura T, Takano T, Takahashi Y. Int Immunol. 2023 May 8;35(5):213-220. doi: 10.1093/intimm/dxac064. PMID: 36566501

Factors related to COVID-19 vaccine hesitancy among middle-income and low-income adults in the USA.
Nguyen VT, Huang Y, Huang M, Tsai J. J Epidemiol Community Health. 2023 May;77(5):328-335. doi: 10.1136/jech-2021-218535. Epub 2023 Mar 8. PMID: 36889909

Implications of potential clinically relevant interactions between COVID-19 vaccines and concomitant medications.
Badary OA. Rev Med Virol. 2023 May;33(3):e2417. doi: 10.1002/rmv.2417. Epub 2023 Apr 6. PMID: 37021389

The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study.
Gastelum-Strozzi A, Flores-Alvarado DE, Pascual-Ramos V, Álvarez-Hernández E, Pacheco-Tena CF, Guaracha-Basáñez GA, García CG, González-Chávez SA, Moctezuma-Ríos JF, Manrique de Lara A, Esquivel-Valerio JA, Contreras-Yáñez I, Galarza-Delgado DÁ, Vázquez-Mellado J, Peláez-Ballestas I, Reyes-Cordero GC. Rheumatol Int. 2023 May 2:1-12. doi: 10.1007/s00296-023-05334-1. Online ahead of print. PMID: 37129609

COVID Vaccine-Associated Uveitis.
Habot-Wilner Z, Neri P, Okada AA, Agrawal R, Xin Le N, Cohen S, Fischer N, Kilmartin F, Coman A, Kilmartin D. Ocul Immunol Inflamm. 2023 May 5:1-8. doi: 10.1080/09273948.2023.2200858. Online ahead of print. PMID: 37145198

Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic.
Zaccardelli A, Wallace ZS, Sparks JA. Curr Opin Rheumatol. 2023 May 1;35(3):175-184. doi: 10.1097/BOR.0000000000000930. Epub 2023 Feb 7. PMID: 36752280

An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines.
Kale A, Gaur A, Menon I, Chirmule N, Bagwe P, Jawa R, Vijayanand S, Patil S, Suresh S, Jawa V. J Pharm Sci. 2023 May;112(5):1345-1350. doi: 10.1016/j.xphs.2023.01.019. Epub 2023 Feb 2. PMID: 36736775

Attitudes toward COVID-19 vaccine among pediatric patients with sickle cell disease and their caregivers.
Persaud Y, Mandrell BN, Sharma A, Carroll Y, Irvine M, Olufadi Y, Kang G, Hijano DR, Rai P, Hankins JS, Johnson LM. Pediatr Blood Cancer. 2023 May;70(5):e30274. doi: 10.1002/pbc.30274. Epub 2023 Mar 1. PMID: 36860093

COVID-19 vaccine effectiveness among healthcare workers: a hospital-based cohort study.
Gaio V, Santos AJ, Amaral P, Faro Viana J, Antunes I, Pacheco V, Paiva A, Pinto Leite P, Antunes Gonçalves L, Araújo L, Silva A, Dias C, Kislaya I, Nunes B, Machado A. BMJ Open. 2023 May 2;13(5):e068996. doi: 10.1136/bmjopen-2022-068996. PMID: 37130692

Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic.

Bukan K, Pearce-Slade T, Eiberg M, Tinelli M, Yahav D, Tuells J, Epaulard O, Holler JG, Roed C, Søborg C, Jensen JS, Harboe ZB. Aging Clin Exp Res. 2023 May;35(5):917-923. doi: 10.1007/s40520-023-02380-4. Epub 2023 Apr 7. PMID: 37027085

Identifying H1N1 and COVID-19 vaccine hesitancy or refusal among health care providers: a scoping review.
Gallant AJ, Harding A, Johnson C, Steenbeek A, Curran JA. JBI Evid Synth. 2023 May 1;21(5):913-951. doi: 10.11124/JBIES-22-00112. PMID: 36917102

Effectiveness and safety of coronavirus disease 2019 vaccines.
Shi T, Robertson C, Sheikh A. Curr Opin Pulm Med. 2023 May 1;29(3):138-142. doi: 10.1097/MCP.0000000000000948. Epub 2023 Feb 24. PMID: 36825398

Addressing Vaccine Hesitancy Among Students and Families: Interventions for School Nurses.
Wilson OF, Mote SL, Morse BL. NASN Sch Nurse. 2023 May;38(3):146-154. doi: 10.1177/1942602X221106945. Epub 2022 Jul 4. PMID: 35786090

The effectiveness of financial incentives for COVID-19 vaccination: A systematic review.
Khazanov GK, Stewart R, Pieri MF, Huang C, Robertson CT, Schaefer KA, Ko H, Fishman J. Prev Med. 2023 May 6:107538. doi: 10.1016/j.ypmed.2023.107538. Online ahead of print. PMID: 37156430

SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design.
Maghsood F, Ghorbani A, Yadegari H, Golsaz-Shirazi F, Amiri MM, Shokri F. Rev Med Virol. 2023 May;33(3):e2431. doi: 10.1002/rmv.2431. Epub 2023 Feb 15. PMID: 36790816

Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review.
Batac ALR, Merrill KA, Askin N, Golding MA, Abrams EM, Bégin P, Ben-Shoshan M, Ladouceur E, Roos LE, Protudjer V, Protudjer JLP. J Allergy Clin Immunol Glob. 2023 May;2(2):100079. doi: 10.1016/j.jacig.2023.100079. Epub 2023 Feb 8. PMID: 36785543

Parents' Discussions of the COVID-19 Pandemic and Death With Young Children.
Su-Russell C, Greiner C, Ermer A, Russell LT. J Fam Nurs. 2023 May;29(2):122-135. doi: 10.1177/10748407231166099. Epub 2023 Apr 21. PMID: 37083106

Emerging technologies for COVID (ET-CoV) detection and diagnosis: Recent advancements, applications, challenges, and future perspectives.
Rehman A, Xing H, Adnan Khan M, Hussain M, Hussain A, Gulzar N. Biomed Signal Process Control. 2023 May;83:104642. doi: 10.1016/j.bspc.2023.104642. Epub 2023 Feb 10. PMID: 36818992

Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review.
Nabizadeh F, Noori M, Rahmani S, Hosseini H. J Clin Neurosci. 2023 May;111:57-70. doi: 10.1016/j.jocn.2023.03.008. Epub 2023 Mar 22. PMID: 36963124

Association between COVID-19 vaccines and the menstrual cycle in young Japanese women.
Kajiwara S, Akiyama N, Baba H, Ohta M. J Infect Chemother. 2023 May;29(5):513-518. doi: 10.1016/j.jiac.2023.01.003. Epub 2023 Jan 7. PMID: 36623727

The effects of Covid-19 mRNA vaccine on adolescence gynecological well-being.
Mohr-Sasson A, Haas J, Sivan M, Zehori Y, Hemi R, Orvieto R, Afek A, Rabinovici J. Arch Gynecol Obstet. 2023 May;307(5):1625-1631. doi: 10.1007/s00404-023-06981-2. Epub 2023 Mar 5. PMID: 36871101

COVID-19 hospitalization and mortality in community-dwelling racially and ethnically diverse persons living with dementia.
Thunell JA, Ferido P, Zissimopoulos JM. J Am Geriatr Soc. 2023 May;71(5):1429-1439. doi: 10.1111/jgs.18230. Epub 2023 Jan 13. PMID: 36637869

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.
Klein NP, Demarco M, Fleming-Dutra KE, Stockwell MS, Kharbanda AB, Gaglani M, Rao S, Lewis N, Irving SA, Hartmann E, Natarajan K, Dalton AF, Zerbo O, DeSilva MB, Konatham D, Stenehjem E, Rowley EAK, Ong TC, Grannis SJ, Sloan-Aagard C, Han J, Verani JR, Raiyani C, Dascomb K, Reese SE, Barron MA, Fadel WF, Naleway AL, Nanez J, Dickerson M, Goddard K, Murthy K, Grisel N, Weber ZA, Dixon BE, Patel P, Fireman B, Arndorfer J, Valvi NR, Griggs EP, Hallowell C, Embi PJ, Ball SW, Thompson MG, Tenforde MW, Link-Gelles R. Pediatrics. 2023 May 1;151(5):e2022060894. doi: 10.1542/peds.2022-060894. PMID: 37026401

Risk aversion and COVID-19 vaccine hesitancy.
Lepinteur A, Borga LG, Clark AE, Vögele C, D'Ambrosio C. Health Econ. 2023 May 5. doi: 10.1002/hec.4693. Online ahead of print. PMID: 37146156

Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
Ali Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, Fadaleh SA, Burey S, Morris SK. Vaccine. 2023 May 5;41(19):3058-3065. doi: 10.1016/j.vaccine.2023.03.041. Epub 2023 Apr 3. PMID: 37045681

Individual and Work-Related Characteristics Associated with COVID-19 Vaccination Status among Ohio Nurses.
Jun J, Tubbs Cooley H, O'Mathúna DP, Kim M, Pignatiello G, Fitzpatrick JJ, Tucker S. Policy Polit Nurs Pract. 2023 May;24(2):81-90. doi: 10.1177/15271544221141060. Epub 2022 Dec 8. PMID: 36482714

The COVID-19 Vaccine: Why Should I Get the Vaccines and the Boosters?
Zanwar PP, Sasson C, Heyn PC, Pinto SM, Magasi S, Hirsch MA, Negm A; American Congress of Rehabilitation Medicine (ACRM) Aging Research & Geriatric Rehabilitation Covid-19 & Frailty Task Force. Arch Phys Med Rehabil. 2023 May;104(5):843-846. doi: 10.1016/j.apmr.2022.10.016. Epub 2022 Dec 10. PMID: 36513123

The 100 Most-Cited Articles in COVID-19 Vaccine Hesitancy Based on Web of Science: A Bibliometric Analysis.
Liu B, You J, Huang L, Chen M, Shen Y, Xiong L, Zheng S, Huang M. Infect Drug Resist. 2023 May 2;16:2625-2646. doi: 10.2147/IDR.S408377. eCollection 2023. PMID: 37159828

Livedo Reticularis After COVID-19 Vaccination.
Horino T, Inotani S, Nakajima K, Terada Y. J Rheumatol. 2023 May;50(5):709. doi: 10.3899/jrheum.220584. Epub 2022 Oct 1. PMID: 36182117

COVID-19 Vaccine Acceptance Among Korean American Immigrants in the United States: A Qualitative Study.
Djapri GM, Lange RM. J Transcult Nurs. 2023 May;34(3):201-210. doi: 10.1177/10436596231158133. Epub 2023 Mar 9. PMID: 36892428

Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies.
Paknahad MH, Yancheshmeh FB, Soleimani A. Heart Lung. 2023 May-Jun;59:173-180. doi: 10.1016/j.hrtlng.2023.02.003. Epub 2023 Feb 8. PMID: 36842342

Perception regarding COVID-19 vaccine and COVID appropriate behavior among adolescents at a tertiary hospital, West Bengal: A longitudinal survey.
Dhankher R, Mukhopadhyay A, Bhowmick S, Thimmappa L, Singh R, Joshi P, Rani J. Clin Epidemiol Glob Health. 2023 May-Jun;21:101277. doi: 10.1016/j.cegh.2023.101277. Epub 2023 Mar 29. PMID: 37016630

[Myocarditis following mRNA vaccine].
Formanek A, Wagner T, Newrkla S, Kurz H. Wien Med Wochenschr. 2023 May;173(7-8):192-197. doi: 10.1007/s10354-022-00959-6. Epub 2022 Aug 30. PMID: 36040634

Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
Darif D, Ejghal R, Desterke C, Outlioua A, Hammi I, Lemrani M, Hilali F, Guessous F, Zaid Y, Akarid K. Cytokine. 2023 May;165:156172. doi: 10.1016/j.cyto.2023.156172. Epub 2023 Mar 13. PMID: 36924609

The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis.
Rimmer MP, Teh JJ, Mackenzie SC, Al Wattar BH. Hum Reprod. 2023 May 2;38(5):840-852. doi: 10.1093/humrep/dead036. PMID: 36794918

Sociocultural and Behavioral Features of Anticipated COVID-19 Vaccine Acceptance in Papua New Guinea: Protocol for a Mixed Methods Study.
Giduthuri JG, Manineng C, Schuele E. JMIR Res Protoc. 2023 May 2;12:e44664. doi: 10.2196/44664. PMID: 37071828

COVID-19 imaging, where do we go from here? Bibliometric analysis of medical imaging in COVID-19.
Wen R, Zhang M, Xu R, Gao Y, Liu L, Chen H, Wang X, Zhu W, Lin H, Liu C, Zeng X. Eur Radiol. 2023 May;33(5):3133-3143. doi: 10.1007/s00330-023-09498-z. Epub 2023 Mar 9. PMID: 36892649

Promoting COVID-19 vaccine confidence through public responses to misinformation: The joint influence of message source and message content.
Wood RM, Juanchich M, Ramirez M, Zhang S. Soc Sci Med. 2023 May;324:115863. doi: 10.1016/j.socscimed.2023.115863. Epub 2023 Mar 22. PMID: 37030097

Intrinsic factors behind long-COVID: I. Prevalence of the extracellular vesicles.
El-Maradny YA, Rubio-Casillas A, Uversky VN, Redwan EM. J Cell Biochem. 2023 May 1. doi: 10.1002/jcb.30415. Online ahead of print. PMID: 37126363

COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).
Best AF, Bowman M, Li J, Mishkin GE, Denicoff A, Shekfeh M, Rubinstein L, Warner JL, Rini B, Korde LA. J Natl Cancer Inst. 2023 May 8;115(5):597-600. doi: 10.1093/jnci/djad015. PMID: 36702472

Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: A systematic review and meta-analysis.
Rahmati M, Yon DK, Lee SW, Butler L, Koyanagi A, Jacob L, Shin JI, Smith L. Rev Med Virol. 2023 May;33(3):e2434. doi: 10.1002/rmv.2434. Epub 2023 Mar 10. PMID: 36896895

Stability of Stated Preferences: Vaccine Priority Setting before and during the First COVID-19 Lockdown.
Luyten J, Kessels R. Med Decis Making. 2023 May;43(4):521-529. doi: 10.1177/0272989X221150185. Epub 2023 Jan 23. PMID: 36688420

Risk of COVID-19 Among Unvaccinated and Vaccinated Patients With Rheumatoid Arthritis: A General Population Study.
Li H, Wallace ZS, Sparks JA, Lu N, Wei J, Xie D, Wang Y, Zeng C, Lei G, Zhang Y. Arthritis Care Res (Hoboken). 2023 May;75(5):956-966. doi: 10.1002/acr.25028. Epub 2022 Nov 17. PMID: 36161711

Development and Beta-Testing of the CONFIDENCE Intervention to Increase Pediatric COVID-19 Vaccination.
Ryan GW, Goulding M, Borg A, Minkah P, Beeler A, Rosal MC, Lemon SC. J Pediatr Health Care. 2023 May-Jun;37(3):244-252. doi: 10.1016/j.pedhc.2022.11.002. Epub 2022 Nov 17. PMID: 36470798

Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy.
Ma Y, Shan Z, Gu Y, Huang Y. Int J Infect Dis. 2023 May;130:196-202. doi: 10.1016/j.ijid.2023.03.017. Epub 2023 Mar 15. PMID: 36924838

COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021-2022: a test-negative case-control study.
Brazete C, Brazete J, Alves F, Aguiar A, Gonçalves AM, Cardoso M, Sá L, Gonçalves E, Pinto M, Duarte R. Public Health. 2023 May;218:84-91. doi: 10.1016/j.puhe.2023.02.015. Epub 2023 Feb 22. PMID: 36989570

Audience segmentation analysis of public intentions to get a COVID-19 vaccine in Australia.
Thaker J, Richardson LM, Holmes DC. Public Underst Sci. 2023 May;32(4):470-488. doi: 10.1177/09636625221138494. Epub 2022 Dec 22. PMID: 36546333

Advancing detection and response capacities for emerging and re-emerging pathogens in Africa.
Nachega JB, Nsanzimana S, Rawat A, Wilson LA, Rosenthal PJ, Siedner MJ, Varma JK, Kilmarx PH, Mutesa L, Tanner M, Binagwaho A, Forrest J, Mbala-Kingebeni P, Muyembe-Tamfum JJ, Ntoumi F, Zumla A, de Oliveira T, Mills EJ. Lancet Infect Dis. 2023 May;23(5):e185-e189. doi: 10.1016/S1473-3099(22)00723-X. Epub 2022 Dec 20. PMID: 36563700

Knowledge and confidence gains after a COVID-19 vaccine continuing education program developed for nurse practitioners.
Roberts EN, Carrico R, Garrett JH, Scalzo P. J Am Assoc Nurse Pract. 2023 May 8. doi: 10.1097/JXX.0000000000000871. Online ahead of print. PMID: 37159448

The severity of COVID-19 across the spectrum of HIV.
Miller KW, Gandhi RT. Curr Opin HIV AIDS. 2023 May 1;18(3):119-125. doi: 10.1097/COH.0000000000000791. Epub 2023 Mar 17. PMID: 37144613

The role of civic capital on vaccination.
Buonanno P, Galletta S, Puca M. Health Econ. 2023 May;32(5):993-999. doi: 10.1002/hec.4662. Epub 2023 Feb 11. PMID: 36772989

Recurrent generalized anhidrosis following COVID-19 vaccinations.
Kwon H, Lee HW, Lee H, Kim HA. Muscle Nerve. 2023 May;67(5):E12-E15. doi: 10.1002/mus.27810. Epub 2023 Mar 13. PMID: 36861924

COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity.
Gragnani L, Visentini M, Lorini S, Santini SA, Lauletta G, Mazzaro C, Urraro T, Quartuccio L, Cacciapaglia F, Ruscitti P, Tavoni A, Marri S, Cusano G, Petraccia L, Naclerio C, Treppo E, Del Frate G, Di Cola I, Raimondo V, Scorpiniti D, Monti M, Puccetti L, Elia G, Fallahi P, Basili S, Scarpato S, Iannone F, Casato M, Antonelli A, Zignego AL, Ferri C. J Clin Immunol. 2023 May;43(4):680-691. doi: 10.1007/s10875-023-01444-4. Epub 2023 Feb 16. PMID: 36795264

Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
Thomas MG, Dermawan A, Teh S. BMJ Case Rep. 2023 May 5;16(5):e251180. doi: 10.1136/bcr-2022-251180. PMID: 37147105

A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention.
Su P, Wu Y, Xie F, Zheng Q, Chen L, Liu Z, Meng X, Zhou F, Zhang L. Adv Sci (Weinh). 2023 May 5:e2206095. doi: 10.1002/advs.202206095. Online ahead of print. PMID: 37144543

Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
Lytras T, Athanasiadou M, Demetriou A, Stylianou D, Heraclides A, Kalakouta O. Vaccine. 2023 May 2;41(18):2941-2946. doi: 10.1016/j.vaccine.2023.03.032. Epub 2023 Apr 1. PMID: 37012116

Parental Perceptions Related to Co-Administration of Adolescent COVID-19 and Routine Vaccines.
Gidengil CA, Parker AM, Gedlinske AM, Askelson NM, Petersen CA, Lindley MC, Woodworth KR, Scherer AM. J Adolesc Health. 2023 May;72(5):667-673. doi: 10.1016/j.jadohealth.2022.11.242. Epub 2022 Dec 6. PMID: 36609120

Three years of COVID-19 and life satisfaction in Europe: A macro view.
Easterlin RA, O'Connor KJ. Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2300717120. doi: 10.1073/pnas.2300717120. Epub 2023 May 1. PMID: 37126673

COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance.
Tan SYS, Yee AM, Sim JJL, Lim CC. Rheumatology (Oxford). 2023 May 2;62(5):1757-1772. doi: 10.1093/rheumatology/keac604. PMID: 36271852

Fair domestic allocation of monkeypox virus countermeasures.
Persad G, Leland RJ, Ottersen T, Richardson HS, Saenz C, Schaefer GO, Emanuel EJ. Lancet Public Health. 2023 May;8(5):e378-e382. doi: 10.1016/S2468-2667(23)00061-0. PMID: 37120261

COVID-19 pandemic in prisons in Spain: characteristics of cases and implemented control measures, March 2020-June 2022.
Hernando V, Vázquez I, Díaz A, Gómez-Pintado P, Martínez-Aznar C, Acín E. Public Health. 2023 May;218:45-52. doi: 10.1016/j.puhe.2023.02.013. Epub 2023 Feb 22. PMID: 36965463

COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint.
Zaeck LM, GeurtsvanKessel CH, de Vries RD. Lancet Respir Med. 2023 May;11(5):395-396. doi: 10.1016/S2213-2600(23)00140-6. Epub 2023 Apr 17. PMID: 37080227

Utility of eConsults for COVID-19 vaccine-related concerns in Ontario: a cross-sectional analysis.
Walter G, Jeimy S, Liddy C, Guglani S, Ellis AK, Blair A, Kobayaa H, Chad Z, Keely E. Allergy Asthma Clin Immunol. 2023 May 4;19(1):38. doi: 10.1186/s13223-023-00789-0. PMID: 37143148

Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
Ma T, Chen X, Wang M. Chembiochem. 2023 May 2;24(9):e202200801. doi: 10.1002/cbic.202200801. Epub 2023 Mar 30. PMID: 36780174

COVID-19 Vaccination and the Incidence of De Novo or Recurrent Rheumatoid Arthritis: A French and International (VigiBase) Signal Detection Study.
Prontskus V, Fresse A, Yelehe-Okouma M, Facile A, Pietri T, Simon C, Le Souder C, Beurrier M, Gillet P; French network of Regional Pharmacovigilance Centres. Clin Pharmacol Ther. 2023 May;113(5):1107-1116. doi: 10.1002/cpt.2866. Epub 2023 Feb 27. PMID: 36752604

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.
De Cagna MR, Colucci V, Di Maggio A, Notaristefano N, Cianciotta F, Danza K, Salvatore F, Santoniccolo A, Lanzillotta SG, Perniola MA, Marangi AL, Morrone LFP, Tampoia M. Clin Exp Nephrol. 2023 May;27(5):445-453. doi: 10.1007/s10157-023-02317-1. Epub 2023 Feb 16. PMID: 36795176

Myotonic dystrophy type 1 in the COVID-19 era.
Ilic Zivojinovic J, Djurdjevic K, Bozovic I, Meola G, Peric M, Azanjac Arsic A, Basta I, Rakocevic-Stojanovic V, Peric S. Neurol Sci. 2023 May 8:1-7. doi: 10.1007/s10072-023-06834-5. Online ahead of print. PMID: 37155112

Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study.
Morello R, Mariani F, Mastrantoni L, De Rose C, Zampino G, Munblit D, Sigfrid L, Valentini P, Buonsenso D. EClinicalMedicine. 2023 May;59:101961. doi: 10.1016/j.eclinm.2023.101961. Epub 2023 Apr 14. PMID: 37073325

metaCOVID: A web-application for living meta-analyses of COVID-19 trials.
Evrenoglou T, Boutron I, Seitidis G, Ghosn L, Chaimani A. Res Synth Methods. 2023 May;14(3):479-488. doi: 10.1002/jrsm.1627. Epub 2023 Feb 20. PMID: 36772980

Understanding and Improving Vaccine Effectiveness Estimates in the Age of Widespread Background Immunity: A Step Toward Improved Science Communication.
Nirenberg E, Perencevich EN. Clin Infect Dis. 2023 May 3;76(9):1535-1538. doi: 10.1093/cid/ciad124. PMID: 36883583

Dietary intervention with functional foods modulating gut microbiota for improving the efficacy of COVID-19 vaccines.
Oh S, Seo H. Heliyon. 2023 May;9(5):e15668. doi: 10.1016/j.heliyon.2023.e15668. Epub 2023 Apr 21. PMID: 37124341

Predicting COVID-19 Vaccination Intention: The Roles of Institutional Trust, Perceived Vaccine Safety, and Interdependent Self-Construal.
Paredes MR, Apaolaza V, Marcos A, Hartmann P. Health Commun. 2023 May;38(6):1189-1200. doi: 10.1080/10410236.2021.1996685. Epub 2021 Nov 3. PMID: 34732090

Adolescent Self-Consent for COVID-19 Vaccination: Views of Healthcare Workers and Their Adolescent Children on Vaccination Autonomy.
Delgado JR, Mansfield LN, Bruxvoort K, Macias M, Grotts J, Lewin B, Bronstein D, Munoz-Plaza C, Szilagyi P, Chang J, Choi K. J Adolesc Health. 2023 May;72(5):674-681. doi: 10.1016/j.jadohealth.2022.12.018. Epub 2023 Feb 10. PMID: 36775750

Short term outcome of myocarditis and pericarditis following COVID-19 vaccines: a cardiac magnetic resonance imaging study.
Galea N, Cundari G, Di Dedda E, Chimenti C, Aquaro GD, Barison A, Cau R, Di Cesare E, Di Renzi P, Esposito A, Faletti R, Gatti M, Liguori C, Lovato L, Mantini C, Monti CB, Palmisano A, Pradella S, Ricci F, Saba L, Secchi F, Catalano C, Francone M. Int J Cardiovasc Imaging. 2023 May;39(5):1031-1043. doi: 10.1007/s10554-023-02799-w. Epub 2023 Mar 13. PMID: 36913155

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
Kemlin D, Gemander N, Depickère S, Olislagers V, Georges D, Waegemans A, Pannus P, Lemy A, Goossens ME, Desombere I, Michiels J, Vandevenne M, Heyndrickx L, Ariën KK, Matagne A, Ackerman ME, Le Moine A, Marchant A. Am J Transplant. 2023 May;23(5):649-658. doi: 10.1016/j.ajt.2023.02.015. Epub 2023 Feb 10. PMID: 36773936

COVID-19 Vaccine Uptake by Infection Status in New South Wales, Australia.
Gidding HF, Stepien S, Qian J, Macartney KK, Liu B. Emerg Infect Dis. 2023 May;29(5):1070-1073. doi: 10.3201/eid2905.230047. Epub 2023 Apr 4. PMID: 37015284

Informing the design of a whole of life immunisation register for Australia.
Kpozehouen EB, Heywood AE, Menzies R, Seale H, Brotherton J, Raina Macintyre C. Vaccine. 2023 May 5;41(19):3011-3018. doi: 10.1016/j.vaccine.2023.03.037. Epub 2023 Apr 8. PMID: 37037706

Current challenges and perspectives in lung cancer care during COVID-19 waves.
Mariniello DF, Aronne L, Vitale M, Schiattarella A, Pagliaro R, Komici K. Curr Opin Pulm Med. 2023 May 3. doi: 10.1097/MCP.0000000000000967. Online ahead of print. PMID: 37132294

CoronaVac, BNT162b2 and heterologous COVID-19 vaccine and ventricular assist device: Correspondence.
Kleebayoon A, Wiwanitkit V. Int J Artif Organs. 2023 May;46(5):255. doi: 10.1177/03913988221150271. Epub 2023 Jan 16. PMID: 36645140

Incidence, features, and outcome of disease relapse after COVID-19 vaccination in patients with idiopathic inflammatory myopathies.
Nagy-Vincze M, Béldi T, Szabó K, Vincze A, Miltényi-Szabó B, Varga Z, Varga J, Griger Z. Muscle Nerve. 2023 May;67(5):371-377. doi: 10.1002/mus.27811. Epub 2023 Mar 15. PMID: 36879542

Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, Khamesipour A, Jalali T, Nakhaeizadeh M, Sharifi H, Mansoori Y, Keramat F, Ghodrati S, Javanian M, Doroud D, Omrani MD, Asadi H, Pouriayevali MH, Ghasemian R, Farshidi H, Pourahmad M, Ghasemzadeh I, Mounesan L, Darvishian M, Mirjalili MR, Toledo-Romani ME, Valenzuela-Silva C, Verez-Bencomo V, Gouya MM, Emadi-Koochak H, Haghdoost AA, Biglari A; Soberana Study Group. JAMA Netw Open. 2023 May 1;6(5):e2310302. doi: 10.1001/jamanetworkopen.2023.10302. PMID: 37133864

Impact of nutraceuticals on immunomodulation against viral infections-A review during COVID-19 pandemic in Indian scenario.
Nathan J, Shameera R, Ramachandran A. J Biochem Mol Toxicol. 2023 May;37(5):e23320. doi: 10.1002/jbt.23320. Epub 2023 Feb 17. PMID: 36799127

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA, Sonneveld P, Ludwig H. Leukemia. 2023 May 4:1-11. doi: 10.1038/s41375-023-01920-1. Online ahead of print. PMID: 37142661

Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth.
Heffernan ME, Bendelow A, Kociolek LK, Smith TL, Menker CG, Davis MM. Pediatrics. 2023 May 5:e2022059191. doi: 10.1542/peds.2022-059191. Online ahead of print. PMID: 37144291

What has vaccination against COVID-19 in CKD patients taught us?
Rossi M, Pessolano G, Gambaro G. J Nephrol. 2023 May 4:1-10. doi: 10.1007/s40620-023-01640-w. Online ahead of print. PMID: 37140817

Factors associated with COVID-19 vaccination likelihood during pregnancy.
Wainstock T, Sergienko R, Orenshtein S, Sheiner E. Int J Gynaecol Obstet. 2023 May;161(2):478-484. doi: 10.1002/ijgo.14680. Epub 2023 Feb 4. PMID: 36651802

Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series.
Pillar S, Weinberg T, Amer R. Int Ophthalmol. 2023 May;43(5):1677-1686. doi: 10.1007/s10792-022-02565-2. Epub 2022 Oct 31. PMID: 36316618

Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand.
Rattanavipapong W, Poonsiri C, Isaranuwatchai W, Iamsirithaworn S, Apakupakul J, Sonthichai C, Kitphati R, Teerawattananon Y. Appl Health Econ Health Policy. 2023 May;21(3):511-522. doi: 10.1007/s40258-023-00796-7. Epub 2023 Mar 16. PMID: 36928779

Effect of COVID-19 vaccinations on menstrual cycle and postmenopausal bleeding among health care workers: A cross-sectional study.
Farah S, Hijazi M, Aoun E, Boueri M, Nasr E, Chlala W, Salem MJ, Moufawad G, Farah D, El Hayek P, Jallad K, Ghaname W, Ziadeh H. Int J Gynaecol Obstet. 2023 May 3. doi: 10.1002/ijgo.14809. Online ahead of print. PMID: 37132636

High Uptake of Three COVID-19 Vaccine Doses Among Liver Transplant Recipients.
Schell TL, Mailig MA, Almasry M, Lazarus S, Richard LJ, Tippins K, Weiss J, Hayney MS, Caldera F. Dig Dis Sci. 2023 May;68(5):2158-2160. doi: 10.1007/s10620-023-07902-8. Epub 2023 Mar 25. PMID: 36964862

Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
Payne JR, Bose S, Kubiak RW, Nolen LD. Vaccine. 2023 May 2;41(18):2996-3002. doi: 10.1016/j.vaccine.2023.03.072. Epub 2023 Apr 5. PMID: 37037710

Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines.
Bolhassani A. Mol Biotechnol. 2023 May;65(5):669-698. doi: 10.1007/s12033-022-00624-8. Epub 2022 Dec 3. PMID: 36462102

A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey.
Yılmaz D, Üstündağ G, Büyükçam A, Salı E, Çelik Ü, Avcu G, Belet N, Çakmak Taşkın E, Öcal Demir S, Birbilen AZ, Kılıç Ö, Metin Akcan Ö, Tekin Yılmaz A, Aldemir Kocabaş B, Hatipoğlu N, Karbuz A, Çakır D, Sütçü M, Aygün FD, Çelik T, Bayturan Şen S, Dalgıç N, Ümit Z, Kara SS, Karadağ Öncel E, Bolat A, Kılıç Çil M, Turan C, Çakıl Güzin A, Topal S, Esen Besli G, Doğan G, Şahin S, Akın F, Bildirici Y, Timurtaş Dayar G, Ergül Sarı E, Kızmaz İşançlı D, Kara M, Önal P, Aylaç H, Lüleci D, Yaşar B, Dede E, Çağlar A, Akova S, Afat Turgut E, Yazıcı Özkaya P, Kandemir Gülmez T, Ulusoy E, Duyu M, Kara Y, Çeliktaş H, Tekeli O, Çağlar F, Gül D, Oral Cebeci S, Battal F, Bal A, Aygün E, Uysalol M, Arslan G, Özkavaklı A, Kızıl MC, Yazar A, Aygün F, Somer A, Kuyucu N, Dinleyici EÇ, Kara A. Eur J Pediatr. 2023 May 4:1-12. doi: 10.1007/s00431-023-04982-6. Online ahead of print. PMID: 37140703

Brain gene therapy with Trojan horse lipid nanoparticles.
Pardridge WM. Trends Mol Med. 2023 May;29(5):343-353. doi: 10.1016/j.molmed.2023.02.004. Epub 2023 Mar 11. PMID: 36907687

Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
Santi Laurini G, Montanaro N, Motola D. Eur J Clin Pharmacol. 2023 May;79(5):657-661. doi: 10.1007/s00228-023-03482-8. Epub 2023 Mar 24. PMID: 36961579

Virtual communication training to address COVID-19 vaccine hesitancy.
Real FJ, Meisman A, Rosen BL. Med Educ. 2023 May;57(5):477-478. doi: 10.1111/medu.15061. Epub 2023 Feb 28. PMID: 36855282

COVID-19 Vaccination Perceptions in Patients With Rheumatic Disease: A Cross-Sectional Online Survey.
Butt IN, van Eeden C, Burns KK, Saxinger L, Clifford A, Tervaert JWC, Yacyshyn EA. J Rheumatol. 2023 May;50(5):690-696. doi: 10.3899/jrheum.220765. Epub 2022 Dec 15. PMID: 36521919

The Initial Relationship Between the United States Department of Health and Human Services' Digital COVID-19 Public Education Campaign and Vaccine Uptake: Campaign Effectiveness Evaluation.
Williams CJ, Kranzler EC, Luchman JN, Denison B, Fischer S, Wonder T, Ostby R, Vines M, Weinberg J, Petrun Sayers EL, Kurti AN, Trigger S, Hoffman L, Peck JFA. J Med Internet Res. 2023 May 3;25:e43873. doi: 10.2196/43873. PMID: 36939670

Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy.
Placke JM, Mertens D, Tasdogan A, Chorti E, Schadendorf D, Ugurel S, Roesch A, Stoffels I, Klode J. J Eur Acad Dermatol Venereol. 2023 May;37(5):907-913. doi: 10.1111/jdv.18847. Epub 2023 Jan 18. PMID: 36606548

Role of Parents' Perceived Risk and Responsibility in Deciding on Children's COVID-19 Vaccination.
Liu Y, Bruine de Buin W, Kapteyn A, Szilagyi PG. Pediatrics. 2023 May 1;151(5):e2022058971. doi: 10.1542/peds.2022-058971. PMID: 37051781

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, Indenbaum V, Halpern O, Katz-Likvornik S, Levin T, Kanaaneh Y, Asraf K, Amit S, Rubin C, Ziv A, Koren R, Mandelboim M, Tokayer NH, Meltzer L, Doolman R, Mendelson E, Alroy-Preis S, Kreiss Y. Lancet Microbe. 2023 May;4(5):e309-e318. doi: 10.1016/S2666-5247(23)00012-5. Epub 2023 Mar 21. PMID: 36963419

Supporting US healthcare providers for successful vaccine communication.
Pierz AJ, Rauh L, Masoud D, Cruz AK, Palmedo PC, Ratzan SC, Parker R. BMC Health Serv Res. 2023 May 2;23(1):423. doi: 10.1186/s12913-023-09348-0. PMID: 37131261

Study of covid-19 vaccine-related cutaneous adverse events following immunization and establishing a causal association.
Sharma R. J Eur Acad Dermatol Venereol. 2023 May;37(5):e576-e577. doi: 10.1111/jdv.18891. Epub 2023 Jan 31. PMID: 36662656

Increased incidence of Graves' disease during the SARS-CoV2 pandemic.
Barajas Galindo DE, Ramos Bachiller B, González Roza L, García Ruiz de Morales JM, Sánchez Lasheras F, González Arnáiz E, Ariadel Cobo D, Ballesteros Pomar MD, Rodríguez IC. Clin Endocrinol (Oxf). 2023 May;98(5):730-737. doi: 10.1111/cen.14860. Epub 2022 Dec 30. PMID: 36510647

Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.
Assantachai P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, Muangpaisan W, Phannarus H, Saichompoo RB, Sura-Amonrattana U, Wongprompitak P, Toh ZQ, Licciardi PV, Srisutthisamphan K, Chokephaibulkit K. J Infect Dis. 2023 May 4:jiad133. doi: 10.1093/infdis/jiad133. Online ahead of print. PMID: 37141388

What contributes to COVID-19 online disinformation among Black Canadians: a qualitative study.
Kemei J, Alaazi DA, Olanlesi-Aliu A, Tunde-Byass M, Sekyi-Otu A, Mohamud H, Salami B. CMAJ Open. 2023 May 2;11(3):E389-E396. doi: 10.9778/cmajo.20220197. Print 2023 May-Jun. PMID: 37130607

Editorial for "Cardiac Magnetic Resonance Imaging Findings in COVID-19 Vaccine-Related Myocarditis: A Pooled Analysis of 468 Patients".
Bart NK. J Magn Reson Imaging. 2023 May;57(5):1531-1532. doi: 10.1002/jmri.28412. Epub 2022 Aug 31. PMID: 36043520

The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
Urquidi C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, Larrañaga N, Gonzalez E, Pavez A, Wosiack A, Maturana M, Moller P, Pablo Torres J, Muñoz S, O'Ryan G M. Vaccine. 2023 May 2;41(18):2947-2955. doi: 10.1016/j.vaccine.2023.03.060. Epub 2023 Apr 3. PMID: 37024408

Covid-19 vaccines and investment performance: Evidence from equity funds in European Union.
Mirza N, Umar M, Mangafic J. Financ Res Lett. 2023 May;53:103650. doi: 10.1016/j.frl.2023.103650. Epub 2023 Jan 18. PMID: 36686060

Nanotechnology-based diagnostic methods for coronavirus: From nucleic acid extraction to amplification.
Huang X, Fu R, Qiao S, Zhang J, Xianyu Y. Biosens Bioelectron X. 2023 May;13:100289. doi: 10.1016/j.biosx.2022.100289. Epub 2022 Dec 10. PMID: 36530849

Spatio-temporal heterogeneity in the international trade resilience during COVID-19.
Luo W, He L, Yang Z, Zhang S, Wang Y, Liu D, Hu S, He L, Xia J, Chen M. Appl Geogr. 2023 May;154:102923. doi: 10.1016/j.apgeog.2023.102923. Epub 2023 Mar 9. PMID: 36915293

The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
Maquiling A, Jeevakanthan A, Ho Mi Fane B. Vaccine. 2023 May 2;41(18):2932-2940. doi: 10.1016/j.vaccine.2023.03.040. Epub 2023 Apr 3. PMID: 37019696

Champions for School Health-An NASN Initiative to Increase Vaccine Confidence, Equity, and Uptake in COVID-19 and School-Required Vaccinations: Part 1.
D'Souza-Vazirani D, Walsh C, Tanner AL, Clark E, Griffin AR, White S. NASN Sch Nurse. 2023 May;38(3):125-130. doi: 10.1177/1942602X231165693. Epub 2023 Apr 12. PMID: 37042123

Effect of female coronavirus disease 2019 vaccination on assisted reproductive outcomes: a systematic review and meta-analysis.
Huang J, Fang Z, Liu Y, Xing C, Huang L, Mao J, Chen H, Huang Z, Xia L, Tang L, Zhang Z, Liu B, Huang H, Tian L, Ai X, Wu Q. Fertil Steril. 2023 May;119(5):772-783. doi: 10.1016/j.fertnstert.2023.01.024. Epub 2023 Jan 23. PMID: 36702343

Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients.
Luxenburger H, Reeg DB, Lang-Meli J, Reinscheid M, Eisner M, Bettinger D, Oberhardt V, Salimi Alizei E, Wild K, Graeser A, Karl V, Sagar, Emmerich F, Klein F, Panning M, Huzly D, Bengsch B, Boettler T, Elling

R, Thimme R, Hofmann M, Neumann-Haefelin C. J Hepatol. 2023 May;78(5):1017-1027. doi: 10.1016/j.jhep.2023.02.007. Epub 2023 Feb 18. PMID: 36804404

Quality of MedDRA® Coding in a Sample of COVID-19 Vaccine Medication Error Data.
Kralova K, Wilson CA, Richebourg N, D'souza J. Drug Saf. 2023 May;46(5):501-507. doi: 10.1007/s40264-023-01294-4. Epub 2023 Apr 23. PMID: 37087705

Authentication of Covid-19 Vaccines Using Synchronous Fluorescence Spectroscopy.
Assi S, Abbas I, Arafat B, Evans K, Al-Jumeily D. J Fluoresc. 2023 May;33(3):1165-1174. doi: 10.1007/s10895-022-03136-5. Epub 2023 Jan 7. PMID: 36609659

COVID-19 Vaccination Clinic for Individuals With Autism Spectrum Disorder and Related Disorders: Feasibility and Acceptability.
Pavlov A, Hodnett JM, Booth C, Wigton S, Bernstein A, Lomas Mevers J, Scheithauer M. J Am Psychiatr Nurses Assoc. 2023 May 9:10783903231172997. doi: 10.1177/10783903231172997. Online ahead of print. PMID: 37160762

Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.
Wang D, Yuan Y, Liu B, Epstein ND, Yang Y. Int J Biol Macromol. 2023 May 1;236:123979. doi: 10.1016/j.ijbiomac.2023.123979. Epub 2023 Mar 10. PMID: 36907305

COVID-19 disease and vaccination in pregnancy: understanding knowledge, perceptions and experiences among pregnant women and community leaders in Uganda.
Nalubega P, Namugumya R, Zalwango F, Ssali A, Mboizi R, Hookham L, Seeley J, Le Doare K. Trans R Soc Trop Med Hyg. 2023 May 3:trad028. doi: 10.1093/trstmh/trad028. Online ahead of print. PMID: 37132467

Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.
Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, Yip D, Bacon SL. Lancet Respir Med. 2023 May;11(5):439-452. doi: 10.1016/S2213-2600(23)00015-2. Epub 2023 Feb 10. PMID: 36780914

The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases.
Retnakumar SV, Chauvin C, Bayry J. Pharmacol Ther. 2023 May;245:108399. doi: 10.1016/j.pharmthera.2023.108399. Epub 2023 Mar 30. PMID: 37001736

Cascading failures in COVID-19 vaccine equity.
Lavery JV, Porter RM, Addiss DG. Science. 2023 May 5;380(6644):460-462. doi: 10.1126/science.add5912. Epub 2023 May 4. PMID: 37141365

[Suspicion of allergy to anti-COVID-19 vaccines].
Kleebayoon A, Wiwanitkit V. Rev Fr Allergol (2009). 2023 May;63(4):103616. doi: 10.1016/j.reval.2023.103616. Epub 2023 Feb 22. PMID: 36844189

Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort.
Gaborit B, Fernandes S, Loubet P, Ninove L, Dutour A, Cariou B, Coupaye M, Clement K, Czernichow S, Carette C, Resseguier N, Esterle L, Kali S, Houssays M, de Lamballerie X, Wittkop L, Launay O, Laville M; ANRS0001S COV-POPART study group. Metabolism. 2023 May;142:155412. doi: 10.1016/j.metabol.2023.155412. Epub 2023 Jan 31. PMID: 36731720

COVID-19 Vaccination Experiences of Family Caregivers of Persons Living with Dementia in Rural Appalachia.
Savla J, Roberto KA, McCann BR, Blieszner R. J Appl Gerontol. 2023 May;42(5):821-831. doi: 10.1177/07334648221147916. Epub 2022 Dec 24. PMID: 36565159

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.
Murray SM, Ansari AM, Frater J, Klenerman P, Dunachie S, Barnes E, Ogbe A. Nat Rev Immunol. 2023 May;23(5):304-316. doi: 10.1038/s41577-022-00809-x. Epub 2022 Dec 20. PMID: 36539527

Has COVID-19 Changed Pediatric Acute Rhinosinusitis Epidemiology During the First 2 Pandemic Years?
Hazan I, Ziv O, Marom T, Zloczower E, Pitaro J, Warman M. Pediatr Infect Dis J. 2023 May 1;42(5):412-417. doi: 10.1097/INF.0000000000003856. Epub 2023 Feb 14. PMID: 36795587

Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.
Aguinam ET, Nadesalingam A, Chan A, Smith P, Paloniemi M, Cantoni D, Gronlund J, Gronlund H, Carnell GW, Castillo-Olivares J, Temperton N, Blacklaws B, Heeney JL, Baxendale H. J Allergy Clin Immunol Glob. 2023 May;2(2):100091. doi: 10.1016/j.jacig.2023.100091. Epub 2023 Mar 15. PMID: 37038555

Acceptability of COVID-19 vaccination in Chinese children aged 3-7 years with bronchopulmonary dysplasia.
Wang D, Li L, Cao J, Hu S, Liu C, Feng Z, Li Q. Pediatr Pulmonol. 2023 May;58(5):1417-1426. doi: 10.1002/ppul.26336. Epub 2023 Feb 8. PMID: 36717531

Stroke After SARS-CoV-2 mRNA Vaccine: A Nationwide Registry Study.
Ihle-Hansen H, Bøås H, Tapia G, Hagberg G, Ihle-Hansen H, Berild JD, Selmer R, Karlstad Ø, Gulseth HL, Ariansen I. Stroke. 2023 May;54(5):e190-e193. doi: 10.1161/STROKEAHA.122.040430. Epub 2023 Mar 30. PMID: 36994734

Updated WHO Guidance for Prioritizing COVID-19 Vaccines.
Harris E. JAMA. 2023 May 2;329(17):1444. doi: 10.1001/jama.2023.6256. PMID: 37043255

Belief in COVID-19 Conspiracy Theories, Level of Trust in Government Information, and Willingness to Take COVID-19 Vaccines Among Health Care Workers in Nigeria: Survey Study.
Oyeyemi SO, Fagbemi S, Busari II, Wynn R. JMIR Form Res. 2023 May 2;7:e41925. doi: 10.2196/41925. PMID: 37068055

Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness.

Dalton AF, Weber ZA, Allen KS, Stenehjem E, Irving SA, Spark TL, Adams K, Zerbo O, Lazariu V, Dixon BE, Dascomb K, Hartmann E, Kharbanda AB, Ong TC, DeSilva MB, Beaton M, Gaglani M, Patel P, Naleway AL, Kish MNS, Grannis SJ, Grisel N, Sloan-Aagard C, Rao S, Raiyani C, Dickerson M, Bassett E, Fadel WF, Arndorfer J, Nanez J, Barron MA, Vazquez-Benitez G, Liao IC, Griggs EP, Reese SE, Valvi NR, Murthy K, Rowley EAK, Embi PJ, Ball S, Link-Gelles R, Tenforde MW. Clin Infect Dis. 2023 May 3;76(9):1615-1625. doi: 10.1093/cid/ciad003. PMID: 36611252

Risk assessment of retinal vascular occlusion after COVID-19 vaccination.
Li JX, Wang YH, Bair H, Hsu SB, Chen C, Wei JC, Lin CJ. NPJ Vaccines. 2023 May 2;8(1):64. doi: 10.1038/s41541-023-00661-7. PMID: 37130882

Disparities in Implementing COVID-19 Prevention Strategies in Public Schools, United States, 2021-22 School Year.
Pampati S, Rasberry CN, Timpe Z, McConnell L, Moore S, Spencer P, Lee S, Murray CC, Adkins SH, Conklin S, Deng X, Iachan R, Tripathi T, Barrios LC. Emerg Infect Dis. 2023 May;29(5):937-944. doi: 10.3201/eid2905.221533. Epub 2023 Mar 29. PMID: 36990463

Equity Considerations in COVID-19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases.
Wang H, Dewidar O, Whittle SL, Ghogomu E, Hazlewood G, Leder K, Mbuagbaw L, Pardo Pardo J, Robinson PC, Buchbinder R, Welch V. Arthritis Care Res (Hoboken). 2023 May;75(5):967-974. doi: 10.1002/acr.25034. Epub 2022 Dec 7. PMID: 36194078

Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform.
Nab L, Parker EPK, Andrews CD, Hulme WJ, Fisher L, Morley J, Mehrkar A, MacKenna B, Inglesby P, Morton CE, Bacon SCJ, Hickman G, Evans D, Ward T, Smith RM, Davy S, Dillingham I, Maude S, Butler-Cole BFC, O'Dwyer T, Stables CL, Bridges L, Bates C, Cockburn J, Parry J, Hester F, Harper S, Zheng B, Williamson EJ, Eggo RM, Evans SJW, Goldacre B, Tomlinson LA, Walker AJ; OpenSAFELY Collaborative. Lancet Public Health. 2023 May;8(5):e364-e377. doi: 10.1016/S2468-2667(23)00079-8. PMID: 37120260

Vaccination recommendations for bivalent mRNA COVID-19 vaccines.
[No authors listed] Med Lett Drugs Ther. 2023 May 1;65(1675):e1. doi: 10.58347/tml.2023.1667f. PMID: 37155253

High incidence of multisystem inflammatory syndrome and other autoimmune diseases after SARS-CoV-2 infection compared to COVID-19 vaccination in children and adolescents in south central Europe.
Bizjak M, Emeršič N, Zajc Avramovič M, Barbone F, Ronchese F, Della Paolera S, Conversano E, Amoroso S, Vidoni M, Vesel Tajnšek T, Mlakar G, Berce V, Markelj G, Plankar Srovin T, Golli T, Osredkar D, Koren Jeverica A, Toplak N, Pokorn M, Avšič Županc T, Ihan A, Fafangel M, Taddio A, Avčin T. Clin Exp Rheumatol. 2023 May;41(5):1183-1191. doi: 10.55563/clinexprheumatol/i1l2xn. Epub 2022 Nov 12. PMID: 36377567

[Immunosuppressed people's beliefs, expectations, and experiences with COVID-19 vaccinations : Results of a longitudinal study].

Müller F, Heinemann S, Hummers E, Noack EM, Heesen G, Dopfer-Jablonka A, Mikuteit M, Niewolik J, Steffens S, Schröder D. Z Rheumatol. 2023 May;82(4):342-354. doi: 10.1007/s00393-022-01213-5. Epub 2022 May 6. PMID: 35523964

Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose.
Kühn T, Speer C, Morath C, Bartenschlager M, Kim H, Beimler J, Buylaert M, Nusshag C, Kälble F, Reineke M, Töllner M, Klein K, Blank A, Parthé S, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Tran TH, Schaier M, Benning L. Transplantation. 2023 May 1;107(5):1139-1150. doi: 10.1097/TP.0000000000004516. Epub 2023 Jan 9. PMID: 36617671

Gadolinium changes detected on cardiovascular magnetic resonance imaging following COVID-19 vaccine-related myocarditis in adolescents.
Kleebayoon A, Wiwanitkit V. Pediatr Radiol. 2023 May;53(5):1041. doi: 10.1007/s00247-023-05613-w. Epub 2023 Feb 9. PMID: 36757489

Knowledge, attitudes, and behaviors with mask use and vaccines for COVID-19 prevention at 13 colleges and universities, April 2021.
Riggs MA, Madni SA, Cornelius J, Zhang A, Czarnik M, Zullig K, Bensley RJ, Gibson-Young L, Gardner M, Waggett CE, Grabeel V, Pettyjohn SJ, Fisher C, Jones RM, Maniccia DM, Doyle J, Treuth M, Neatherlin J, Thomas E, Barrios L. J Am Coll Health. 2023 May 2:1-11. doi: 10.1080/07448481.2022.2122719. Online ahead of print. PMID: 37130266

Sputnik V vaccine-related complications and its impression on inflammatory biomarkers in healthcare providers.
Akrami M, Hosamirudsari H, Faraji N, Behnush B, Goudarzi F, Hesari E, Akbarpour S, Najafi A, Nateghi S. Indian J Med Microbiol. 2023 May-Jun;43:79-84. doi: 10.1016/j.ijmmb.2022.10.012. Epub 2022 Nov 7. PMID: 36357266

An outpatient model of care for COVID-19 infected kidney transplant patients - The hospital-at-home.
Liew IT, Tan WJM, Ho QY, Chung SJ, Thangaraju S, Yong J, Ng E, He X, Kwan N, Kee T. Nephrology (Carlton). 2023 May;28(5):283-291. doi: 10.1111/nep.14155. Epub 2023 Mar 11. PMID: 36872077

Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions.
Fonseca EMD, Shadlen KC, Achcar HM. Res Policy. 2023 May;52(4):104739. doi: 10.1016/j.respol.2023.104739. Epub 2023 Feb 8. PMID: 36785560

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines.
Kandeel M, Morsy MA, Abd El-Lateef HM, Marzok M, El-Beltagi HS, Al Khodair KM, Albokhadaim I, Venugopala KN. Int Immunopharmacol. 2023 May;118:109998. doi: 10.1016/j.intimp.2023.109998. Epub 2023 Mar 29. PMID: 37004348

The relationship between COVID-19 vaccines and increased blood pressure: A word of caution.
Buso G, Agabiti-Rosei C, Muiesan ML. Eur J Intern Med. 2023 May;111:27-29. doi: 10.1016/j.ejim.2023.03.002. Epub 2023 Mar 6. PMID: 36914539

Is the COVID-19 bad news game good news? Testing whether creating and disseminating fake news about vaccines in a computer game reduces people's belief in anti-vaccine arguments.
Rędzio AM, Izydorczak K, Muniak P, Kulesza W, Doliński D. Acta Psychol (Amst). 2023 May 1;236:103930. doi: 10.1016/j.actpsy.2023.103930. Online ahead of print. PMID: 37146384

Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy.
Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, Sullivan D, Paneth N, Focosi D. Expert Rev Respir Med. 2023 May 2:1-15. doi: 10.1080/17476348.2023.2208349. Online ahead of print. PMID: 37129285

Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
Hulme WJ, Williamson E, Horne EMF, Green A, McDonald HI, Walker AJ, Curtis HJ, Morton CE, MacKenna B, Croker R, Mehrkar A, Bacon S, Evans D, Inglesby P, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Tomlinson L, Douglas IJ, Evans SJW, Smeeth L, Palmer T, Goldacre B, Hernán MA, Sterne JAC. Ann Intern Med. 2023 May 2:M21-4269. doi: 10.7326/M21-4269. Online ahead of print. PMID: 37126810

Predictors and barriers to vaccination among older Syrian refugees in Lebanon: a cross-sectional analysis of a multi-wave longitudinal study.
Abi Zeid B, El Khoury T, Ghattas H, Alawieh MF, Ramadan Z, Anouti S, Abdulrahim S, McCall SJ. Lancet Healthy Longev. 2023 May;4(5):e219-e227. doi: 10.1016/S2666-7568(23)00038-7. PMID: 37148894

Influenza prevalence and vaccine efficacy among diabetic patients in Qatar.
Thomas S, Emara MM, Ouhtit A, Nader JD, Nasrallah GK, Coyle PV, Althani AA, Al Maslamani MA, Yassine HM. J Infect Public Health. 2023 May;16(5):808-815. doi: 10.1016/j.jiph.2023.03.011. Epub 2023 Mar 14. PMID: 36996614

Are the thorax Computed Tomography findings of ICU patients diagnosed with COVID-19 pneumonia related to the duration of hospital stay and mortality?
Topal Ü, Yılmaz G, Şahin AS. J Infect Chemother. 2023 May;29(5):495-501. doi: 10.1016/j.jiac.2022.12.016. Epub 2023 Jan 7. PMID: 36627082

Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity.
Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, Liu B, Ma X, Zhao F, Jiang H, Chen C, Shen H, Li H, Mathews DH, Zhang Y, Huang L. Nature. 2023 May 2. doi: 10.1038/s41586-023-06127-z. Online ahead of print. PMID: 37130545

China Needs Evidence-Based COVID Vaccines, and Its Government Now Has a Political Opening to Provide Them.
Sabet C, Hammond A, Jain B, Zhang T. J Public Health Manag Pract. 2023 May-Jun 01;29(3):281-283. doi: 10.1097/PHH.0000000000001731. Epub 2023 Mar 1. PMID: 36867518

Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population.
Genç Bahçe Y, Acer Ö, Özüdoğru O. Curr Microbiol. 2023 May 9;80(6):206. doi: 10.1007/s00284-023-03322-z. PMID: 37160453

Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes.
Hui L, Marzan MB, Rolnik DL, Potenza S, Pritchard N, Said JM, Palmer KR, Whitehead CL, Sheehan PM, Ford J, Mol BW, Walker SP. Am J Obstet Gynecol. 2023 May;228(5):585.e1-585.e16. doi: 10.1016/j.ajog.2022.10.040. Epub 2022 Nov 3. PMID: 36336084

Pain paths among post-COVID-19 condition subjects: A prospective cross-sectional study with in-person evaluation.
Kubota GT, Soares FHC, da Fonseca AS, Rosa TDS, da Silva VA, Gouveia GR, Faria VG, da Cunha PHM, Brunoni AR, Teixeira MJ, de Andrade DC. Eur J Pain. 2023 May;27(5):636-650. doi: 10.1002/ejp.2094. Epub 2023 Mar 7. PMID: 36799447

Lipid nanoparticle-mediated drug delivery to the brain.
Khare P, Edgecomb SX, Hamadani CM, E L Tanner E, Manickam DS. Adv Drug Deliv Rev. 2023 May 5:114861. doi: 10.1016/j.addr.2023.114861. Online ahead of print. PMID: 37150326

Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients.
Graninger M, Stumpf J, Bond G, Görzer I, Springer DN, Kessel F, Kröger H, Frank K, Tonn T, Hugo C, Puchhammer-Stöckl E. J Clin Virol. 2023 May;162:105428. doi: 10.1016/j.jcv.2023.105428. Epub 2023 Mar 24. PMID: 36989730

Determinants of COVID-19 vaccine hesitancy among pregnant persons.
Ramonfaur D, Hinojosa-González DE, Rodríguez RG, Melchor AL, Rodríguez-Ramírez A, Rodríguez-Gómez GP, Cantú-Santos M, Fernández-Gómez A. J Am Pharm Assoc (2003). 2023 May 4:S1544-3191(23)00142-5. doi: 10.1016/j.japh.2023.05.002. Online ahead of print. PMID: 37149143

'Getting the vaccine makes me a champion of it': Exploring perceptions towards peer-to-peer communication about the COVID-19 vaccines amongst Australian adults.
Karras J, Harrison M, Seale H. Health Expect. 2023 May 3. doi: 10.1111/hex.13751. Online ahead of print. PMID: 37132297

Dosing recommendations for Novavax and Johnson & Johnson vaccine COVID-19 vaccines.
[No authors listed] Med Lett Drugs Ther. 2023 May 1;65(1675):e1. doi: 10.58347/tml.2023.1667g. PMID: 37155254

Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
Fadlyana E, Setiabudi D, Kartasasmita CB, Putri ND, Rezeki Hadinegoro S, Mulholland K; BCOV21 study group. Lancet Infect Dis. 2023 May;23(5):545-555. doi: 10.1016/S1473-3099(22)00800-3. Epub 2023 Jan 11. PMID: 36640798

Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients.

Overheu O, Lendowski S, Quast DR, Marheinecke CS, Kourti E, Lugnier C, Andreica I, Kiltz U, Pfaender S, Reinacher-Schick A. J Cancer Res Clin Oncol. 2023 May;149(5):1985-1992. doi: 10.1007/s00432-022-04099-7. Epub 2022 Jun 22. PMID: 35731276

Tracking the Influence of Misinformation on Elderly People's Perceptions and Intention to Accept COVID-19 Vaccines.
Chia SC, Lu F, Sun Y. Health Commun. 2023 May;38(5):855-865. doi: 10.1080/10410236.2021.1980251. Epub 2021 Sep 23. PMID: 34555979

Indian microbiology EQAS registered laboratory's capacity building and infection control practices during the COVID-19 pandemic in India: Lessons learnt and gaps identified.
Murugesan M, Raveendran R, Kannangai R, Ramasamy J, Ray P, Gope M, Natarajan V, Walia K, Wattal C, Veeraraghavan B. Indian J Med Microbiol. 2023 May-Jun;43:51-57. doi: 10.1016/j.ijmmb.2022.09.009. Epub 2022 Oct 17. PMID: 36266150

What are the key pediatric public policy priorities as the COVID-19 pandemic persists?
Schleiss MR, Permar SR, John CC. Pediatr Res. 2023 May;93(6):1451-1455. doi: 10.1038/s41390-023-02529-x. Epub 2023 Feb 25. PMID: 36841882

Effect of psychological factors on COVID-19 vaccine hesitancy.
Kim HJ, Kim E, Han DH. J Public Health (Oxf). 2023 May 5:fdad050. doi: 10.1093/pubmed/fdad050. Online ahead of print. PMID: 37147915

COVID-19 and Vaccination Status in Lysosomal Storage Diseases: A Single-Center Experience.
Yoldaş Çelik M, Canda E, Yazıcı H, Erdem F, Yazıcı Özkaya P, Bal Sahbudak Z, Kalkan Uçar S, Çoker M. Turk Arch Pediatr. 2023 May;58(3):262-267. doi: 10.5152/TurkArchPediatr.2023.22233. PMID: 37144258

COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study.
Ogasawara F, Yoshida S, Yamane M, Takamatsu K, Arakawa Y, Nishida Y, Komatsu M, Yokoyama A, Yamagishi Y, Kojima K. Intern Med. 2023 May 1;62(9):1265-1271. doi: 10.2169/internalmedicine.1252-22. Epub 2023 Feb 15. PMID: 36792189

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications.
Cook CE, Patel NJ, Fu X, Wang X, Kawano Y, Vanni KMM, Qian G, Banasiak E, Kowalski E, Choi HK, Zhang Y, Sparks JA, Wallace ZS. J Rheumatol. 2023 May;50(5):697-703. doi: 10.3899/jrheum.220870. Epub 2023 Jan 15. PMID: 36642428

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.
Nouailles G, Adler JM, Pennitz P, Peidli S, Teixeira Alves LG, Baumgardt M, Bushe J, Voss A, Langenhagen A, Langner C, Martin Vidal R, Pott F, Kazmierski J, Ebenig A, Lange MV, Mühlebach MD, Goekeri C, Simmons S, Xing N, Abdelgawad A, Herwig S, Cichon G, Niemeyer D, Drosten C, Goffinet C, Landthaler M, Blüthgen N, Wu H, Witzenrath M, Gruber AD, Praktiknjo SD, Osterrieder N, Wyler E, Kunec D, Trimpert J. Nat Microbiol. 2023 May;8(5):860-874. doi: 10.1038/s41564-023-01352-8. Epub 2023 Apr 3. PMID: 37012419

COVID-19 Booster Vaccination Bellwethers: Factors Predictive of Older Adults' Adoption of the Second Booster COVID-19 Vaccine in Israel: A Longitudinal Study.
Ben-David BM, Keisari S, Regev T, Palgi Y. J Appl Gerontol. 2023 May;42(5):1113-1117. doi: 10.1177/07334648221145837. Epub 2023 Feb 16. PMID: 36794638

Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned.
Khawaja F, Srinivasan K, Spallone A, Feldman A, Cantu S, Ariza-Heredia E, Dvordak T, Alousi A, Ahmed S, George M, Frenzel E, Bhatti M, Chemaly RF. Am J Infect Control. 2023 May;51(5):506-513. doi: 10.1016/j.ajic.2022.07.019. Epub 2022 Jul 25. PMID: 35901993

Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum.
Quiroga B, Soler MJ, Ortiz A, de Sequera P; SENCOVAC collaborative network. Nefrologia (Engl Ed). 2023 May 5:S2013-2514(23)00074-3. doi: 10.1016/j.nefroe.2023.04.005. Online ahead of print. PMID: 37150670

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. NPJ Vaccines. 2023 May 10;8(1):67. doi: 10.1038/s41541-023-00662-6. PMID: 37164959

Impact of COVID-19 vaccination on menstrual cycle in women of reproductive age.
Qazi TB, Dkhar SA, Quansar R, Khan SMS. Int J Gynaecol Obstet. 2023 May 3. doi: 10.1002/ijgo.14822. Online ahead of print. PMID: 37132582

COVID-19 mRNA vaccination status and concerns among pregnant women in Japan: a multicenter questionnaire survey.
Takahashi K, Samura O, Hasegawa A, Okubo H, Morimoto K, Horiya M, Okamoto A, Ochiai D, Tanaka M, Sekiguchi M, Miyasaka N, Suzuki Y, Tabata T, Hayata E, Nakata M, Suzuki T, Nishi H, Toda Y, Tanigaki S, Furuya N, Hasegawa J, Tamaru S, Kamei Y, Sayama S, Nagamatsu T, Takahashi YO, Kitagawa M, Arakaki T, Sekizawa A. BMC Pregnancy Childbirth. 2023 May 9;23(1):332. doi: 10.1186/s12884-023-05669-4. PMID: 37161480

Density estimation of SARS-CoV2 spike proteins using super pixels segmentation technique.
Taha BA, Al-Jubouri Q, Al Mashhadany Y, Hafiz Mokhtar MH, Bin Zan MSD, Bakar AAA, Arsad N. Appl Soft Comput. 2023 May;138:110210. doi: 10.1016/j.asoc.2023.110210. Epub 2023 Mar 16. PMID: 36960080

COVID-19 vaccination and HIV transmission among persons who inject drugs during the first two years of the COVID-19 pandemic in New York City.

Des Jarlais DC, Weng CA, Feelemyer J, McKnight C. Harm Reduct J. 2023 May 3;20(1):63. doi: 10.1186/s12954-023-00791-0. PMID: 37138304

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-González L, Madrenas L, Güell I, Clotet B, Izquierdo-Useros N, Raïch-Regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, Prado JG, Blanch-Lombarte O, Pérez-Caballero R, Plana M, Esteban I, Pastor-Quiñones C, Núñez-Costa X, Taleb RA, McSkimming P, Soriano A, Nava J, Anagua JO, Ramos R, Lluch RM, Comes AC, Romero SO, Gomez XM, Sans-Pola C, Moltó J, Benet S, Bailón L, Arribas JR, Borobia AM, Parada JQ, Navarro-Pérez J, Forner Giner MJ, Lucas RO, Jiménez MDMV, Compán SO, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, García PM, de la Villa Martínez S, Fernández SR, Prat T, Torroella È, Ferrer L. Lancet Reg Health Eur. 2023 May;28:100613. doi: 10.1016/j.lanepe.2023.100613. Epub 2023 Apr 14. PMID: 37131861

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
Cheng A, Hsieh MJ, Chang SY, Ieong SM, Cheng CY, Sheng WH, Chang SC. J Formos Med Assoc. 2023 May;122(5):384-392. doi: 10.1016/j.jfma.2022.12.002. Epub 2022 Dec 15. PMID: 36564299

Media coverage of COVID-19 vaccines: sources of information, and verification practices of journalists in Ghana.
Gadzekpo A, Tietaah GKM, Yeboah-Banin AA, Kwame Ampofo Adjei D. J Commun Healthc. 2023 May 10:1-15. doi: 10.1080/17538068.2023.2208893. Online ahead of print. PMID: 37161948

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.
Chen C, Dai L, Zheng C, Li H, Li X, Yang M, Gao R, Yao J, Zhang Z, Shi Y, Han X. J Hematol Oncol. 2023 May 3;16(1):47. doi: 10.1186/s13045-023-01443-3. PMID: 37138279

Demographic and clinical feature disparity between progress and non-progress patients with vitiligo after COVID-19 vaccination: A cross-sectional study.
Hou X, Wu N, Xu M, Kharel P, Wu F, Wu Y, Wang R, Chen J. Exp Dermatol. 2023 May 4. doi: 10.1111/exd.14825. Online ahead of print. PMID: 37140178

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases.
Yu MKL, Chan SHS, Cheng S, Leung D, Chan SM, Yan ASK, Wong WHS, Peiris M, Lau YL, Rosa Duque JS. Hum Vaccin Immunother. 2023 May 9:2206278. doi: 10.1080/21645515.2023.2206278. Online ahead of print. PMID: 37157992

Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19.
Hasanpourghadi M, Novikov M, Ambrose R, Chekaoui A, Newman D, Ding J, Giles-Davis W, Xiang Z, Zhou XY, Liu Q, Swagata K, Ertl HC. Microbes Infect. 2023 May;25(4):105082. doi: 10.1016/j.micinf.2022.105082. Epub 2022 Dec 17. PMID: 36539010

Sociocultural and moral narratives influencing the decision to vaccinate among rheumatic disease patients: a qualitative study.
Manrique de Lara A, Colmenares-Roa T, Pascual-Ramos V, Moctezuma-Rios JF, Contreras-Yañez I, Guaracha-Basañez GA, Álvarez-Hernández E, Meza-López Y Olguín G, Peláez-Ballestas I. Clin Rheumatol. 2023 May 2:1-9. doi: 10.1007/s10067-023-06609-5. Online ahead of print. PMID: 37129776

Biodegradable Microrobots for DNA Vaccine Delivery.
Chen S, Tan Z, Liao P, Li Y, Qu Y, Zhang Q, Yang M, Chan KWY, Zhang L, Man K, Chen Z, Sun D. Adv Healthc Mater. 2023 May 8:e2202921. doi: 10.1002/adhm.202202921. Online ahead of print. PMID: 37156574

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
Hu Y, Wang Y, Shao T, Tang W, Hu K, Zhou Y, Miao L, Liu J, Wang B, Yu W. Vaccine. 2023 May 2;41(18):3003-3010. doi: 10.1016/j.vaccine.2023.03.056. Epub 2023 Mar 30. PMID: 37037708

COVID-19 vaccination elicited *de novo* and recurrence of cluster headache: A case series.
Chen SP, Takizawa T, Sekiguchi K, Nakahara J, Wang SJ. Cephalalgia. 2023 May;43(5):3331024231173354. doi: 10.1177/03331024231173354. PMID: 37138462

An Integrated Health Belief Model: Predicting Uptake of the First COVID-19 Booster Vaccine.
DeBeck DP, Scudder JN. Health Commun. 2023 May 2:1-11. doi: 10.1080/10410236.2023.2204583. Online ahead of print. PMID: 37128817

The effect of COVID-19 vaccination on the menstrual cycle in female in Riyadh, Saudi Arabia.
Saleh Alzahrani H, Ali Algashami S, Abdulaziz Alharkan A, Sultan Alotaibi N, Waseem Algahs N. Saudi Pharm J. 2023 May;31(5):746-751. doi: 10.1016/j.jsps.2023.03.015. Epub 2023 Mar 31. PMID: 37128295

Lexicon-based sentiment analysis to detect opinions and attitude towards COVID-19 vaccines on Twitter in Italy.
Catelli R, Pelosi S, Comito C, Pizzuti C, Esposito M. Comput Biol Med. 2023 May;158:106876. doi: 10.1016/j.compbiomed.2023.106876. Epub 2023 Apr 5. PMID: 37030266

Attitudes towards booster, testing and isolation, and their impact on COVID-19 response in winter 2022/2023 in France, Belgium, and Italy: a cross-sectional survey and modelling study.
de Meijere G, Valdano E, Castellano C, Debin M, Kengne-Kuetche C, Turbelin C, Noël H, Weitz JS, Paolotti D, Hermans L, Hens N, Colizza V. Lancet Reg Health Eur. 2023 May;28:100614. doi: 10.1016/j.lanepe.2023.100614. Epub 2023 Mar 23. PMID: 37131863

Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.
Zitvogel L, Derosa L, Kroemer G. Blood Cancer Discov. 2023 May 1;4(3):172-175. doi: 10.1158/2643-3230.BCD-22-0213. PMID: 37078891

Can psychological distress account for the associations between COVID-19 vaccination acceptance and socio-economic vulnerability?

Yuan J, Dong M, Wong IOL, Cowing BJ, Lam WWT, Ni MY, Liao Q. Appl Psychol Health Well Being. 2023 May 4. doi: 10.1111/aphw.12452. Online ahead of print. PMID: 37142547

Characterization of BNT162b2 mRNA to Evaluate Risk of Off-Target Antigen Translation.
Patel HK, Zhang K, Utegg R, Stephens E, Salem S, Welch H, Grobe S, Schlereth J, Kuhn AN, Ryczek J, Cirelli DJ, Lerch TF. J Pharm Sci. 2023 May;112(5):1364-1371. doi: 10.1016/j.xphs.2023.01.007. Epub 2023 Jan 13. PMID: 36642376

Protocol of a scoping review of systematic reviews and meta-analyses about COVID-19 vaccines and associated adverse events from vaccination.
Pranić SM, Vasanthan LT, Thompson JY, Mishra V, Kumar P, Ananda RA, Malih N, Chan KK. PLoS One. 2023 May 10;18(5):e0285442. doi: 10.1371/journal.pone.0285442. eCollection 2023. PMID: 37163502

Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada.
Breznik JA, Rahim A, Kajaks T, Hagerman M, Bilaver L, Colwill K, Dayam RM, Gingras AC, Verschoor CP, McElhaney JE, Bramson JL, Bowdish DME, Costa AP. J Am Med Dir Assoc. 2023 May;24(5):753-758. doi: 10.1016/j.jamda.2023.02.105. Epub 2023 Mar 28. PMID: 37001559

Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations.
Lee TH, Nam M, Seo JD, Kim H, Kim HR, Hur M, Yun YM, Moon HW. Ann Lab Med. 2023 May 1;43(3):290-294. doi: 10.3343/alm.2023.43.3.290. Epub 2022 Dec 22. PMID: 36544341

Low Peripheral B-Cell Counts in Patients With Systemic Rheumatic Diseases Due to Treatment With Belimumab and/or Rituximab Are Associated With Low Antibody Responses to Primary COVID-19 Vaccination.
Zhang-Sun J, Kirou RA, Kirou KA. HSS J. 2023 May;19(2):180-186. doi: 10.1177/15563316221142846. Epub 2022 Dec 16. PMID: 37051614

A population-based assessment of avoidable hospitalizations and resource use of non-vaccinated patients with COVID-19.
Bagshaw SM, Abbott A, Beesoon S, Bowker SL, Zuege DJ, Thanh NX. Can J Public Health. 2023 May 10. doi: 10.17269/s41997-023-00777-2. Online ahead of print. PMID: 37165140

COVID-19 infection and vaccination uptake in men and gender-diverse people who have sex with men in the UK: analyses of a large, online community cross-sectional survey (RiiSH-COVID) undertaken November-December 2021.
Ogaz D, Allen H, Reid D, Brown JRG, Howarth AR, Pulford CV, Mercer CH, Saunders J, Hughes G, Mohammed H. BMC Public Health. 2023 May 5;23(1):829. doi: 10.1186/s12889-023-15779-5. PMID: 37147609

Characteristics of the Moveable Middle: Opportunities Among Adults Open to COVID-19 Vaccination.
Omari A, Boone KD, Zhou T, Lu PJ, Kriss JL, Hung MC, Carter RJ, Black C, Weiss D, Masters NB, Lee JT, Brewer NT, Szilagyi PG, Singleton JA. Am J Prev Med. 2023 May;64(5):734-741. doi: 10.1016/j.amepre.2022.11.003. Epub 2022 Dec 21. PMID: 36690543

Sequential provocation of Ekbom's syndrome and acute mania following AstraZeneca COVID-19 vaccination.

Chang FY, Chen PA, Siao WH, Chen YC. Asian J Psychiatr. 2023 May;83:103569. doi: 10.1016/j.ajp.2023.103569. Epub 2023 Mar 25. PMID: 37012199

Integrated factors affecting intention of COVID-19 preventive behaviours including vaccination in Korea.
Lee WK, Shin SR. Nurs Open. 2023 May;10(5):3424-3431. doi: 10.1002/nop2.1597. Epub 2023 Jan 7. PMID: 36611182

Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
Lefferts B, Bruden D, Plumb ID, Hodges E, Bates E, January G, Bruce MG. Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.04.070. Online ahead of print. PMID: 37150620

Analysis of COVID-19 vaccine uptake among people with underlying chronic conditions in 2022: A cross-sectional study.
Bulusu A, Segarra C, Khayat L. SSM Popul Health. 2023 Jun;22:101422. doi: 10.1016/j.ssmph.2023.101422. Epub 2023 May 2. PMID: 37151914

Exploring consumers' perspective of community pharmacists delivering COVID-19 vaccinations: an Australian pilot study.
Bui TNT, Janetzki JL, Chai WC, Suppiah V. Int J Pharm Pract. 2023 May 7;31(3):337-340. doi: 10.1093/ijpp/riad014. PMID: 36795621

Tick-borne encephalitis epidemiology and surveillance in Poland, and comparison with selected European countries before and during the COVID-19 pandemic, 2008 to 2020.
Paradowska-Stankiewicz I, Pancer K, Poznańska A, Hordowicz M, Skibicka M, Słowiński M, Motak G, Falkiewicz B. Euro Surveill. 2023 May;28(18):2200452. doi: 10.2807/1560-7917.ES.2023.28.18.2200452. PMID: 37140452

Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.
Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d'Andrea V, Trentini F, Ajelli M, Poletti P, Merler S. JAMA Netw Open. 2023 May 1;6(5):e2310650. doi: 10.1001/jamanetworkopen.2023.10650. PMID: 37133863

The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment.
AlMalki FA, Albukhaty S, Alyamani AA, Khalaf MN, Thomas S. Environ Sci Pollut Res Int. 2023 May;30(22):61430-61454. doi: 10.1007/s11356-022-18868-x. Epub 2022 Feb 17. PMID: 35175517

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K, Jungsomsri P, Pinijnai O, Tavonvunchai F, Lievjaroen A, Suwannaroj P, Siripongboonsitti T, Porntharukchareon T, Sornsamdang G, Ungtrakul T. Hum Vaccin Immunother. 2023 May 4:2206360. doi: 10.1080/21645515.2023.2206360. Online ahead of print. PMID: 37140889

The new generation of messenger RNA (mRNA) vaccines against influenza.
Reina J. Enferm Infecc Microbiol Clin (Engl Ed). 2023 May;41(5):301-304. doi: 10.1016/j.eimce.2022.07.006. Epub 2022 Jul 26. PMID: 35906174

All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
Izu A, Nunes MC, Solomon F, Baillie V, Serafin N, Verwey C, Moore DP, Laubscher M, Ncube M, Olwagen C, Dangor Z, Madhi SA. Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200-1. doi: 10.1016/S1473-3099(23)00200-1. Online ahead of print. PMID: 37141913

Protein Aggregates in Inhaled Biologics: Challenges and Considerations.
Ibrahim M, Wallace I, Ghazvini S, Manetz S, Cordoba-Rodriguez R, Patel SM. J Pharm Sci. 2023 May;112(5):1341-1344. doi: 10.1016/j.xphs.2023.02.010. Epub 2023 Feb 14. PMID: 36796636

Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics.
Yang W, Cao J, Cheng H, Chen L, Yu M, Chen Y, Cui X. Bioact Mater. 2023 May;23:438-470. doi: 10.1016/j.bioactmat.2022.11.014. Epub 2022 Dec 1. PMID: 36471724

Towards a new model of global health justice: the case of COVID-19 vaccines.
Jecker NS, Atuire CA, Bull SJ. J Med Ethics. 2023 May;49(5):367-374. doi: 10.1136/medethics-2022-108165. Epub 2022 Apr 29. PMID: 35487676

Hopes fizzle that a TB vaccine also fends off COVID.
[No authors listed] Nature. 2023 May;617(7959):10. doi: 10.1038/d41586-023-01426-x. PMID: 37101078

Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study.
Dey M, R N, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Selva O'Callaghan A, Kim M, Chatterjee T, Tan AL, Makol A, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manoj MM, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Pauling JD, Wincup C, Üsküdar Cansu D, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bartoloni Bocci E, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Traboco LS, Hoff LS, Kusumo Wibowo SA, Tomaras S, Langguth D, Limaye V, Needham M, Srivastav N, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Loarce-Martos J, Prieto-González S, Gil-Vila A, Gonzalez RA, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Rheumatology (Oxford). 2023 May 2;62(5):e147-e152. doi: 10.1093/rheumatology/keac603. PMID: 36282492

Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
Santi Laurini G, Montanaro N, Broccoli M, Bonaldo G, Motola D. Vaccine. 2023 May 2;41(18):2879-2886. doi: 10.1016/j.vaccine.2023.03.054. Epub 2023 Mar 28. PMID: 37024412

Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
Kaur U, Fatima Z, Maheshwari K, Sahni V, Dehade A, Kl A, Yadav AK, Kansal S, Jaisawal V, Chakrabarti SS. Drug Saf. 2023 May 3:1-11. doi: 10.1007/s40264-023-01301-8. Online ahead of print. PMID: 37133805

Prevalence of Anti-PF4 Antibodies After First and Second ChAdOx1 nCoV-19 Vaccinations in Women With Adverse Events: A Brief Report and Literature Review.
Choe KW, Lim YK, Kweon OJ, Lee MK, Chung JW, Kim HR. Ann Lab Med. 2023 May 1;43(3):299-302. doi: 10.3343/alm.2023.43.3.299. Epub 2022 Dec 22. PMID: 36544343

Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment.
Ehteshaminia Y, Jalali SF, Jadidi-Niaragh F, Enderami SE, Pagheh AS, Akbari E, Kenari SA, Hassannia H. Life Sci. 2023 May 1;320:121525. doi: 10.1016/j.lfs.2023.121525. Epub 2023 Feb 24. PMID: 36841470

Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ, Jiang CL, Chao TL, Lin SY, Tsai YM, Chao CS, Su YT, Chen CJ, Chang SY, Lin FJ, Chang SC. Appl Microbiol Biotechnol. 2023 May;107(9):2983-2995. doi: 10.1007/s00253-023-12490-8. Epub 2023 Mar 29. PMID: 36988669

From iatrogenesis to vaccine skepticism: US mothers' negative vaccine perceptions and non-vaccination practices as reverberations of medical harm.
Richlin JB. Med Anthropol Q. 2023 May 10. doi: 10.1111/maq.12764. Online ahead of print. PMID: 37161842

The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-The results of ProBCG: a multicenter randomized clinical trial in Brazil.
Santos AP, Werneck GL, Dalvi APR, Dos Santos CC, Tierno PFGMM, Condelo HS, Macedo B, de Medeiros Leung JA, de Souza Nogueira J, Malvão L, Galliez R, Aguiar R, Stefan R, Knackfuss SM, da Silva EC, Castineiras TMPP, de Andrade Medronho R, E Silva JRL, Alves RLR, de Moraes Sobrino Porto LC, Rodrigues LS, Kritski AL, de Queiroz Mello FC. Int J Infect Dis. 2023 May;130:8-16. doi: 10.1016/j.ijid.2023.02.014. Epub 2023 Feb 24. PMID: 36841502

A machine learning method for the identification and characterization of novel COVID-19 drug targets.
Schultz B, DeLong LN, Masny A, Lentzen M, Raschka T, van Dijk D, Zaliani A; COPERIMOplus; Fröhlich H. Sci Rep. 2023 May 3;13(1):7159. doi: 10.1038/s41598-023-34287-5. PMID: 37137934

Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease.
Simão AL, Palma CS, Izquierdo-Sanchez L, Putignano A, Carvalho-Gomes A, Posch A, Zanaga P, Girleanu I, Henrique MM, Araújo C, Degre D, Gustot T, Sahuco I, Spagnolo E, Carvalhana S, Moura M, Fernandes DA, Banales JM, Romero-Gomez M, Trifan A, Russo FP, Stauber R, Berenguer M, Moreno C, Gonçalves J, Cortez-Pinto H, Castro RE. JHEP Rep. 2023 May;5(5):100697. doi: 10.1016/j.jhepr.2023.100697. Epub 2023 Feb 20. PMID: 36844943

Biochemical and histopathological evaluation of ChAdOx1-S and BBIBP-CorV vaccination in normal and streptozotocin-induced diabetic Wistar rats.
Teymoorzadeh M, Daneshfar N, Yazdanparast R. PLoS One. 2023 May 4;18(5):e0284601. doi: 10.1371/journal.pone.0284601. eCollection 2023. PMID: 37141219

Decompressive surgery in cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia.
Krzywicka K, Aguiar de Sousa D, Cordonnier C, Bode FJ, Field TS, Michalski D, Pelz J, Skjelland M, Wiedmann M, Zimmermann J, Wittstock M, Zanotti B, Ciccone A, Bandettini di Poggio M, Borhani-Haghighi A, Chatterton S, Aujayeb A, Devroye A, Dizonno V, Geeraerts T, Giammello F, Günther A, Ichaporia NR, Kleinig T, Kristoffersen ES, Lemmens R, De Maistre E, Mirzaasgari Z, Payen JF, Putaala J, Petruzzellis M, Raposo N, Sadeghi-Hokmabadi E, Schoenenberger S, Umaiorubahan M, Sylaja PN, van de Munckhof A, Sánchez van Kammen M, Lindgren E, Jood K, Scutelnic A, Heldner MR, Poli S, Kruip MJHA, Arauz A, Conforto AB, Aaron S, Middeldorp S, Tatlisumak T, Arnold M, Coutinho JM, Ferro JM; Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group. Eur J Neurol. 2023 May;30(5):1335-1345. doi: 10.1111/ene.15735. Epub 2023 Mar 5. PMID: 36773014

Adherence to preventive behaviours and associated factors towards COVID-19 among adults in Gurage zone, Ethiopia, 2020: a community-based cross-sectional study.
Bedewi J, Girum T, Tsegay T, Derese M, Yasin F, Kasahun A. BMJ Open. 2023 May 5;13(5):e068090. doi: 10.1136/bmjopen-2022-068090. PMID: 37147102

Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review.
Camargo-Coronel A, Quiñones-Moya H, Hernández-Zavala MR, Hernández-Vázquez JR, Vázquez-Zaragoza MÁ. Reumatismo. 2023 May 8;75(1). doi: 10.4081/reumatismo.2023.1548. PMID: 37154256

Global caregiver concerns of SARS-CoV-2 vaccination in children with cancer: a cross-sectional mixed-methods study.
Gumy JM, Silverstein A, Kaye EC, Caniza MA, Homsi MR, Pritchard-Jones K, Bate JM; St Jude/SIOP Parent and Carer Advisory Group. Pediatr Hematol Oncol. 2023 May;40(4):341-351. doi: 10.1080/08880018.2022.2101724. Epub 2022 Jul 25. PMID: 35876691

Clinical prediction rules for adverse evolution in patients with COVID-19 by the Omicron variant.
Portuondo-Jiménez J, Barrio I, España PP, García J, Villanueva A, Gascón M, Rodríguez L, Larrea N, García-Gutierrez S, Quintana JM; COVID-Health Basque Country Research Group. Int J Med Inform. 2023 May;173:105039. doi: 10.1016/j.ijmedinf.2023.105039. Epub 2023 Mar 7. PMID: 36921481

Similar deposition of neutrophil extracellular traps in the dermis among COVID-19-associated IgA vasculitis, post-COVID-19 vaccination IgA vasculitis, and COVID-19-unrelated IgA vasculitis.
Kawakami T, Yokoyama K, Ikeda T, Nishibata Y, Masuda S, Tomaru U, Ishizu A. J Dermatol. 2023 May;50(5):e151-e152. doi: 10.1111/1346-8138.16673. Epub 2022 Dec 15. PMID: 36523151

Efficient capture of recombinant SARS-CoV-2 receptor-binding domain (RBD) with citrate-coated magnetic iron oxide nanoparticles.
González-Martínez DA, González Ruíz G, Escalante-Bermúdez C, García Artalejo JA, Gómez Peña T, Gómez JA, González-Martínez E, Cazañas Quintana Y, Fundora Barrios T, Hernández T, Varela Pérez

RC, Díaz Goire D, Castro López D, Ruíz Ramirez I, Díaz-Águila CR, Moran-Mirabal JM. Nanoscale. 2023 May 4;15(17):7854-7869. doi: 10.1039/d3nr01109g. PMID: 37060148

The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C, Boziki MK, Karakasi MV, Moysiadis T, Grigoriadis N. Muscle Nerve. 2023 May;67(5):412-416. doi: 10.1002/mus.27805. Epub 2023 Mar 3. PMID: 36814101

A study on clinicodemographic profile, severity, and outcome of Covid-19 in hospitalized vaccinated individuals at tertiary care centre.
Gali JH, Shah C, Keerthi BY, Thomas V. Lung India. 2023 May-Jun;40(3):215-221. doi: 10.4103/lungindia.lungindia_28_22. PMID: 37148018

The Last Mile Problem-Coronavirus Disease 2019 Vaccine Coverage Among the Most Socially Vulnerable.
Titanji BK. Clin Infect Dis. 2023 May 3;76(9):1626-1627. doi: 10.1093/cid/ciad006. PMID: 36611245

Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers.
Radner H, Sieghart D, Jorda A, Fedrizzi C, Hasenöhrl T, Zdravkovic A, Redlberger-Fritz M, Puchammer-Stoeckl E, Anderle K, Bergmann F, Firbas C, Jordakieva G, Wagner B, Haslacher H, Perkmann T, Heinz LX, Bonelli M, Crevenna R, Aletaha D, Zeitlinger M. Clin Microbiol Infect. 2023 May;29(5):635-641. doi: 10.1016/j.cmi.2022.12.008. Epub 2022 Dec 9. PMID: 36509374

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. EClinicalMedicine. 2023 May;59:101983. doi: 10.1016/j.eclinm.2023.101983. Epub 2023 Apr 27. PMID: 37128256

Timing matters for COVID vaccine effectiveness.
[No authors listed] Nature. 2023 May;617(7960):226. doi: 10.1038/d41586-023-01463-6. PMID: 37138072

COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined.
Kim S, Eun MY, Seok HY. Neurol Sci. 2023 May;44(5):1503-1504. doi: 10.1007/s10072-023-06694-z. Epub 2023 Feb 18. PMID: 36808584

Impact of the COVID-19 lockdown on routine childhood vaccination coverage rates in Catalonia (Spain): a public health register-based study.
Martínez-Marcos M, Zabaleta-Del-Olmo E, Gómez-Durán EL, Reñé-Reñé A, Cabezas-Peña C. Public Health. 2023 May;218:68-74. doi: 10.1016/j.puhe.2023.02.017. Epub 2023 Feb 27. PMID: 36972643

Conformational characterization of the mammalian-expressed SARS-CoV-2 recombinant receptor binding domain, a COVID-19 vaccine.

Moro-Pérez L, Boggiano-Ayo T, Lozada-Chang SL, Fernández-Saiz OL, de la Luz KR, Gómez-Pérez JA. Biol Res. 2023 May 8;56(1):22. doi: 10.1186/s40659-023-00434-5. PMID: 37150832

Comments on COVID Vaccine Hesitancy and Traffic Crashes.
Mungmunpuntipantip R, Wiwanitkit V. Am J Med. 2023 May;136(5):e100. doi: 10.1016/j.amjmed.2022.12.024. PMID: 37137572

Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
Sun L, Brazão C, Mancha D, Soares-de-Almeida L, Filipe P. J Eur Acad Dermatol Venereol. 2023 May;37(5):e578-e580. doi: 10.1111/jdv.18893. Epub 2023 Jan 31. PMID: 36681888

Political variations in pandemic lifestyles and COVID-19 vaccination by age cohort in the United States.
Dowd-Arrow B, Burdette AM, Smith A. Prev Med. 2023 May 8:107525. doi: 10.1016/j.ypmed.2023.107525. Online ahead of print. PMID: 37164162

Use of the Healthy Living Medicine Platform to Minimize COVID-19 Vaccination: Dispelling This Myth Before It Takes Hold.
Arena R. Am J Med. 2023 May;136(5):403-404. doi: 10.1016/j.amjmed.2022.12.035. Epub 2023 Jan 14. PMID: 36649840

Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses.
Fumagalli V, Di Lucia P, Ravà M, Marotta D, Bono E, Grassi S, Donnici L, Cannalire R, Stefanelli I, Ferraro A, Esposito F, Pariani E, Inverso D, Montesano C, Delbue S, Perlman S, Tramontano E, De Francesco R, Summa V, Guidotti LG, Iannacone M. EMBO Mol Med. 2023 May 8;15(5):e17580. doi: 10.15252/emmm.202317580. Epub 2023 Mar 22. PMID: 36946379

Mucosal vaccines for SARS-CoV-2: triumph of hope over experience.
Pilapitiya D, Wheatley AK, Tan HX. EBioMedicine. 2023 May 3;92:104585. doi: 10.1016/j.ebiom.2023.104585. Online ahead of print. PMID: 37146404

HostSeq: a Canadian whole genome sequencing and clinical data resource.
Yoo S, Garg E, Elliott LT, Hung RJ, Halevy AR, Brooks JD, Bull SB, Gagnon F, Greenwood C, Lawless JF, Paterson AD, Sun L, Zawati MH, Lerner-Ellis J, Abraham R, Birol I, Bourque G, Garant JM, Gosselin C, Li J, Whitney J, Thiruvahindrapuram B, Herbrick JA, Lorenti M, Reuter MS, Adeoye OO, Liu S, Allen U, Bernier FP, Biggs CM, Cheung AM, Cowan J, Herridge M, Maslove DM, Modi BP, Mooser V, Morris SK, Ostrowski M, Parekh RS, Pfeffer G, Suchowersky O, Taher J, Upton J, Warren RL, Yeung R, Aziz N, Turvey SE, Knoppers BM, Lathrop M, Jones S, Scherer SW, Strug LJ. BMC Genom Data. 2023 May 2;24(1):26. doi: 10.1186/s12863-023-01128-3. PMID: 37131148

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome.
Robinson ML, Morris CP, Betz JF, Zhang Y, Bollinger R, Wang N, Thiemann DR, Fall A, Eldesouki RE, Norton JM, Gaston DC, Forman M, Luo CH, Zeger SL, Gupta A, Garibaldi BT, Mostafa HH. Clin Infect Dis. 2023 May 3;76(9):1539-1549. doi: 10.1093/cid/ciac957. PMID: 36528815

Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.

Sherman AC, Cheng CA, Swank Z, Zhou G, Li X, Issa NC, Walt DR, Baden LR, Soiffer RJ. Transplant Cell Ther. 2023 May;29(5):337.e1-337.e5. doi: 10.1016/j.jtct.2023.01.025. Epub 2023 Feb 2. PMID: 36736784

Severe cutaneous adverse reactions after COVID-19 vaccination: A systematic review.
Wu PC, Huang IH, Wang CW, Chung WH, Chen CB. Allergy. 2023 May;78(5):1383-1386. doi: 10.1111/all.15642. Epub 2023 Jan 27. PMID: 36627233

Comments on "Goyal M, Murthy SI and Annum S, Bilateral Multifocal Choroiditis following COVID-19 Vaccination".
Khochtali S, Nabi W, Khairallah M. Ocul Immunol Inflamm. 2023 May;31(4):880. doi: 10.1080/09273948.2022.2058557. Epub 2022 Apr 20. PMID: 35442844

Correspondence on acceptability of COVID-19 vaccination with bronchopulmonary dysplasia.
Kleebayoon A, Wiwanitkit V. Pediatr Pulmonol. 2023 May;58(5):1610. doi: 10.1002/ppul.26347. Epub 2023 Feb 13. PMID: 36751970

An evaluation of the early impact of the COVID-19 pandemic on Zambia's routine immunization program.
Winter AK, Takahashi S, Carcelen AC, Hayford K, Mutale W, Mwansa FD, Sinyange N, Ngula D, Moss WJ, Mutembo S. PLOS Glob Public Health. 2023 May 2;3(5):e0000554. doi: 10.1371/journal.pgph.0000554. eCollection 2023. PMID: 37130089

Pfizer-BioNTech vaccine induces the production of cross-reactive antibodies against Trypanosoma cruzi proteins: A preliminary study.
López-Monteon A, Balderas-Caballero AE, Domínguez-Guillén JA, Romero-Ramírez H, Baltierra-Uribe SL, Ramos-Ligonio A. Trop Med Int Health. 2023 May;28(5):384-390. doi: 10.1111/tmi.13869. Epub 2023 Mar 13. PMID: 36879355

Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study.
Seree-Aphinan C, Suchonwanit P, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Suangtamai T, Chanprapaph K; COVIDVAC-DERM study group. J Eur Acad Dermatol Venereol. 2023 May;37(5):e572-e575. doi: 10.1111/jdv.18890. Epub 2023 Jan 31. PMID: 36662625

An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.
Wang HY, Qiu L, Ou CY, Lin ZQ, Huang ZD, Chen P, Ma Q, Lu YR, Ran H, Liu WB. Neurol Sci. 2023 May 9. doi: 10.1007/s10072-023-06811-y. Online ahead of print. PMID: 37160544

Understanding barriers to vaccination against invasive meningococcal disease: a survey of the knowledge gap and potential solutions.
Ballalai I, Dawson R, Horn M, Smith V, Bekkat-Berkani R, Soumahoro L, Vicic N. Expert Rev Vaccines. 2023 May 5. doi: 10.1080/14760584.2023.2211163. Online ahead of print. PMID: 37144283

Detection of antibodies to SARS-CoV-2 after vaccination in seminal plasma and their association to sperm parameters.
Chillon TS, Demircan K, Weiss G, Minich WB, Schenk M, Schomburg L. Int J Infect Dis. 2023 May;130:161-165. doi: 10.1016/j.ijid.2023.03.018. Epub 2023 Mar 16. PMID: 36933610

Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination: From the National MS Society Case Conference Proceedings.
Roy S, Barreras P, Pardo CA, Graves JS, Zamvil SS, Newsome SD. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 4;10(3):e200112. doi: 10.1212/NXI.0000000000200112. Print 2023 May. PMID: 37015826

Read science news critically and look for original studies: An example of misleading headlines related to COVID-19 vaccines in mainstream media.
Milovanovic P. Health Inf Manag. 2023 May;52(2):132. doi: 10.1177/18333583211060034. Epub 2021 Dec 9. PMID: 34886690

Hypereosinophilia after vaccination with the SARS-CoV-2 mRNA vaccines.
Westreich A, Zelarney P, Wechsler ME. J Allergy Clin Immunol Pract. 2023 May;11(5):1564-1566. doi: 10.1016/j.jaip.2023.01.024. Epub 2023 Jan 30. PMID: 36720388

Assessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study.
Nisar MI, Ansari N, Malik AA, Shahid S, Lalani KRA, Chandna MA, Younus AM, Hasan Z, Khan U, Khalid F, Mahesar M, Farrukh Qazi M, Yildirim I, Jehan F, Omer SB. J Infect. 2023 May;86(5):e144-e147. doi: 10.1016/j.jinf.2023.01.016. Epub 2023 Jan 25. PMID: 36708775

Understanding public perceptions in social media responses to posts about acute severe hepatitis of unknown etiology in Indonesia: a qualitative study.
Asa GA, Fauk NK, Gesesew HA, Foley KM, Lunnay B, Ward PR. BMC Infect Dis. 2023 May 8;23(1):306. doi: 10.1186/s12879-023-08195-y. PMID: 37158814

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
Jin P, Zhu F. Lancet Reg Health Eur. 2023 May;28:100623. doi: 10.1016/j.lanepe.2023.100623. Epub 2023 Mar 31. PMID: 37131864

Factors Associated With Influenza Vaccination During the COVID-19 Pandemic in Older Adults Residing in Brazil.
Luchesi BM, de Oliveira Andrade N, Carrijo MF, Azambuja HCS, Martins TCR, Seixas RAM. J Gerontol Nurs. 2023 May;49(5):31-38. doi: 10.3928/00989134-20230414-03. Epub 2023 May 1. PMID: 37126013

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies.
Carreño JM, Singh G, Simon V, Krammer F; PVI study group. Lancet Microbe. 2023 May 1:S2666-5247(23)00118-0. doi: 10.1016/S2666-5247(23)00118-0. Online ahead of print. PMID: 37141905

Long-term transition of antibody titers in healthcare workers following the first to fourth doses of mRNA COVID-19 vaccine: Comparison of two automated SARS-CoV-2 immunoassays.
Taniguchi Y, Suemori K, Tanaka K, Okamoto A, Murakami A, Miyamoto H, Takasuka Y, Yamashita M, Takenaka K. J Infect Chemother. 2023 May;29(5):534-538. doi: 10.1016/j.jiac.2023.01.007. Epub 2023 Jan 22. PMID: 36696921

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D, Hu J, Medina T, Kessler ER, Lam ET. Hum Vaccin Immunother. 2023 May 9:2207438. doi: 10.1080/21645515.2023.2207438. Online ahead of print. PMID: 37157982

Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
Mesina FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, Sy CES, Oquendo RAA, Lirasan MRA. Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.04.066. Online ahead of print. PMID: 37150619

Atypical follicular hyperplasia with light chain-restricted germinal centers after COVID-19 booster: a diagnostic pitfall.
Patil A, Swerdlow SH, Lossos IS, Chapman JR. Virchows Arch. 2023 May;482(5):905-910. doi: 10.1007/s00428-022-03400-w. Epub 2022 Sep 13. PMID: 36098816

Epstein-Barr Virus-Positive Hemophagocytic Lymphohistiocytosis Following COVID-19 Vaccination in a Pediatric Patient.
Arand A, Overholt K, Jacob SA, Belsky JA. Pediatr Blood Cancer. 2023 May;70(5):e30189. doi: 10.1002/pbc.30189. Epub 2023 Jan 11. PMID: 36632038

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders.
Magen H, Avigdor A, Nevo L, Fried S, Gibori A, Levin EG, Lustig Y, Shkury E, Rahav G. PLoS One. 2023 May 1;18(5):e0284925. doi: 10.1371/journal.pone.0284925. eCollection 2023. PMID: 37126496

STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications.
Xu C, Dobson HE, Yu M, Gong W, Sun X, Park KS, Kennedy A, Zhou X, Xu J, Xu Y, Tai AW, Lei YL, Moon JJ. J Control Release. 2023 May;357:84-93. doi: 10.1016/j.jconrel.2023.03.036. Epub 2023 Mar 28. PMID: 36948420

Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.
Mauas R, Urueña A, Cecchini D, Strada ML, Arietti S, Cassetti I, Nogueira NF, Salazar AS, Rodriguez VJ, Jones DL, Alcaide ML. AIDS. 2023 May 1;37(6):941-946. doi: 10.1097/QAD.0000000000003483. Epub 2023 Jan 13. PMID: 36728228

Maternal and cord anti-SARS-CoV-2-spike IgG following COVID-19 vaccination vs. infection during pregnancy: a prospective study, Israel October 2021-March 2022.
Abu Shqara R, Wolf M, Mikhail Mustafa S, Sgayer I, Assulyn T, Abu Zraki A, Askhar Majadla N, Rechnitzer H, Shehadeh M, Fleisher Sheffer V, Bordeynik-Cohen M, Yakir O, Lowenstein L, Sela E, Edelstein M, Dror A. Am J Perinatol. 2023 May 10. doi: 10.1055/a-2090-5402. Online ahead of print. PMID: 37164317

Prediction of effective humoral response to SARS-CoV-2 vaccines in healthy subjects by cortical thickness of post-vaccination reactive lymphadenopathy.
Igual-Rouilleault AC, Soriano I, Quan PL, Reina G, Del Pozo JL, Gónzalez Á, Fernández-Ciriza L, Fernández-Montero A, Pina L, Elizalde A. Eur Radiol. 2023 May 5:1-8. doi: 10.1007/s00330-023-09662-5. Online ahead of print. PMID: 37142867

A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process.
Riguero V, Delmar J, Dippel A, McTamney P, Luo E, Martinez A, Ren K, van Dyk N, O'Connor E. Protein Expr Purif. 2023 May;205:106241. doi: 10.1016/j.pep.2023.106241. Epub 2023 Feb 1. PMID: 36736512

How Parents' Views Are Tied to Children's COVID-19 Vaccination.
Harris E. JAMA. 2023 May 9;329(18):1544. doi: 10.1001/jama.2023.6292. PMID: 37075231

Frontline Worker Safety in the Age of COVID-19: A Global Perspective.
Kavanagh KT, Maiwald M, Pontus C, Cimiotti JP, Palmieri PA, Cormier LE. J Patient Saf. 2023 May 9. doi: 10.1097/PTS.0000000000001132. Online ahead of print. PMID: 37162150

Identification and genome sequencing of an influenza H3N2 variant in wastewater from elementary schools during a surge of influenza A cases in Las Vegas, Nevada.
Vo V, Harrington A, Chang CL, Baker H, Moshi MA, Ghani N, Itorralba JY, Tillett RL, Dahlmann E, Basazinew N, Gu R, Familara TD, Boss S, Vanderford F, Ghani M, Tang AJ, Matthews A, Papp K, Khan E, Koutras C, Kan HY, Lockett C, Gerrity D, Oh EC. Sci Total Environ. 2023 May 10;872:162058. doi: 10.1016/j.scitotenv.2023.162058. Epub 2023 Feb 8. PMID: 36758698

Determinants of COVID-19 vaccination decision among Filipino adults.
Tejero LMS, Seva RR, Petelo Ilagan BJ, Almajose KL. BMC Public Health. 2023 May 10;23(1):851. doi: 10.1186/s12889-023-15712-w. PMID: 37165332

Immunization status in patients with multiple sclerosis: A cross-sectional, monocenter study in Austria.
Berek K, Deisl P, Bichler M, Auer M, Barket R, Bauer A, Zinganell A, Di Pauli F, Deisenhammer F, Hegen H. Eur J Neurol. 2023 May;30(5):1400-1408. doi: 10.1111/ene.15748. Epub 2023 Feb 26. PMID: 36786310

[Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes : Two-year experience of an allergy center in North Rhine-Westphalia].
Leonidou Floruß E, Demidova A, Hofmann SC, Balakirski G. Dermatologie (Heidelb). 2023 May 4:1-8. doi: 10.1007/s00105-023-05152-3. Online ahead of print. PMID: 37140637

Antibody responses to second doses of COVID-19 vaccination in lung cancer patients: comment.
Mungmunpuntipantip R, Wiwanitkit V. Respir Investig. 2023 May;61(3):332. doi: 10.1016/j.resinv.2023.02.001. Epub 2023 Mar 1. PMID: 36907110

Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study.
Prather AA, Dutcher EG, Robinson J, Lin J, Blackburn E, Hecht FM, Mason AE, Fromer E, Merino B, Frazier R, O'Bryan J, Drury S, Epel ES. Sci Rep. 2023 May 9;13(1):6505. doi: 10.1038/s41598-023-33320-x. PMID: 37160978

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X, Munro AP, Feng S, Janani L, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dejnirattisai W, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Serafimova T, Saralaya D, Screaton GR, Sharma S, Sheridan R, Sturdy A, Supasa P, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T,

Nguyen-Van-Tam JS, Cornelius V, Snape MD, Faust SN; COV-BOOST study group. J Infect. 2023 May;86(5):540-541. doi: 10.1016/j.jinf.2023.03.025. Epub 2023 Apr 12. PMID: 37055303

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E, Khan MS, Ferrari A, Huang S, Sammartino JC, Percivalle E, Kenniston TW, Cassaniti I, Baldanti F, Gambotto A. Microbiol Spectr. 2023 May 10:e0436322. doi: 10.1128/spectrum.04363-22. Online ahead of print. PMID: 37162333

Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
Fukunaga R, Kaplan ZE, Rodriguez T, Hagan L, Aarvig K, Dusseau C, Crockett M, Long M. Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.04.077. Online ahead of print. PMID: 37164822

Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds.
Cui Z, Luo W, Chen R, Li Y, Wang Z, Liu Y, Liu S, Feng L, Jia Z, Cheng R, Tang J, Huang W, Zhang Y, Liu H, Wang X, Li W. Signal Transduct Target Ther. 2023 May 4;8(1):179. doi: 10.1038/s41392-023-01422-7. PMID: 37142583

Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.
Islam N, Griffin DO, Jarvis MS, Cohen K. Heliyon. 2023 May;9(5):e16006. doi: 10.1016/j.heliyon.2023.e16006. Epub 2023 May 4. PMID: 37163164

Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via Salmonella elicited MHC class I and II based protective immunity.
Sivasankar C, Hewawaduge C, Lee JH. J Control Release. 2023 May;357:404-416. doi: 10.1016/j.jconrel.2023.04.015. Epub 2023 Apr 13. PMID: 37044178

Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey.
Ravindran R, Szadkowski L, Lovblom LE, Clarke R, Huang QW, Manase D, Parente L, Walmsley S; STOPCoV research team. PLOS Digit Health. 2023 May 9;2(5):e0000242. doi: 10.1371/journal.pdig.0000242. eCollection 2023 May. PMID: 37159470

A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P, Sancho-Saldaña A, Gil Sánchez A, Peralta S, Solana MJ, Bakkioui S, González-Mingot C, Quibus L, Ruiz-Fernández E, San Pedro-Murillo E, Brieva L. J Neurol. 2023 May;270(5):2380-2391. doi: 10.1007/s00415-023-11575-8. Epub 2023 Mar 18. PMID: 36933032

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.
Guo L, Lin S, Chen Z, Cao Y, He B, Lu G. Signal Transduct Target Ther. 2023 May 10;8(1):197. doi: 10.1038/s41392-023-01472-x. PMID: 37164987

Anti-human leukocyte antigen and anti-ABO antibodies after SARS-CoV-2 mRNA vaccination in kidney transplant recipients.

Nishida H, Takai S, Ito H, Fukuhara H, Nawano T, Narisawa T, Kanno H, Yagi M, Yamagishi A, Sakurai T, Naito S, Tsuchiya N. Clin Transplant. 2023 May;37(5):e14952. doi: 10.1111/ctr.14952. Epub 2023 Mar 6. PMID: 36846878

Oral booster vaccine antigen-Expression of full-length native SARS-CoV-2 spike protein in lettuce chloroplasts.
Singh R, Lin S, Nair SK, Shi Y, Daniell H. Plant Biotechnol J. 2023 May;21(5):887-889. doi: 10.1111/pbi.13993. Epub 2023 Jan 9. PMID: 36577691

PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
Tenchov R, Sasso JM, Zhou QA. Bioconjug Chem. 2023 May 10. doi: 10.1021/acs.bioconjchem.3c00174. Online ahead of print. PMID: 37162501

An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination.
da Silva Antunes R, Grifoni A, Frazier A, Weiskopf D, Sette A. Int Immunol. 2023 May 6:dxad014. doi: 10.1093/intimm/dxad014. Online ahead of print. PMID: 37148294

Comparative analysis of humoral immune response upon the three first vaccines applied in Argentina: IgG production and neutralizing capacity against SARS-CoV-2.
Giai C, Salassa BN, Zarelli VE, Bello OD, Vanrell MC, Ojeda DS, Gamarnik A, Colombo MI. Heliyon. 2023 May;9(5):e15211. doi: 10.1016/j.heliyon.2023.e15211. Epub 2023 Apr 19. PMID: 37090429

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.
Feng Y, Yuan M, Powers JM, Hu M, Munt JE, Arunachalam PS, Leist SR, Bellusci L, Kim J, Sprouse KR, Adams LE, Sundaramurthy S, Zhu X, Shirreff LM, Mallory ML, Scobey TD, Moreno A, O'Hagan DT, Kleanthous H, Villinger FJ, Veesler D, King NP, Suthar MS, Khurana S, Baric RS, Wilson IA, Pulendran B. Sci Transl Med. 2023 May 10;15(695):eadg7404. doi: 10.1126/scitranslmed.adg7404. Epub 2023 May 10. PMID: 37163615

Community pharmacists as vaccinators in the Italian SARS-CoV-2 immunization campaign: implications beyond the pandemic.
Baratta F, Enri LR, Brusa P. Health Policy. 2023 May;131:104798. doi: 10.1016/j.healthpol.2023.104798. Epub 2023 Mar 22. PMID: 36966630

Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy.
Hodl I, Sallegger C, Forstner P, Sareban N, Moritz M, Dreo B, Schulz E, Lackner A, Kleinhappl B, Hatzl S, Moazedi-Fürst F, Seifert-Held T, Heschl B, Khalil M, Enzinger C, Greinix H, Stradner MH, Steinmetz I, Schlenke P, Fessler J. Microbes Infect. 2023 May;25(4):105103. doi: 10.1016/j.micinf.2023.105103. Epub 2023 Jan 19. PMID: 36681177

The inverse care law and COVID-19 vaccination for refugees.
Kondilis E, Gallo V. Lancet Healthy Longev. 2023 May;4(5):e183-e184. doi: 10.1016/S2666-7568(23)00061-2. PMID: 37148889

XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1.
Devasundaram S, Terpos E, Rosati M, Ntanasis-Stathopoulos I, Bear J, Burns R, Skourti S, Malandrakis P, Trougakos IP, Dimopoulos MA, Pavlakis GN, Felber BK. Am J Hematol. 2023 May;98(5):E123-E126. doi: 10.1002/ajh.26887. Epub 2023 Mar 7. PMID: 36810791

Mucosal immunity in health care workers' respiratory tracts in the post-COVID-19 period.
Kryukova N, Baranova I, Abramova N, Khromova E, Pachomov D, Svitich O, Chuchalin A, Kostinov M. Sci Rep. 2023 May 3;13(1):7162. doi: 10.1038/s41598-023-32670-w. PMID: 37138005

COVID-19 vaccine uptake among patients undergoing treatment for lung cancer: A cross-sectional study in India.
Suri TM, Ghosh T, Singhal S, Arunachalam M, Alwani H, Mohan A. Lung India. 2023 May-Jun;40(3):294-296. doi: 10.4103/lungindia.lungindia_539_22. PMID: 37148035

Vaccination from the early second trimester onwards gives a robust SARS-CoV-2 antibody response throughout pregnancy and provides antibodies for the neonate.
Zilver SJM, de Groot CJM, Grobben M, Remmelzwaal S, Burgers E, Velasco DN, Juncker HG, van Keulen BJ, van Goudoever JB, de Leeuw RA, van Gils MJ, Ris-Stalpers C, van Leeuwen E. Int J Infect Dis. 2023 May;130:126-135. doi: 10.1016/j.ijid.2023.02.022. Epub 2023 Mar 1. PMID: 36868302

Investigating Social Media to Evaluate Emergency Medicine Physicians' Emotional Well-being During COVID-19.
Agarwal AK, Mittal J, Tran A, Merchant R, Guntuku SC. JAMA Netw Open. 2023 May 1;6(5):e2312708. doi: 10.1001/jamanetworkopen.2023.12708. PMID: 37163264

Mining adverse events in large frequency tables with ontology, with an application to the vaccine adverse event reporting system.
Zhao B, Zhao L. Stat Med. 2023 May 10;42(10):1512-1524. doi: 10.1002/sim.9684. Epub 2023 Feb 15. PMID: 36791465

Does Relationship Matter during a Health Crisis: Examining the Role of Local Government- Public Relationship in the Public Acceptance of COVID-19 Vaccines.
Liu W, Huang Y. Health Commun. 2023 May;38(6):1146-1156. doi: 10.1080/10410236.2021.1993586. Epub 2021 Oct 28. PMID: 34711119

Complete childhood vaccination and associated factors among children aged 12-23 months in Dabat demographic and health survey site, Ethiopia, 2022.
Gelagay AA, Worku AG, Bashah DT, Tebeje NB, Gebrie MH, Yeshita HY, Cherkose EA, Ayana BA, Lakew AM, Bitew DA, Asmamaw DB, Negash WD, Belachew TB, Fentie EA. BMC Public Health. 2023 May 2;23(1):802. doi: 10.1186/s12889-023-15681-0. PMID: 37131146

Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver After Local Administration in Mice.
Kawaguchi M, Noda M, Ono A, Kamiya M, Matsumoto M, Tsurumaru M, Mizukami S, Mukai H, Kawakami S. J Pharm Sci. 2023 May;112(5):1401-1410. doi: 10.1016/j.xphs.2022.12.026. Epub 2022 Dec 31. PMID: 36596392

Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study.
Ravussin A, Robertson AH, Wolf AS, Blix K, Kjønstad IF, Solum G, Feiring B, Strand BH, Lund-Johansen F, Munthe LA, Magnus P, Trogstad L, Mjaaland S. Lancet Healthy Longev. 2023 May;4(5):e188-e199. doi: 10.1016/S2666-7568(23)00055-7. PMID: 37148891

BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS-CoV-2 Infection Among Patients With Cardiovascular Disease.
Ye X, Yan VKC, Yiu HHE, Shami JJP, Kang W, Ma T, Qin X, Chui CSL, Lai FTT, Li X, Wan EYF, Wong CKH, Wong ICK, Chan EW. J Am Heart Assoc. 2023 May 2;12(9):e029291. doi: 10.1161/JAHA.122.029291. Epub 2023 Apr 29. PMID: 37119083

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G, Gherardin NA, Wong CY, Grimley SL, Cooney JP, Redmond SJ, Ellenberg P, Davidson KC, Mordant FL, Smith T, Gillard M, Lopez E, McAuley J, Tan CW, Wang JJ, Zeng W, Littlejohn M, Zhou R, Fuk-Woo Chan J, Chen ZW, Hartwig AE, Bowen R, Mackenzie JM, Vincan E, Torresi J, Kedzierska K, Pouton CW, Gordon TP, Wang LF, Kent SJ, Wheatley AK, Lewin SR, Subbarao K, Chung AW, Pellegrini M, Munro T, Nolan T, Rockman S, Jackson DC, Purcell DFJ, Godfrey DI. EBioMedicine. 2023 May 4;92:104574. doi: 10.1016/j.ebiom.2023.104574. Online ahead of print. PMID: 37148585

Side Effects Reported by Moroccan Medical Students Who Received COVID-19 Vaccines.
Moukafih B, Belaroussi L, Achour S, Kartouti AE. Curr Drug Saf. 2023 May 3. doi: 10.2174/1574886318666230503113713. Online ahead of print. PMID: 37138485

Barriers to access to antiretroviral therapy by people living with HIV in an indonesian remote district during the COVID-19 pandemic: a qualitative study.
Fauk NK, Gesesew HA, Seran AL, Ward PR. BMC Infect Dis. 2023 May 5;23(1):296. doi: 10.1186/s12879-023-08221-z. PMID: 37147599

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7. PMID: 36898405

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
Kleebayoon A, Wiwanitkit V. J Formos Med Assoc. 2023 May;122(5):432-433. doi: 10.1016/j.jfma.2022.12.018. Epub 2022 Dec 30. PMID: 36610888

Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
Chen TY, Wang SI, Hung YM, Hartman JJ, Chang R, Wei JC. Drugs. 2023 May 10. doi: 10.1007/s40265-023-01867-8. Online ahead of print. PMID: 37162705

Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
Beraud G, Bouetard L, Civljak R, Michon J, Tulek N, Lejeune S, Millot R, Garchet-Beaudron A, Lefebvre M, Velikov P, Festou B, Abgrall S, Lizatovic IK, Baldolli A, Esmer H, Blanchi S, Froidevaux G, Kapincheva N, Faucher JF, Duvnjak M, Afşar E, Švitek L, Yarimoglu S, Yarimoglu R, Janssen C, Epaulard O; EVASG (ESCMID vaccination study group). Clin Microbiol Infect. 2023 May;29(5):642-650. doi: 10.1016/j.cmi.2022.12.020. Epub 2022 Dec 29. PMID: 36587737

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022.
Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, Bøås H, Bragstad K, Hungnes O, Meijerink H. Int J Infect Dis. 2023 May;130:182-188. doi: 10.1016/j.ijid.2023.03.004. Epub 2023 Mar 8. PMID: 36893942

Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study.
Ljung R, Xu Y, Sundström A, Leach S, Hallberg E, Bygdell M, Larsson M, Arthurson V, Gisslén M, Gedeborg R, Nyberg F. BMJ. 2023 May 3;381:e074778. doi: 10.1136/bmj-2023-074778. PMID: 37137493

Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study.
Callaghan CJ, Curtis RMK, Mumford L, Whitaker H, Pettigrew G, Gardiner D, Marson L, Thorburn D, White S, Parmar J, Ushiro-Lumb I, Manas D, Ravanan R; NHS Blood and Transplant Organ and Tissue Donation and Transplantation Clinical Team. Transplantation. 2023 May 1;107(5):1124-1135. doi: 10.1097/TP.0000000000004535. Epub 2023 Jan 25. PMID: 36727724

SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for.
Thompson MA, Martinez-Barbini F, Mendizabal M. Ann Hepatol. 2023 May-Jun;28(3):101081. doi: 10.1016/j.aohep.2023.101081. Epub 2023 Mar 5. PMID: 36882137

Who gives? Characteristics of those who have taken the Giving What We Can pledge.
Wilks M, McCurdy J, Bloom P. J Pers. 2023 May 8. doi: 10.1111/jopy.12842. Online ahead of print. PMID: 37157888

Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting.
Espíndola OM, Fuller TL, de Araújo MF, Tort LFL, Guaraldo L, Calvet G, Resende P, Bonaldo M, Whitworth J, Smith C, Siqueira M, Brasil P. Sci Rep. 2023 May 8;13(1):7437. doi: 10.1038/s41598-023-34035-9. PMID: 37156846

Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants.
Lei H, Alu A, Yang J, He X, He C, Ren W, Chen Z, Hong W, Chen L, He X, Yang L, Li J, Wang Z, Wang W, Wei Y, Lu S, Lu G, Song X, Wei X. Nat Commun. 2023 May 9;14(1):2678. doi: 10.1038/s41467-023-38066-8. PMID: 37160882

Big knowledge visualization of the COVID-19 CIDO ontology evolution.
Zheng L, Perl Y, He Y. BMC Med Inform Decis Mak. 2023 May 9;23(Suppl 1):88. doi: 10.1186/s12911-023-02184-6. PMID: 37161560

Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
Stefanelli I, Corona A, Cerchia C, Cassese E, Improta S, Costanzi E, Pelliccia S, Morasso S, Esposito F, Paulis A, Scognamiglio S, Di Leva FS, Storici P, Brindisi M, Tramontano E, Cannalire R, Summa V. Eur J Med Chem. 2023 May 5;253:115311. doi: 10.1016/j.ejmech.2023.115311. Epub 2023 Mar 31. PMID: 37043904

Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab.
Zhao P, Rusu CA, Schenck OL. JAAD Case Rep. 2023 May;35:52-56. doi: 10.1016/j.jdcr.2023.03.003. Epub 2023 Mar 15. PMID: 37034027

Evaluation of behavioral economic strategies to raise influenza vaccination rates across a health system: Results from a randomized clinical trial.
Szilagyi PG, Casillas A, Duru OK, Ong MK, Vangala S, Tseng CH, Albertin C, Humiston SG, Ross MK, Friedman SR, Evans S, Sloyan M, Bogard JE, Fox CR, Lerner C. Prev Med. 2023 May;170:107474. doi: 10.1016/j.ypmed.2023.107474. Epub 2023 Mar 2. PMID: 36870572

Facial fat necrosis after autologous fat transfer possibly associated with SARS-CoV-2 vaccine.
Brau-Javier CN, Caro-Muniz AP, Canizares O. J Cosmet Dermatol. 2023 May;22(5):1477-1480. doi: 10.1111/jocd.15635. Epub 2023 Mar 9. PMID: 36891961

Adapting SARS-CoV-2 vaccination delivery in England to population needs: a thematic analysis of providers and commissioner's perceptions.
Ismail S, Chantler T, Paterson P, Letley L, Bell S, Mounier-Jack S. BMC Health Serv Res. 2023 May 1;23(1):417. doi: 10.1186/s12913-023-09350-6. PMID: 37127638

Intranasal administration of sodium nitroprusside augments antigen-specific mucosal and systemic antibody production in mice.
Tada R, Yamazaki H, Nagai Y, Takeda Y, Ohshima A, Kunisawa J, Negishi Y. Int Immunopharmacol. 2023 May 5;119:110262. doi: 10.1016/j.intimp.2023.110262. Online ahead of print. PMID: 37150015

Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.
Amano M, Ichikawa Y, Uemura Y, Matsumoto S, Maeda K, Matsushita S, Shimada S, Mitsuya H. J Infect. 2023 May;86(5):e130-e132. doi: 10.1016/j.jinf.2023.01.038. Epub 2023 Feb 2. PMID: 36736492

Short-term outcome of late gadolinium changes detected on cardiovascular magnetic resonance imaging following coronavirus disease 2019 Pfizer/BioNTech vaccine-related myocarditis in adolescents.
Krupickova S, Voges I, Mohiaddin R, Bautista C, Li W, Herberg J, Daubeney PEF, Pennell DJ, Fraisse A. Pediatr Radiol. 2023 May;53(5):892-899. doi: 10.1007/s00247-022-05573-7. Epub 2023 Jan 9. PMID: 36622403

Reply to letter to the editor "antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment".
Narita D, Ebina-Shibuya R. Respir Investig. 2023 May;61(3):347-348. doi: 10.1016/j.resinv.2023.02.004. Epub 2023 Mar 7. PMID: 36947984

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
Yamamoto S, Matsuda K, Maeda K, Oshiro Y, Inamura N, Mizoue T, Konishi M, Takeuchi JS, Horii K, Ozeki M, Sugiyama H, Mitsuya H, Sugiura W, Ohmagari N. BMC Infect Dis. 2023 May 4;23(1):282. doi: 10.1186/s12879-023-08272-2. PMID: 37142992

[Vaccine hesitancy: current status, associated factors, measurement, and approach].
Machida M, Inoue S. Nihon Koshu Eisei Zasshi. 2023 May 10. doi: 10.11236/jph.23-004. Online ahead of print. PMID: 37164752

Comparing the Use of a Mobile App and a Web-Based Notification Platform for Surveillance of Adverse Events Following Influenza Immunization: Randomized Controlled Trial.
Bota AB, Bettinger JA, Sarfo-Mensah S, Lopez J, Smith DP, Atkinson KM, Bell C, Marty K, Serhan M, Zhu DT, McCarthy AE, Wilson K. JMIR Public Health Surveill. 2023 May 8;9:e39700. doi: 10.2196/39700. PMID: 37155240

Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy.
Gonzalez MA, Bhatti AM, Fitzpatrick K, Boonyaratanakornkit J, Huang ML, Campbell VL, Hecht J, Ibrahimi S, Wanner SN, Green DJ, Maloney DG, Gauthier J, Cowan AJ, Greninger AL, Krantz EM, Koelle DM, Hill JA. Blood Adv. 2023 May 9;7(9):1849-1853. doi: 10.1182/bloodadvances.2022008338. PMID: 36094846

Factor H autoantibodies contribute to complement dysregulation in multisystem inflammatory syndrome in children (MIS-C).
Zerra PE, Stowell J, Verkerke H, McCoy J, Jones J, Graciaa S, Lu A, Hussaini L, Anderson EJ, Rostad CA, Stowell SR, Chonat S. Am J Hematol. 2023 May;98(5):E98-E101. doi: 10.1002/ajh.26868. Epub 2023 Feb 13. PMID: 36715424

SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022.
Bloomfield LE, Ngeh S, Cadby G, Hutcheon K, Effler PV. Emerg Infect Dis. 2023 May 4;29(6). doi: 10.3201/eid2906.230130. Online ahead of print. PMID: 37141626

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
Zhan H, Yang L, Liu Y, Li H, Li X, Wang H, Cao J, Kang S, Guo X, Dai E, Li Y. J Infect. 2023 May;86(5):e138-e141. doi: 10.1016/j.jinf.2023.01.030. Epub 2023 Jan 22. PMID: 36693568

Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology.

Shamseldin MM, Kenney A, Zani A, Evans JP, Zeng C, Read KA, Hall JM, Chaiwatpongsakorn S, Mahesh KC, Lu M, Eltobgy M, Denz P, Deora R, Li J, Peeples ME, Oestreich KJ, Liu SL, Corps KN, Yount JS, Dubey P. J Immunol. 2023 May 1;210(9):1257-1271. doi: 10.4049/jimmunol.2200297. PMID: 36881867

Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis.
Barmada A, Klein J, Ramaswamy A, Brodsky NN, Jaycox JR, Sheikha H, Jones KM, Habet V, Campbell M, Sumida TS, Kontorovich A, Bogunovic D, Oliveira CR, Steele J, Hall EK, Pena-Hernandez M, Monteiro V, Lucas C, Ring AM, Omer SB, Iwasaki A, Yildirim I, Lucas CL. Sci Immunol. 2023 May 12;8(83):eadh3455. doi: 10.1126/sciimmunol.adh3455. Epub 2023 May 5. PMID: 37146127

Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination.
Zhang L, Yang J, Deng M, Xu C, Lai C, Deng X, Wang Y, Zhou Q, Liu Y, Wan L, Li P, Fang J, Hou J, Lai X, Ma F, Li N, Li G, Kong W, Zhang W, Li J, Cao M, Feng L, Chen Z, Chen L, Ji T. Sci Rep. 2023 May 4;13(1):7263. doi: 10.1038/s41598-023-29669-8. PMID: 37142713

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature.
Marangoni D, Antonello RM, Coppi M, Palazzo M, Nassi L, Streva N, Povolo L, Malentacchi F, Zammarchi L, Rossolini GM, Vannucchi AM, Bartoloni A, Spinicci M. Int J Infect Dis. 2023 May 5:S1201-9712(23)00546-5. doi: 10.1016/j.ijid.2023.04.412. Online ahead of print. PMID: 37150351

Third-degree atrioventricular block associated with the SARS-CoV-2 mRNA vaccine.
Pons-Riverola A, Mañas P, Claver E, Meroño O, Comín-Colet J, Anguera I. Rev Esp Cardiol (Engl Ed). 2023 May;76(5):384-386. doi: 10.1016/j.rec.2022.10.004. Epub 2022 Oct 24. PMID: 36302470

The efficacy and safety of SARS-CoV-2 vaccines mRNA1273 and BNT162b2 might be complicated by rampant C-to-U RNA editing.
Bian Z, Wu Z, Liu N, Jiang X. J Appl Genet. 2023 May;64(2):361-365. doi: 10.1007/s13353-023-00756-w. Epub 2023 Mar 21. PMID: 36943642

Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.
Hwang IC, Valeriano VD, Song JH, Pereira M, Oh JK, Han K, Engstrand L, Kang DK. Microb Cell Fact. 2023 May 9;22(1):96. doi: 10.1186/s12934-023-02100-7. PMID: 37161468

Immune thrombocytopenia following SARS-CoV-2 vaccination in a female: Report of one case.
Lee ZM, Chen YC, Liu SC, Wang CC. Pediatr Blood Cancer. 2023 May;70(5):e30211. doi: 10.1002/pbc.30211. Epub 2023 Feb 1. PMID: 36726145

Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial.
Bhat S, Das L, Maheshwari D, Badal D, Sarkar R, Gupta M, Pandav SS, Padhi BK, Bhadada SK, Holick MF, Dutta P, Sachdeva N, Marwaha RK. J Infect. 2023 May;86(5):e120-e122. doi: 10.1016/j.jinf.2023.03.004. Epub 2023 Mar 6. PMID: 36889512

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
Chantasrisawad N, Techasaensiri C, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaru-Ampornpan P, Sophonphan J, Suntarattiwong P, Puthanakit T; KIDSVAX study team. Int J Infect Dis. 2023 May;130:52-59. doi: 10.1016/j.ijid.2023.02.017. Epub 2023 Feb 24. PMID: 36841501

Loading dynamics of one SARS-CoV-2-derived peptide into MHC-II revealed by kinetic models.
Song K, Xu H, Da LT. Biophys J. 2023 May 2;122(9):1665-1677. doi: 10.1016/j.bpj.2023.03.032. Epub 2023 Mar 24. PMID: 36964657

Radiation Recall Dermatitis after Donor Lymphocyte Infusion for Adult T-Cell Leukemia Lymphoma Post-Allogeneic Stem Cell Transplant.
Hardy-Abeloos C, Gerber N, Shaikh F. Pract Radiat Oncol. 2023 May-Jun;13(3):179-182. doi: 10.1016/j.prro.2022.10.008. Epub 2022 Nov 5. PMID: 36347452

Comparison of renal histopathology in three patients with gross hematuria after SARS-CoV-2 vaccination.
Ota K, Yonekura Y, Saigan M, Goto K, Nishi S. CEN Case Rep. 2023 May;12(2):176-183. doi: 10.1007/s13730-022-00743-w. Epub 2022 Oct 11. PMID: 36219335

The Nucleocapsid Proteins of SARS-CoV-2 and Its Close Relative Bat Coronavirus RaTG13 Are Capable of Inhibiting PKR- and RNase L-Mediated Antiviral Pathways.
LeBlanc K, Lynch J, Layne C, Vendramelli R, Sloan A, Tailor N, Deschambault Y, Zhang F, Kobasa D, Safronetz D, Xiang Y, Cao J. Microbiol Spectr. 2023 May 8:e0099423. doi: 10.1128/spectrum.00994-23. Online ahead of print. PMID: 37154717

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose.
Lim SH, Choi SH, Kim JY, Kim B, Kim HJ, Kim SH, Kim CK, Park SK, Yun J. J Korean Med Sci. 2023 May 8;38(18):e139. doi: 10.3346/jkms.2023.38.e139. PMID: 37158775

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022.
Groenheit R, Bacchus P, Galanis I, Sondén K, Bujila I, Efimova T, Garli F, Lindsjö OK, Mansjö M, Movert E, Pettke A, Rapp M, Sperk M, Söderholm S, Asin KV, Zanetti S, Karlberg ML, Bråve A, Blom K, Klingström J. Emerg Infect Dis. 2023 May 4;29(6). doi: 10.3201/eid2906.221862. Online ahead of print. PMID: 37141616

The social value of a SARS-CoV-2 vaccine: Willingness to pay estimates from four western countries.
Costa-Font J, Rudisill C, Harrison S, Salmasi L. Health Econ. 2023 May 7. doi: 10.1002/hec.4690. Online ahead of print. PMID: 37151130

Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report.
Alebna PL, Shahid MA, Brannan T, Shen T, Marian V. J Med Case Rep. 2023 May 5;17(1):202. doi: 10.1186/s13256-023-03831-2. PMID: 37143149

Gut microbiota as a potential key to modulating humoral immunogenicity of new platform COVID-19 vaccines.

Seong H, Choi BK, Han YH, Kim JH, Gim JA, Lim S, Noh JY, Cheong HJ, Kim WJ, Song JY. Signal Transduct Target Ther. 2023 May 3;8(1):178. doi: 10.1038/s41392-023-01445-0. PMID: 37137906

Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it?
Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferrò MT, Rilla MT, Gandoglia I, Gazzola P, Brichetto G, Pasquali L, Grimaldi L, Ulivelli M, Marinelli F, Cordera S, Clerico M, Conte A, Salvetti M, Battaglia MA, Franciotta D, Uccelli A, Sormani MP; CovaXiMS study group. Eur J Neurol. 2023 May 8. doi: 10.1111/ene.15830. Online ahead of print. PMID: 37154406

The role of children in transmission of SARS-CoV-2 variants of concern within households: an updated systematic review and meta-analysis, as at 30 June 2022.
Zhu Y, Xia Y, Pickering J, Bowen AC, Short KR. Euro Surveill. 2023 May;28(18):2200624. doi: 10.2807/1560-7917.ES.2023.28.18.2200624. PMID: 37140450

The immune response to SARS-CoV-2 vaccination in older people.
Fedele G, Palmieri A, Onder G. Lancet Healthy Longev. 2023 May;4(5):e177-e178. doi: 10.1016/S2666-7568(23)00060-0. PMID: 37148886

Fibrodysplasia Ossificans Progressiva.
Akesson LS, Savarirayan R. 2020 Jun 11 [updated 2023 May 11]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 32525643

Vaccination-Associated Myocarditis and Myocardial Injury.
Altman NL, Berning AA, Mann SC, Quaife RA, Gill EA, Auerbach SR, Campbell TB, Bristow MR. Circ Res. 2023 May 12;132(10):1338-1357. doi: 10.1161/CIRCRESAHA.122.321881. Epub 2023 May 11. PMID: 37167355

COVID-19, Myocarditis and Pericarditis.
Fairweather D, Beetler DJ, Di Florio DN, Musigk N, Heidecker B, Cooper LT Jr. Circ Res. 2023 May 12;132(10):1302-1319. doi: 10.1161/CIRCRESAHA.123.321878. Epub 2023 May 11. PMID: 37167363

Human Papillomavirus Vaccination.
Markowitz LE, Unger ER. N Engl J Med. 2023 May 11;388(19):1790-1798. doi: 10.1056/NEJMcp2108502. PMID: 37163625

Detection of SARS-CoV-2 Antibodies in Immunoglobulin Products.
Cousins K, Sano K, Lam B, Röltgen K, Bhavsar D, Singh G, Jeong S, Aboelregal N, Ho HE, Boyd S, Krammer F, Cunningham-Rundles C. J Allergy Clin Immunol Pract. 2023 May 12:S2213-2198(23)00541-X. doi: 10.1016/j.jaip.2023.05.005. Online ahead of print. PMID: 37182564

A systematic review of pre-service training on vaccination and immunization.
Tchoualeu DD, Fleming M, Traicoff DA. Vaccine. 2023 May 11;41(20):3156-3170. doi: 10.1016/j.vaccine.2023.03.062. Epub 2023 Apr 15. PMID: 37069032

Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.

Datar RS, Fette LM, Hinkelman AN, Hammershaimb EA, Friedman-Klabanoff DJ, Mongraw-Chaffin M, Weintraub WS, Ahmed N, Gibbs MA, Runyon MS, Plumb ID, Thompson W, Saydah S, Edelstein SL, Berry AA; COVID-19 Community Research Partnership. Vaccine. 2023 May 11;41(20):3204-3214. doi: 10.1016/j.vaccine.2023.03.057. Epub 2023 Mar 31. PMID: 37069033

The Effect of Combining the COVID-19 Vaccine with the Seasonal Influenza Vaccine on Reducing COVID-19 Vaccine Rejection Among Libyans.
Ghazy RM, Sallam M, Abdullah FSA, Hussein M, Hussein MF. J Epidemiol Glob Health. 2023 May 12:1-11. doi: 10.1007/s44197-023-00107-2. Online ahead of print. PMID: 37171545

Spatial distribution and determinants of childhood vaccination refusal in the United States.
Kang B, Goldlust S, Lee EC, Hughes J, Bansal S, Haran M. Vaccine. 2023 May 11;41(20):3189-3195. doi: 10.1016/j.vaccine.2023.04.019. Epub 2023 Apr 15. PMID: 37069031

Evaluation of Willingness to Accept COVID-19 Vaccine and Willingness to Pay among Pakistani Parents for Their Children Aged 5 to 11 Years: Findings and Implications.
Hayat K, Farooq Umer M, Mujtaba H, Babar Kawish A, Azam Tahir M, Ullah Khan F, Ullah Khan F, Omer Iqbal M, Hussain T, Ur Rehman A, Fang Y. Am J Trop Med Hyg. 2023 May 15:tpmd220363. doi: 10.4269/ajtmh.22-0363. Online ahead of print. PMID: 37188339

COVID-19 Booster Vaccine Hesitancy in the Emergency Department.
Molina MF, Nichol G, Eucker SA, Addo N, Rising K, Arreguin M, Morse D, Pauley A, Chavez CL, O'Laughlin KN, Duber H, Rodriguez RM. Ann Emerg Med. 2023 May 12:S0196-0644(23)00296-2. doi: 10.1016/j.annemergmed.2023.04.009. Online ahead of print. PMID: 37178104

Attitudes and Misconceptions of Coronavirus Disease and Vaccination Among African Americans in Rural Mississippi.
Omondi AA, Day AM, Washington R, Burns PB. Health Commun. 2023 May 15:1-14. doi: 10.1080/10410236.2023.2212443. Online ahead of print. PMID: 37190668

What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
Toshkov D. Vaccine. 2023 May 11;41(20):3178-3188. doi: 10.1016/j.vaccine.2023.03.030. Epub 2023 Apr 4. PMID: 37059674

Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, Van Oyen H, Stouten V, Hubin P, Billuart M, Djiena A, Mahieu R, Hammami N, Van Cauteren D, Wyndham-Thomas C. Vaccine. 2023 May 11;41(20):3292-3300. doi: 10.1016/j.vaccine.2023.03.069. Epub 2023 Apr 5. PMID: 37085456

Immunology of SARS-CoV-2 infection and vaccination.
Lin B, Cheng L, Zhang J, Yang M, Zhang Y, Liu J, Qin X. Clin Chim Acta. 2023 May 13:117390. doi: 10.1016/j.cca.2023.117390. Online ahead of print. PMID: 37187222

Temporal, age and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022.

Blanquart F, Abad C, Ambroise J, Bernard M, Débarre F, Giannoli JM, Rey T, Vieillefond V. Int J Infect Dis. 2023 May 12:S1201-9712(23)00539-8. doi: 10.1016/j.ijid.2023.04.410. Online ahead of print. PMID: 37182550

Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.
Roper RL, Garzino-Demo A, Del Rio C, Bréchot C, Gallo R, Hall W, Esparza J, Reitz M, Schinazi RF, Parrington M, Tartaglia J, Koopmans M, Osorio J, Nitsche A, Huan TB, LeDuc J, Gessain A, Weaver S, Mahalingam S, Abimiku A, Vahlne A, Segales J, Wang L, Isaacs SN, Osterhaus A, Scheuermann RH, McFadden G. Vaccine. 2023 May 11;41(20):3171-3177. doi: 10.1016/j.vaccine.2023.04.010. Epub 2023 Apr 21. PMID: 37088603

Air pollution and COPD: GOLD 2023 committee report.
Sin DD, Doiron D, Agusti A, Anzueto A, Barnes PJ, Celli BR, Criner GJ, Halpin D, Han MK, Martinez FJ, Montes de Oca M, Papi A, Pavord I, Roche N, Singh D, Stockley R, Lopez Varlera MV, Wedzicha J, Vogelmeier C, Bourbeau J; GOLD Scientific Committee. Eur Respir J. 2023 May 11;61(5):2202469. doi: 10.1183/13993003.02469-2022. Print 2023 May. PMID: 36958741

Exploring the vaccine conversation on TikTok in Italy: beyond classic vaccine stances.
Parisi L, Mulargia S, Comunello F, Bernardini V, Bussoletti A, Nisi CR, Russo L, Campagna I, Lanfranchi B, Croci I, Grassucci E, Gesualdo F. BMC Public Health. 2023 May 12;23(1):880. doi: 10.1186/s12889-023-15748-y. PMID: 37173677

Immunosenescence: molecular mechanisms and diseases.
Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, Cheng Q, Luo P, Zhang Y, Han X. Signal Transduct Target Ther. 2023 May 13;8(1):200. doi: 10.1038/s41392-023-01451-2. PMID: 37179335

An immunoinformatics approach to epitope-based vaccine design against PspA in Streptococcus pneumoniae.
Mazumder L, Shahab M, Islam S, Begum M, Oliveira JIN, Begum S, Akter S. J Genet Eng Biotechnol. 2023 May 11;21(1):57. doi: 10.1186/s43141-023-00506-9. PMID: 37166683

COVID-19 vaccine hesitancy and social contact patterns in Pakistan: results from a national cross-sectional survey.
Quaife M, Torres-Rueda S, Dobreva Z, van Zandvoort K, Jarvis CI, Gimma A, Zulfiqar W, Khalid M, Vassall A. BMC Infect Dis. 2023 May 11;23(1):321. doi: 10.1186/s12879-023-08305-w. PMID: 37170085

Identifying and managing those at risk for vaccine related allergy and anaphylaxis.
Stone CA Jr, Garvey LH, Nasser S, Lever C, Triggiani M, Parente R, Phillips E. J Allergy Clin Immunol Pract. 2023 May 12:S2213-2198(23)00540-8. doi: 10.1016/j.jaip.2023.05.004. Online ahead of print. PMID: 37182566

A national survey of parents' views on childhood vaccinations in Ireland.
Marron L, Ferenczi A, O'Brien KM, Cotter S, Jessop L, Morrissey Y, Migone C. Vaccine. 2023 May 13:S0264-410X(23)00522-4. doi: 10.1016/j.vaccine.2023.05.004. Online ahead of print. PMID: 37183073

Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.
Lee SE, Greene SA, Burns CC, Tallis G, Wassilak SGF, Bolu O. MMWR Morb Mortal Wkly Rep. 2023 May 12;72(19):517-522. doi: 10.15585/mmwr.mm7219a3. PMID: 37167156

Reliability and validity evaluation of the chinese revision of the attitude towards adult vaccination scale.
Kong J, Liang C, Fu D, Wang L, Yan X, Li S, Zhang H. BMC Public Health. 2023 May 12;23(1):883. doi: 10.1186/s12889-023-15684-x. PMID: 37173680

Nanomedicine to overcome antimicrobial resistance: challenges and prospects.
Zou W, McAdorey A, Yan H, Chen W. Nanomedicine (Lond). 2023 May 12. doi: 10.2217/nnm-2023-0022. Online ahead of print. PMID: 37170884

TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity.
Ali S, Rehman MU, Yatoo AM, Arafah A, Khan A, Rashid S, Majid S, Ali A, Ali MN. Eur J Pharmacol. 2023 May 15;947:175678. doi: 10.1016/j.ejphar.2023.175678. Epub 2023 Mar 27. PMID: 36990262

COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration - United States, May 11, 2023.
Silk BJ, Scobie HM, Duck WM, Palmer T, Ahmad FB, Binder AM, Cisewski JA, Kroop S, Soetebier K, Park M, Kite-Powell A, Cool A, Connelly E, Dietz S, Kirby AE, Hartnett K, Johnston J, Khan D, Stokley S, Paden CR, Sheppard M, Sutton P, Razzaghi H, Anderson RN, Thornburg N, Meyer S, Womack C, Weakland AP, McMorrow M, Broeker LR, Winn A, Hall AJ, Jackson B, Mahon BE, Ritchey MD. MMWR Morb Mortal Wkly Rep. 2023 May 12;72(19):523-528. doi: 10.15585/mmwr.mm7219e1. PMID: 37167154

The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
Frodlund M, Nived P, Chatzidionysiou A, Södergren A, Klingberg E, Bengtsson A, Hansson M, Olsson S, Pin E, Klareskog L, Kapetanovic MC. Vaccine. 2023 May 11;41(20):3247-3257. doi: 10.1016/j.vaccine.2023.03.065. Epub 2023 Apr 4. PMID: 37076360

Nanotechnologies for the Diagnosis and Treatment of SARS-CoV-2 and Its Variants.
Park E, Choi SY, Kim J, Hildebrandt N, Lee JS, Nam JM. Small Methods. 2023 May 15:e2300034. doi: 10.1002/smtd.202300034. Online ahead of print. PMID: 37189215

Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML, van Pul L, Grobben M, Boyd A, Wit FWNM, van Nuenen AC, van Dort KA, Tejjani K, van Rijswijk J, Bakker M, van der Hoek L, Schim van der Loeff MF, van der Valk M, van Gils MJ, Kootstra NA, Reiss P. Microbiol Spectr. 2023 May 11:e0115523. doi: 10.1128/spectrum.01155-23. Online ahead of print. PMID: 37166335

Tick-Borne Encephalitis: An Update for the Special Operations Forces Provider.
Kaur H, Shishido AA. J Spec Oper Med. 2023 May 12:KAY2-1QTV. doi: 10.55460/KAY2-1QTV. Online ahead of print. PMID: 37126779

Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain.
Lazarus JV, Villota-Rivas M, Ryan P, Buti M, Grau-López L, Cuevas G, Espada JL, Morón W, Palma-Álvarez RF, Feld JJ, Valencia J. Commun Med (Lond). 2023 May 12;3(1):66. doi: 10.1038/s43856-023-00292-y. PMID: 37173456

Apelin receptor antagonist boosts dendritic cell vaccine efficacy in controlling angiogenic, metastatic and apoptotic-related factors in 4T1 breast tumor-bearing mice.
Masoumi J, Zainodini N, Basirjafar P, Tavakoli T, Zandvakili R, Nemati M, Ramezani M, Rezayati MT, Ayoobi F, Khademalhosseini M, Khorramdelazad H, Arman R, Jafarzadeh A. Med Oncol. 2023 May 15;40(6):179. doi: 10.1007/s12032-023-02030-9. PMID: 37188900

Tackling Counterfeit Drugs: The Challenges and Possibilities.
Pathak R, Gaur V, Sankrityayan H, Gogtay J. Pharmaceut Med. 2023 May 15. doi: 10.1007/s40290-023-00468-w. Online ahead of print. PMID: 37188891

Association of Vaccine Pass Policy and Omicron Incidence with COVID vaccine uptakes in Hong Kong.
Qiu H, Zhao S, Cheung AW, Yeoh EK, Wong EL. J Travel Med. 2023 May 11:taad061. doi: 10.1093/jtm/taad061. Online ahead of print. PMID: 37166362

Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders.
Mäkitie O, Vakkilainen S. 2012 Mar 15 [updated 2023 May 11]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 22420014

Choosing the Right Path toward Polio Eradication.
John TJ, Hirschhorn N, Dharmapalan D. N Engl J Med. 2023 May 11;388(19):1824. doi: 10.1056/NEJMc2303169. PMID: 37163639

Diphtheria in Pakistan post-COVID-19, a potential public health threat: an update.
Saeed M, Shahid MB, Naeem A, Tabassum S, Dave T. Trop Med Health. 2023 May 11;51(1):24. doi: 10.1186/s41182-023-00522-y. PMID: 37165432

Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis.
Barmada A, Klein J, Ramaswamy A, Brodsky NN, Jaycox JR, Sheikha H, Jones KM, Habet V, Campbell M, Sumida TS, Kontorovich A, Bogunovic D, Oliveira CR, Steele J, Hall EK, Pena-Hernandez M, Monteiro V, Lucas C, Ring AM, Omer SB, Iwasaki A, Yildirim I, Lucas CL. Sci Immunol. 2023 May 12;8(83):eadh3455. doi: 10.1126/sciimmunol.adh3455. Epub 2023 May 5. PMID: 37146127

A computational quest for identifying potential vaccine candidates against *Moraxella lacunata*: a multi-pronged approach.
Ullah A, Ul Haq M, Iqbal M, Irfan M, Khan S, Muhammad R, Ullah A, Khurram M, Alharbi M, Alasmari AF, Ahmad S. J Biomol Struct Dyn. 2023 May 12:1-14. doi: 10.1080/07391102.2023.2212793. Online ahead of print. PMID: 37177816

Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelets donors.
Desjardins M, Cunningham PH, Mitre X, Pierre D, Montesano C, Woods T, Oganezova K, Krauss JH, Von SS, Kupelian JA, Li X, Gothing JA, Kleinjan JA, Zhou G, Piantadosi S, Sherman AC, Walsh SR, Issa NC, Kaufman RM, Baden LR. Blood. 2023 May 12:blood.2022019482. doi: 10.1182/blood.2022019482. Online ahead of print. PMID: 37172200

Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
George TK, Nair NP, Singh AK, Dilesh Kumar A, Roy AD, Mohan VN, Kang G. Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.04.062. Online ahead of print. PMID: 37183072

Cross-sectional health centre and community-based evaluation of the impact of pneumococcal and malaria vaccination on antibiotic prescription and usage, febrile illness and antimicrobial resistance in young children in Malawi: the IVAR study protocol.
Singleton D, Ibarz-Pavon A, Swarthout TD, Bonomali F, Cornick J, Kalizang'oma A, Ntiza N, Brown C, Chipatala R, Nyangulu W, Chirombo J, Kawalazira G, Chibowa H, Mwansambo C, Maleta KM, French N, Heyderman RS. BMJ Open. 2023 May 12;13(5):e069560. doi: 10.1136/bmjopen-2022-069560. PMID: 37173105

Synthetic Self-adjuvanted Lipopeptide Vaccines Conferred Protection Against Helicobacter pylori Infection.
Xue RY, Liu C, Wang JQ, Deng Y, Feng R, Li GC, Liu JY, Cheng H, Shan Zhang S, Duan H, Jin Z, Zou QM, Bo Li H. Adv Healthc Mater. 2023 May 12:e2300085. doi: 10.1002/adhm.202300085. Online ahead of print. PMID: 37171889

IgG4-related Disease Emerging after COVID-19 mRNA Vaccination.
Aochi S, Uehara M, Yamamoto M. Intern Med. 2023 May 15;62(10):1547-1551. doi: 10.2169/internalmedicine.1125-22. Epub 2023 Mar 8. PMID: 36889713

Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
Choi Y, Lee GS, Li S, Lee JW, Mixson-Hayden T, Woo J, Xia D, Prausnitz MR, Kamili S, Purdy MA, Tohme RA. Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.05.005. Online ahead of print. PMID: 37179166

The association of care burden with motivation of vaccine acceptance among caregivers of stroke patients during the COVID-19 pandemic: mediating roles of problematic social media use, worry, and fear.
Kukreti S, Strong C, Chen JS, Chen YJ, Griffiths MD, Hsieh MT, Lin CY. BMC Psychol. 2023 May 15;11(1):157. doi: 10.1186/s40359-023-01186-3. PMID: 37183253

Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
Topazian HM, Schmit N, Gerard-Ursin I, Charles GD, Thompson H, Ghani AC, Winskill P. Vaccine. 2023 May 11;41(20):3215-3223. doi: 10.1016/j.vaccine.2023.04.011. Epub 2023 Apr 18. PMID: 37080831

Inhaled drug delivery for the targeted treatment of asthma.
Boboltz A, Kumar S, Duncan GA. Adv Drug Deliv Rev. 2023 May 11:114858. doi: 10.1016/j.addr.2023.114858. Online ahead of print. PMID: 37178928

Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
Harris JN, Mauro CM, Morgan TL, de Roche A, Zimet GD, Rosenthal SL. Vaccine. 2023 May 11;41(20):3151-3155. doi: 10.1016/j.vaccine.2023.04.001. Epub 2023 Apr 7. PMID: 37045680

Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
Kehagia E, Papakyriakopoulou P, Valsami G. Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.05.011. Online ahead of print. PMID: 37179163

Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection.
Diallo BK, Chasaide CN, Wong TY, Schmitt P, Lee KS, Weaver K, Miller O, Cooper M, Jazayeri SD, Damron FH, Mills KHG. NPJ Vaccines. 2023 May 13;8(1):68. doi: 10.1038/s41541-023-00665-3. PMID: 37179389

Intention to receive COVID-19 vaccine and its health belief model (HBM)-based predictors: A systematic review and meta-analysis.
Yenew C, Dessie AM, Gebeyehu AA, Genet A. Hum Vaccin Immunother. 2023 May 12:2207442. doi: 10.1080/21645515.2023.2207442. Online ahead of print. PMID: 37170620

[Role of MAIT cells in immunity against *Mycobacterium tuberculosis*].
Cao ZH, Cheng XX. Zhonghua Jie He He Hu Xi Za Zhi. 2023 May 12;46(5):511-516. doi: 10.3760/cma.j.cn112147-20230307-00117. PMID: 37147816

Durability of immune responses to mRNA booster vaccination against COVID-19.
Arunachalam PS, Lai L, Samaha H, Feng Y, Hu M, Hui HS, Wali B, Ellis M, Davis-Gardner ME, Huerta C, Bechnak K, Bechnak S, Lee M, Litvack MB, Losada C, Grifoni A, Sette A, Zarnitsyna VI, Rouphael N, Suthar MS, Pulendran B. J Clin Invest. 2023 May 15;133(10):e167955. doi: 10.1172/JCI167955. PMID: 36951954

Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem.
Clarke L, Brighton T, Chunilal SD, Lee CSM, Passam F, Curnow J, Chen VM, Tran HA. Vaccine. 2023 May 11;41(20):3285-3291. doi: 10.1016/j.vaccine.2023.03.071. Epub 2023 Apr 19. PMID: 37085453

Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Freitag TL, Fagerlund R, Karam NL, Leppänen VM, Ugurlu H, Kant R, Mäkinen P, Tawfek A, Jha SK, Strandin T, Leskinen K, Hepojoki J, Kesti T, Kareinen L, Kuivanen S, Koivulehto E, Sormunen A, Laidinen S, Khattab A, Saavalainen P, Meri S, Kipar A, Sironen T, Vapalahti O, Alitalo K, Ylä-Herttuala S, Saksela K. Vaccine. 2023 May 11;41(20):3233-3246. doi: 10.1016/j.vaccine.2023.04.020. Epub 2023 Apr 14. PMID: 37085458

Prediction of hospitalisations based on wastewater-based SARS-CoV-2 epidemiology.
Schenk H, Heidinger P, Insam H, Kreuzinger N, Markt R, Nägele F, Oberacher H, Scheffknecht C, Steinlechner M, Vogl G, Wagner AO, Rauch W. Sci Total Environ. 2023 May 15;873:162149. doi: 10.1016/j.scitotenv.2023.162149. Epub 2023 Feb 10. PMID: 36773921

GM-CSF and IL-7 fusion cytokine engineered tumor vaccine generates long-term Th-17 memory cells and increases overall survival in aged syngeneic mouse models of glioblastoma.
Shireman JM, Gonugunta N, Zhao L, Pattnaik A, Distler E, Her S, Wang X, Das R, Galipeau J, Dey M. Aging Cell. 2023 May 11:e13864. doi: 10.1111/acel.13864. Online ahead of print. PMID: 37165998

COVID-19 Vaccination and the Development of Autoimmune Diseases.
Yoshimi R, Nakajima H. Intern Med. 2023 May 15;62(10):1387-1388. doi: 10.2169/internalmedicine.1490-22. Epub 2023 Mar 8. PMID: 36889704

Stroffolini T, Ciancio A, Federico A, Benigno RG, Colloredo G, Lombardi A, Cotugno R, Verucchi G, Ferrigno L, Gioli F, Marignani M, Troshina Y, Romeo M, Di Costanzo F, Niro GA, Badia L. Eur J Clin Microbiol Infect Dis. 2023 May 12. doi: 10.1007/s10096-023-04614-9. Online ahead of print. PMID: 37169944

Disparities in greenspace access during COVID-19 mobility restrictions.
Lusseau D, Baillie R. Environ Res. 2023 May 15;225:115551. doi: 10.1016/j.envres.2023.115551. Epub 2023 Feb 24. PMID: 36841525

Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency.
Noonan E, Straesser MD, Makin T, Williams A, Al-Hazaymeh A, Routes JM, Verbsky J, Borish L, Lawrence MG. J Clin Immunol. 2023 May 12. doi: 10.1007/s10875-023-01501-y. Online ahead of print. PMID: 37169968

Choosing the Right Path toward Polio Eradication. Reply.
Chumakov K, Plotkin S. N Engl J Med. 2023 May 11;388(19):1824. doi: 10.1056/NEJMc2303169. PMID: 37163640

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Girndt M, Houser P, Manllo-Karim R, Ervin JE, Charytan C, Chow S, Symonian-Silver M, Lehrner L, Linfert D, Shemin D, Michelsen A, Xie F, Janssen RS. Vaccine. 2023 May 11;41(20):3224-3232. doi: 10.1016/j.vaccine.2023.04.028. Epub 2023 Apr 19. PMID: 37085451

Synthetic RNA therapeutics in cancer.
Han Y, Shin SH, Lim CG, Heo YH, Choi IY, Kim HH. J Pharmacol Exp Ther. 2023 May 15:JPET-MR-2023-001587. doi: 10.1124/jpet.123.001587. Online ahead of print. PMID: 37188531

The impacts of COVID-19 and its policy response on access and utilization of maternal and child health services in Tanzania: A mixed methods study.
Shayo EH, Nassor NK, Mboera LEG, Ngadaya E, Mangesho P, Bakari M, Urassa M, Seif M, Tarimo C, Masemo A, Mmbaga BT, O'Sullivan N, McCoy D, Russo G. PLOS Glob Public Health. 2023 May 12;3(5):e0001549. doi: 10.1371/journal.pgph.0001549. eCollection 2023. PMID: 37172038

Explaining the gender gap in COVID-19 vaccination attitudes.
Toshkov D. Eur J Public Health. 2023 May 13:ckad052. doi: 10.1093/eurpub/ckad052. Online ahead of print. PMID: 37178211

Cost-Effectiveness Analyses of Digital Health Technology for Improving the Uptake of Vaccination Programs: Systematic Review.
Wang Y, Fekadu G, You JH. J Med Internet Res. 2023 May 15;25:e45493. doi: 10.2196/45493. PMID: 37184916

Using conditional inference to quantify interaction effects of socio-demographic covariates of US COVID-19 vaccine hesitancy.
Shen K, Kejriwal M. PLOS Glob Public Health. 2023 May 12;3(5):e0001151. doi: 10.1371/journal.pgph.0001151. eCollection 2023. PMID: 37172006

Cross sectional survey of Varicella-Zoster virus and measles seropositivity in people living with HIV in a Parisian suburb and a review of current immunization guidelines.
Kolakowska A, Brichler S, Delagrèverie H, Marin J, Alloui AC, Cailhol J. Vaccine. 2023 May 11;41(20):3266-3274. doi: 10.1016/j.vaccine.2023.03.058. Epub 2023 Apr 19. PMID: 37085454

The protein kinases of Dictyostelia and their incorporation into a signalome.
Kin K, Chen ZH, Forbes G, Lawal H, Schilde C, Singh R, Cole C, Barton GJ, Schaap P. Cell Signal. 2023 May 13:110714. doi: 10.1016/j.cellsig.2023.110714. Online ahead of print. PMID: 37187217

Epitope-based vaccine design against the membrane and nucleocapsid proteins of SARS-CoV-2.
Moballegh Naseri M, Moballegh Naseri M, Maurya VK, Shams S, Pitaloka DAE. Dent Med Probl. 2023 May 15. doi: 10.17219/dmp/161742. Online ahead of print. PMID: 37184460

Time-dependent vaccine efficacy estimation quantified by a mathematical model.
Loria J, Albani VVL, Coutinho FAB, Covas DT, Struchiner CJ, Zubelli JP, Massad E. PLoS One. 2023 May 11;18(5):e0285466. doi: 10.1371/journal.pone.0285466. eCollection 2023. PMID: 37167285

Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.
Kakavandi S, Zare I, VaezJalali M, Dadashi M, Azarian M, Akbari A, Ramezani Farani M, Zalpoor H, Hajikhani B. Cell Commun Signal. 2023 May 15;21(1):110. doi: 10.1186/s12964-023-01104-5. PMID: 37189112

Field Research Is Essential to Counter Virological Threats.
Runstadler JA, Lowen AC, Kayali G, Tompkins SM, Albrecht RA, Fouchier RAM, Stallknecht DE, Lakdawala SS, Goodrum FD, Casadevall A, Enquist LW, Alwine JC, Imperiale MJ, Schultz-Cherry S, Webby RJ. J Virol. 2023 May 11:e0054423. doi: 10.1128/jvi.00544-23. Online ahead of print. PMID: 37166327

Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
Prada E, Langbecker A, Catalan-Matamoros D. Vaccine. 2023 May 11;41(20):3196-3203. doi: 10.1016/j.vaccine.2023.03.068. Epub 2023 Apr 4. PMID: 37080830

Genome-Wide Libraries for Protozoan Pathogen Drug Target Screening Using Yeast Surface Display.
Heslop R, Gao M, Brito Lira A, Sternlieb T, Loock M, Sanghi SR, Cestari I. ACS Infect Dis. 2023 May 12;9(5):1078-1091. doi: 10.1021/acsinfecdis.2c00568. Epub 2023 Apr 21. PMID: 37083339

Accelerated waning of the humoral response to COVID-19 vaccines in obesity.
van der Klaauw AA, Horner EC, Pereyra-Gerber P, Agrawal U, Foster WS, Spencer S, Vergese B, Smith M, Henning E, Ramsay ID, Smith JA, Guillaume SM, Sharpe HJ, Hay IM, Thompson S, Innocentin S, Booth LH, Robertson C, McCowan C, Kerr S, Mulroney TE, O'Reilly MJ, Gurugama TP, Gurugama LP, Rust MA, Ferreira A, Ebrahimi S, Ceron-Gutierrez L, Scotucci J, Kronsteiner B, Dunachie SJ, Klenerman P; PITCH Consortium; Park AJ, Rubino F, Lamikanra AA, Stark H, Kingston N, Estcourt L, Harvala H, Roberts DJ, Doffinger R, Linterman MA, Matheson NJ, Sheikh A, Farooqi IS, Thaventhiran JED. Nat Med. 2023 May 11. doi: 10.1038/s41591-023-02343-2. Online ahead of print. PMID: 37169862

Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants.
DeSantis SM, Yaseen A, Hao T, León-Novelo L, Talebi Y, Valerio-Shewmaker MA, Pinzon Gomez CL, Messiah SE, Kohl HW, Kelder SH, Ross JA, Padilla LN, Silberman M, Tuzo S, Lakey D, Shuford JA, Pont SJ, Boerwinkle E, Swartz MD. J Infect Dis. 2023 May 12;227(10):1164-1172. doi: 10.1093/infdis/jiad020. PMID: 36729177

Metabolic Adaptations Correlated with Antibody Response after Immunization with Inactivated SARS-CoV-2 in Brazilian Subjects.
de Souza Nogueira J, Santos-Rebouças CB, Piergiorge RM, Valente AP, Gama-Almeida MC, El-Bacha T, Lopes Moreira ML, Baptista Marques BS, de Siqueira JR, de Carvalho EM, da Costa Ferreira O Jr, Porto LC, Kelly da Silva Fidalgo T, Costa Dos Santos G Jr. J Proteome Res. 2023 May 11. doi: 10.1021/acs.jproteome.3c00014. Online ahead of print. PMID: 37167433

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Choi YH, Kang YA, Park KJ, Choi JC, Cho KG, Ko DY, Ahn JH, Lee B, Ahn E, Woo YJ, Jung K, Kim NY, Reese VA, Larsen SE, Baldwin SL, Reed SG, Coler RN, Lee H, Cho SN. Infect Dis Ther. 2023 May 11:1-20. doi: 10.1007/s40121-023-00806-0. Online ahead of print. PMID: 37166567

Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral $CD103^{int}CD11b^{+}$ dendritic cell population.
Stellas D, Karaliota S, Stravokefalou V, Angel M, Nagy BA, Goldfarbmuren KC, Bergamaschi C, Felber BK, Pavlakis GN. Cell Rep. 2023 May 12;42(5):112501. doi: 10.1016/j.celrep.2023.112501. Online ahead of print. PMID: 37178117

Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged $IFNAR^{-/-}$ mice.
Guerra GS, Barriales D, Lorenzo G, Moreno S, Anguita J, Brun A, Abrescia NGA. Vaccine. 2023 May 11;41(20):3275-3284. doi: 10.1016/j.vaccine.2023.04.027. Epub 2023 Apr 19. PMID: 37085455

A Single Nasal Dose Vaccination with a Brucella abortus Mutant Potently Protects against Pulmonary Infection.
Wang H, Clapp B, Hoffman C, Yang X, Pascual DW. J Immunol. 2023 May 15;210(10):1576-1588. doi: 10.4049/jimmunol.2300071. PMID: 37036290

No woman left behind: achieving cervical cancer elimination among women living with HIV.

Sharma K, Machalek DA, Toh ZQ, Amenu D, Muchengeti M, Ndlovu AK, Mremi A, Mchome B, Vallely AJ, Denny L, Rees H, Garland SM. Lancet HIV. 2023 May 11:S2352-3018(23)00082-6. doi: 10.1016/S2352-3018(23)00082-6. Online ahead of print. PMID: 37182539

Long-term consequences of COVID-19 on mental health and the impact of a physically active lifestyle: a narrative review.
Roever L, Cavalcante BRR, Improta-Caria AC. Ann Gen Psychiatry. 2023 May 11;22(1):19. doi: 10.1186/s12991-023-00448-z. PMID: 37170283

The relationship between mental health, sleep quality and the immunogenicity of COVID-19 vaccinations.
Wagenhäuser I, Reusch J, Gabel A, Mees J, Nyawale H, Frey A, Lâm TT, Schubert-Unkmeir A, Dölken L, Kurzai O, Frantz S, Petri N, Krone M, Krone LB. J Sleep Res. 2023 May 13:e13929. doi: 10.1111/jsr.13929. Online ahead of print. PMID: 37177872

Considerations for post-licensure group B streptococcus vaccine effectiveness studies.
Skirrow H, Kajungu D, Le Doare K, Chantler T, Kampmann B. Int J Gynaecol Obstet. 2023 May 11. doi: 10.1002/ijgo.14845. Online ahead of print. PMID: 37165788

Characterization of Duffy Binding Protein II-specific CD4$^+$T cell responses in Plasmodium vivax patients.
Thawornpan P, Malee C, Kochayoo P, Wangriatisak K, Leepiyasakulchai C, Ntumngia FB, De SL, Adams JH, Chootong P. Sci Rep. 2023 May 12;13(1):7741. doi: 10.1038/s41598-023-34903-4. PMID: 37173361

Making Sense of Late Tissue Nodules Associated With Hyaluronic Acid Injections.
Goodman GJ, McDonald CB, Lim A, Porter CE, Deva AK, Magnusson M, Patel A, Hart S, Callan P, Rudd A, Roberts S, Wallace K, Bekhor P, Clague M, Williams L, Corduff N, Wines N, Al-Niaimi F, Fabi SG, Studniberg HM, Smith S, Tsirbas A, Arendse S, Ciconte A, Poon T. Aesthet Surg J. 2023 May 15;43(6):NP438-NP448. doi: 10.1093/asj/sjad028. PMID: 36759325

Parental motivated helplessness in vaccinating children against COVID-19: Its association with fear, effectiveness and willingness to vaccinate.
Kretchner M, Lifshin U, Mikulincer M. J Health Psychol. 2023 May 15:13591053231170055. doi: 10.1177/13591053231170055. Online ahead of print. PMID: 37183794

Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Capuano R, Prosperini L, Altieri M, Lorefice L, Fantozzi R, Cavalla P, Guaschino C, Radaelli M, Cordioli C, Nociti V, Boffa L, Ragonese P, Di Gregorio M, Pinardi F, Torri Clerici V, De Luca G, Gajofatto A, Paolicelli D, Tortorella C, Gasperini C, Solaro C, Cocco E, Bisecco A, Gallo A. Mult Scler. 2023 May 11:13524585231167515. doi: 10.1177/13524585231167515. Online ahead of print. PMID: 37165941

Challenges in the development of novel therapies, vaccines and siRNAs for the treatment of hypertension.
Nakagami H. Hypertens Res. 2023 May 11. doi: 10.1038/s41440-023-01302-1. Online ahead of print. PMID: 37169884

Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.

Lilleby W, Seierstad T, Inderberg EM, Hole KH. Int J Cancer. 2023 May 15;152(10):2166-2173. doi: 10.1002/ijc.34448. Epub 2023 Feb 4. PMID: 36715014

Evolution of antibody immunity following Omicron BA.1 breakthrough infection.
Kaku CI, Starr TN, Zhou P, Dugan HL, Khalifé P, Song G, Champney ER, Mielcarz DW, Geoghegan JC, Burton DR, Andrabi R, Bloom JD, Walker LM. Nat Commun. 2023 May 12;14(1):2751. doi: 10.1038/s41467-023-38345-4. PMID: 37173311

Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19.
Martin SD, Davis ES, Dai C, Boal LH, Araya B, Brackett J, Dickens D, Kahn A, Martinez I, Sharma A, Schwalm C, Aguayo-Hiraldo P, Bhatia S, Levine JM, Johnston EE, Wolfson JA; Pediatric Oncology COVID-19 Case Consortium. JAMA Oncol. 2023 May 11:e230525. doi: 10.1001/jamaoncol.2023.0525. Online ahead of print. PMID: 37166782

New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
Srikantiah P, Klugman KP. BMC Med. 2023 May 15;21(1):177. doi: 10.1186/s12916-023-02883-x. PMID: 37183242

Preclinical development of a novel Group B Streptococcus (GBS) vaccine candidate for maternal immunization based upon the alpha-like protein family of GBS surface proteins (Alp).
Banks C, Lindbom BJ, Kitson G, Darsley M, Fischer PB. Birth Defects Res. 2023 May 15;115(9):933-944. doi: 10.1002/bdr2.2173. Epub 2023 Apr 3. PMID: 37010372

Correction to: Vaccine Effectiveness Against 12-Month Incident and Persistent Anal Human Papillomavirus Infection Among Gay, Bisexual, and Other Men Who Have Sex With Men.
[No authors listed] J Infect Dis. 2023 May 12;227(10):1219. doi: 10.1093/infdis/jiad097. PMID: 37072685

Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study.
Morais S, Wissing MD, Khosrow-Khavar F, Burchell AN, Tellier PP, Coutlée F, Waterboer T, El-Zein M, Franco EL. J Infect Dis. 2023 May 12;227(10):1173-1184. doi: 10.1093/infdis/jiac437. PMID: 36322543

Construction of a CCL20-centered circadian-signature based prognostic model in cervical cancer.
Yu Y, Liu Y, Li Y, Yang X, Han M, Fan Q. Cancer Cell Int. 2023 May 15;23(1):92. doi: 10.1186/s12935-023-02926-6. PMID: 37183243

Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand.
Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, Chotirosniramit N, Noppakun K, Khwanngern K, Teacharak W, Piamanant P, Chantaklang P, Khammawan P. PLoS One. 2023 May 11;18(5):e0284130. doi: 10.1371/journal.pone.0284130. eCollection 2023. PMID: 37167215

Precise Epitope Organization with Self-adjuvant Framework Nucleic Acid for Efficient COVID-19 Peptide Vaccine Construction.

Shen F, Xiong Z, Wu Y, Peng R, Wang Y, Sun L, Fan C, Liu Z. Angew Chem Int Ed Engl. 2023 May 15;62(21):e202301147. doi: 10.1002/anie.202301147. Epub 2023 Apr 17. PMID: 36961090

Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year.
Pierre É, Pladys A, Bayat-Makoei S, Tattevin P, Vigneau C. Vaccine. 2023 May 11:S0264-410X(23)00521-2. doi: 10.1016/j.vaccine.2023.05.003. Online ahead of print. PMID: 37179164

Qualitative assessment of COVID-19 vaccination acceptance among healthcare workers in Pima County.
Block Ngaybe M, Schmitt HJ, Mallahan S, Sena R, Werts S, Rooney B, Magrath P, Madhivanan P. Hum Vaccin Immunother. 2023 May 15:2211464. doi: 10.1080/21645515.2023.2211464. Online ahead of print. PMID: 37190772

Developments in pharmacotherapeutic agents for hepatitis B - how close are we to a functional cure?
Khan N, Almajed MR, Fitzmaurice MG, Jafri SM. Expert Opin Pharmacother. 2023 May 15:1-11. doi: 10.1080/14656566.2023.2211259. Online ahead of print. PMID: 37163255

Development of a bivalent mucoadhesive nanovaccine to prevent francisellosis and columnaris diseases in Nile tilapia (Oreochromis niloticus).
Bunnoy A, Thompson KD, Thangsunan P, Chokmangmeepisarn P, Yata T, Pirarat N, Kitiyodom S, Thangsunan P, Sukkarun P, Prukbenjakul P, Panthukumphol N, Morishita M, Srisapoome P, Rodkhum C. Fish Shellfish Immunol. 2023 May 12:108813. doi: 10.1016/j.fsi.2023.108813. Online ahead of print. PMID: 37182796

Deployment of a Reservoir-Targeted Vaccine Against Borrelia burgdorferi Reduces the Prevalence of Babesia microti Coinfection in Ixodes scapularis Ticks.
Vannier E, Richer LM, Dinh DM, Brisson D, Ostfeld RS, Gomes-Solecki M. J Infect Dis. 2023 May 12;227(10):1127-1131. doi: 10.1093/infdis/jiac462. PMID: 36416014

COVID-19 Vaccination Among Skilled Nursing Facility Staff: Challenges and Strategies Identified by Administrators.
Gadbois EA, Brazier JF, Meehan A, Madrigal C, White EM, Rafat A, Grabowski D, Shield RR. Med Care Res Rev. 2023 May 12:10775587231168435. doi: 10.1177/10775587231168435. Online ahead of print. PMID: 37170944

Antimicrobial-resistant Shigella: where do we go next?
Baker S, Scott TA. Nat Rev Microbiol. 2023 May 15. doi: 10.1038/s41579-023-00906-1. Online ahead of print. PMID: 37188805

Risk of Autoimmune Skin and Connective Tissue Disorders After mRNA-based COVID-19 Vaccination.
Jeong Ju H, Lee JY, Han JH, Lee JH, Bae JM, Lee S. J Am Acad Dermatol. 2023 May 13:S0190-9622(23)00829-0. doi: 10.1016/j.jaad.2023.05.017. Online ahead of print. PMID: 37187424

Symptoms and risk factors for long COVID in Tunisian population.
Chelly S, Rouis S, Ezzi O, Ammar A, Fitouri S, Soua A, Fathallah I, Njah M, Mahjoub M. BMC Health Serv Res. 2023 May 15;23(1):487. doi: 10.1186/s12913-023-09463-y. PMID: 37189141

Vaccine Refusal: A Major, Underestimated Obstacle for the Poliomyelitis Eradication Initiative.

Seytre B. Am J Trop Med Hyg. 2023 May 15:tpmd230154. doi: 10.4269/ajtmh.23-0154. Online ahead of print. PMID: 37188348

Associations between an international COVID-19 job exposure matrix and SARS-CoV-2 infection among 2 million workers in Denmark.
van der Feltz S, Schlünssen V, Basinas I, Begtrup LM, Burdorf A, Bonde JPE, Flachs EM, Peters S, Pronk A, Stokholm ZA, van Tongeren M, van Veldhoven K, Oude Hengel KM, Kolstad HA. Scand J Work Environ Health. 2023 May 11:4099. doi: 10.5271/sjweh.4099. Online ahead of print. PMID: 37167299

Simultaneous detection and phylogenetic analysis of porcine epidemic diarrhea virus and porcine circovirus 4 in Henan province, China.
Li HX, Chen XM, Zhao YY, Zhang HL, Zheng LL, Wang LQ, Ma SJ, Chen HY. Arch Virol. 2023 May 13;168(6):161. doi: 10.1007/s00705-023-05791-w. PMID: 37179263

Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
Yamaki H, Kono M, Wakisaka R, Komatsuda H, Kumai T, Hayashi R, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Hayashi T, Kobayashi H, Katada A. Cancer Immunol Immunother. 2023 May 12. doi: 10.1007/s00262-023-03460-0. Online ahead of print. PMID: 37173455

Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination.
DeSilva MB, Haapala J, Vazquez-Benitez G, Boyce TG, Fuller CC, Daley MF, Getahun D, Hambidge SJ, Lipkind HS, Naleway AL, Nelson JC, Vesco KK, Weintraub ES, Williams JTB, Zerbo O, Kharbanda EO. Obstet Gynecol. 2023 May 11. doi: 10.1097/AOG.0000000000005241. Online ahead of print. PMID: 37167612

Geographic Variation in Racial Disparities in Receipt of High-Dose Influenza Vaccine Among US Older Adults.
Silva JBB, Howe CJ, Jackson JW, Riester MR, Bardenheier BH, Xu L, Puckrein G, van Aalst R, Loiacono MM, Zullo AR. J Racial Ethn Health Disparities. 2023 May 15. doi: 10.1007/s40615-023-01628-z. Online ahead of print. PMID: 37184814

The Mashpee Wampanoag Tribe COVID-19 Pandemic Response: A Case Study.
Wong B, Andrews N Jr, Hathaway A, Burpee A, Agyemang E, Cooper B, Santibañez S. Health Secur. 2023 May 15. doi: 10.1089/HS.2022.0158. Online ahead of print. PMID: 37184662

Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris.
Bérot V, Eremin A, Fauchois A, Dechamp J, Schneider L, Chermak A, Faycal A, Sellem B, Orriere T, Favier M, Tubiana R, Valantin MA, Pourcher V, Todesco E, Monsel G, Agher R, Palich R, Katlama C. Sex Transm Infect. 2023 May 12:sextrans-2023-055802. doi: 10.1136/sextrans-2023-055802. Online ahead of print. PMID: 37173130

BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.

Bao Y, He L, Miao B, Zhong Z, Lu G, Bai Y, Liang Q, Ling Y, Ji P, Su B, Zhao GP, Wu H, Zhang W, Wang Y, Chen Y, Xu J. Vaccine. 2023 May 11;41(20):3258-3265. doi: 10.1016/j.vaccine.2023.03.070. Epub 2023 Apr 19. PMID: 37085449

Immunological response of 35 and 42 days old Asian seabass (Lates calcarifer, Bloch 1790) fry following immersion immunization with Streptococcus iniae heat-killed vaccine.
Vinh NT, Dong HT, Lan NGT, Sangsuriya P, Salin KR, Chatchaiphan S, Senapin S. Fish Shellfish Immunol. 2023 May 11:108802. doi: 10.1016/j.fsi.2023.108802. Online ahead of print. PMID: 37178986

Circulation of unusual and diverse enteric virus strains in adults with acute gastroenteritis: a study from Pune (Maharashtra), Western India.
Tatte VS, Gopalkrishna V. Arch Virol. 2023 May 12;168(6):160. doi: 10.1007/s00705-023-05771-0. PMID: 37169986

Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China.
Jiang M, Yao X, Peng J, Feng L, Ma Y, Shi X, Fang Y, Fang H. Am J Prev Med. 2023 May 12:S0749-3797(23)00225-8. doi: 10.1016/j.amepre.2023.05.007. Online ahead of print. PMID: 37182556

Molecular Farming Strategy for the Rapid Production of Protein-Based Reagents for Use in Infectious Disease Diagnostics.
Shanmugaraj B, Jirarojwattana P, Phoolcharoen W. Planta Med. 2023 May 15. doi: 10.1055/a-2076-2034. Online ahead of print. PMID: 37072112

Cardiovascular implications and physical activity in middle-aged and older adults with a history of COVID-19 (CV COVID): a protocol for a randomised controlled trial.
Rahman M, Russell SL, Okwose NC, Hood OMA, Harwood AE, McGregor G, Raleigh SM, Sandhu H, Roden LC, Maddock H, Banerjee P, Jakovljevic DG. Trials. 2023 May 13;24(1):328. doi: 10.1186/s13063-023-07360-7. PMID: 37179415

Immune response after rabies pre-exposure prophylaxis and a booster dose in Australian bat carers.
Guo Y, Mills DJ, Lau CL, Mills C, Furuya-Kanamori L. Zoonoses Public Health. 2023 May 11. doi: 10.1111/zph.13048. Online ahead of print. PMID: 37170441

The stigma associated with cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL): A protocol for a systematic review.
Nuwangi H, Agampodi TC, Price HP, Shepherd T, Weerakoon KG, Agampodi SB. PLoS One. 2023 May 11;18(5):e0285663. doi: 10.1371/journal.pone.0285663. eCollection 2023. PMID: 37167276

Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.
Seighali N, Shafiee A, Rafiee MA, Aminzade D, Mozhgani SH. BMC Infect Dis. 2023 May 11;23(1):320. doi: 10.1186/s12879-023-08289-7. PMID: 37170214

Exacerbation of Chronic Spontaneous Urticaria Following COVID-19 Vaccination in Omalizumab-Treated Patients.
Lee JH, Shin E, Kim HK, Song WJ, Kwon HS, Kim TB, Cho YS. J Allergy Clin Immunol Pract. 2023 May 12:S2213-2198(23)00535-4. doi: 10.1016/j.jaip.2023.04.050. Online ahead of print. PMID: 37182571

Investigation of Anti-PF4 versus Anti-PF4/Heparin Reactivities by Fluid-Phase EIA for Four Anti-PF4 Disorders: Classic HIT, Autoimmune HIT, VITT, Spontaneous HIT.
Warkentin TE, Arnold DM, Sheppard JI, Moore JC, Kelton JG, Nazy I. J Thromb Haemost. 2023 May 12:S1538-7836(23)00395-1. doi: 10.1016/j.jtha.2023.04.034. Online ahead of print. PMID: 37182698

Crystal structure of the dimerized of porcine circovirus type II replication-related protein Rep'.
Guan S, Tian A, Jing H, Yuan H, Jia H, Shi Y, Chen H, Cao S, Peng G, Song Y. Proteins. 2023 May 12. doi: 10.1002/prot.26498. Online ahead of print. PMID: 37171131

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
Ilchmann H, Samy N, Reichhardt D, Schmidt D, Powell JD, Meyer TPH, Silbernagl G, Nichols R, Weidenthaler H, De Moerlooze L, Chen L, Chaplin P. J Infect Dis. 2023 May 12;227(10):1203-1213. doi: 10.1093/infdis/jiac455. PMID: 36408618

A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus.
Woolsey C, Borisevich V, Agans KN, O'Toole R, Fenton KA, Harrison MB, Prasad AN, Deer DJ, Gerardi C, Morrison N, Cross RW, Eldridge JH, Matassov D, Geisbert TW. J Infect Dis. 2023 May 12:jiad157. doi: 10.1093/infdis/jiad157. Online ahead of print. PMID: 37171813

Nanovaccine Displaying Immunodominant T Cell Epitopes of Fibroblast Activation Protein Is Effective Against Desmoplastic Tumors.
Shin H, Kim Y, Jon S. ACS Nano. 2023 May 15. doi: 10.1021/acsnano.3c00764. Online ahead of print. PMID: 37184372

The Association of Mobility, Social Deprivation and Pediatric Primary Care Outcomes in Community Health Centers.
Lucas JA, Hsu A, Heintzman J, Bailey SR, Suglia SF, Bazemore A, Giebultowicz S, Marino M. J Pediatr. 2023 May 11:113465. doi: 10.1016/j.jpeds.2023.113465. Online ahead of print. PMID: 37179014

Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group.
Cazé AB, Cerqueira-Silva T, Bomfim AP, de Souza GL, Azevedo AC, Brasil MQ, Santos NR, Khouri R, Dan J, Bandeira AC, Cavalcanti LP, Barral-Netto M, Barral A, Barbosa CG, Boaventura VS. J Glob Health. 2023 May 12;13:06015. doi: 10.7189/jogh.13.06015. PMID: 37166260

Public relations strategies employed by the Ghana Health Service to address COVID-19 vaccine hesitancy: a qualitative inquiry.
McCarthy RNE, Donkoh ET, Arthur DD, Dassah ET, Boadu KO, Otoo JE, Boadu IWO, Gyasi SF. Trop Med Health. 2023 May 12;51(1):26. doi: 10.1186/s41182-023-00519-7. PMID: 37170342

Analysis of Alternative Splicing and Long Noncoding RNAs After the Edwardsiella anguillarum Infected the Immunized European Eels (Anguilla anguilla) Revealed the Role of Outer Membrane Protein A in OmpA Subunit Vaccine.
Guo S, Chen M, Li W, Wan Q, Xu M. Mar Biotechnol (NY). 2023 May 12. doi: 10.1007/s10126-023-10210-x. Online ahead of print. PMID: 37171708

Betulinic acid mitigates zearalenone-induced liver injury by ERS/MAPK/Nrf2 signaling pathways in mice.
Wu J, Li J, Wu Y, Yang M, Chen Y, Wang N, Wang J, Yuan Z, Yi J, Yang C. Food Chem Toxicol. 2023 May 11:113811. doi: 10.1016/j.fct.2023.113811. Online ahead of print. PMID: 37179046

Prefilled Syringe Injection Force Impact Assessment from Back Pressure: An Approach for Testing Syringe Injectability In Situ vs. In Vitro.
Megna C, Wells O, Bonanno D, Rasheed W, Cristofolli E. PDA J Pharm Sci Technol. 2023 May 15:pdajpst.2021.012654. doi: 10.5731/pdajpst.2021.012654. Online ahead of print. PMID: 37188533

A case of erythema elevatum diutinum after COVID-19 vaccination.
Muna B. J Eur Acad Dermatol Venereol. 2023 May 12. doi: 10.1111/jdv.19188. Online ahead of print. PMID: 37170942

Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches.
Rehman HM, Sajjad M, Ali MA, Gul R, Naveed M, Aslam MS, Shinwari K, Bhinder MA, Ghani MU, Saleem M, Rather MA, Ahmad I, Amin A. Int J Biol Macromol. 2023 May 15;237:124169. doi: 10.1016/j.ijbiomac.2023.124169. Epub 2023 Mar 28. PMID: 36990409

Public health concerns surrounding the cVDPV2 outbreak in Africa: Strategies for prevention and control with a special focus on Nigeria.
Adesola RO, Idris I, Opuni E. Health Sci Rep. 2023 May 12;6(5):e1269. doi: 10.1002/hsr2.1269. eCollection 2023 May. PMID: 37187504

A new neurodevelopmental disorder linked to heterozygous variants in UNC79.
Bayat A, Liu Z, Luo S, Fenger CD, Hojte AF, Isidor B, Cogne B, Larson A, Zanus C, Flavio F, Keren B, Musante L, Gourfinkel-An I, Perrine C, Demily C, Lesca G, Liao W, Ren D. Genet Med. 2023 May 11:100894. doi: 10.1016/j.gim.2023.100894. Online ahead of print. PMID: 37183800

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods.
Jordaens S, Zwaenepoel K, Tjalma W, Deben C, Beyers K, Vankerckhoven V, Pauwels P, Vorsters A. Int J Cancer. 2023 May 15;152(10):2186-2205. doi: 10.1002/ijc.34434. Epub 2023 Jan 22. PMID: 36647333

Succinate based polymers drive immunometabolism in dendritic cells to generate cancer immunotherapy.
Inamdar S, Suresh AP, Mangal JL, Ng ND, Sundem A, Behbahani HS, Rubino TE Jr, Shi X, Loa ST, Yaron JR, Hitosugi T, Green M, Gu H, Curtis M, Acharya AP. J Control Release. 2023 May 12:S0168-3659(23)00327-9. doi: 10.1016/j.jconrel.2023.05.014. Online ahead of print. PMID: 37182805

The Adjuvant Combination of dmLT and Monophosphoryl Lipid A Activates the Canonical, Nonpyroptotic NLRP3 Inflammasome in Dendritic Cells and Significantly Interacts to Expand Antigen-Specific CD4 T Cells.
Bauer DL, Bachnak L, Limbert VM, Horowitz RM, Baudier RL, D'Souza SJ, Immethun VE, Kurtz JR, Grant SB, McLachlan JB. J Immunol. 2023 May 15;210(10):1519-1530. doi: 10.4049/jimmunol.2200221. PMID: 37023458

Lactiplantibacillus plantarum attenuates Coxsackievirus B3-induced pancreatitis through the BAX/BCL2/CASP3 signaling pathway.
Yu X, Zhang Y, Pei K, Tan J, Tian H, Xu T, Liu F, Peng N, Huang Y, Huang X, Huang X, Wu J, Liu Q, Zeng L, Hua W, Huang X. Food Funct. 2023 May 11;14(9):4129-4142. doi: 10.1039/d3fo00390f. PMID: 37042256

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
Forte-Soto P, Albayaty M, Brooks D, Arends RH, Tillinghast J, Aksyuk AA, Bouquet J, Chen C, Gebre A, Kubiak RJ, Pilla Reddy V, Seegobin S, Streicher K, Templeton A, Esser MT. J Infect Dis. 2023 May 12;227(10):1153-1163. doi: 10.1093/infdis/jiad014. PMID: 36683419

Vaccination coverage reinforced by an infectious disease consultation during pretransplant check-up in patients awaiting kidney transplantation: a randomized study.
Calmels A, Heng AE, Corbin V, Garrouste C, Greze C, Pereira B, Lesens O. Infect Dis Now. 2023 May 11:104718. doi: 10.1016/j.idnow.2023.104718. Online ahead of print. PMID: 37178869

Exosome and epithelial-mesenchymal transition: A complex secret of cancer progression.
Dhar R, Devi A, Gorai S, Jha SK, Alexiou A, Papadakis M. J Cell Mol Med. 2023 May 15. doi: 10.1111/jcmm.17755. Online ahead of print. PMID: 37183560

Factors influencing and changes in childhood vaccination coverage over time in Bangladesh: a multilevel mixed-effects analysis.
Kundu S, Kundu S, Seidu AA, Okyere J, Ghosh S, Hossain A, Alshahrani NZ, Banna MHA, Rahman MA, Ahinkorah BO. BMC Public Health. 2023 May 11;23(1):862. doi: 10.1186/s12889-023-15711-x. PMID: 37170088

Interaction of the Hemagglutinin Stalk Region with Cell Adhesion Molecule (CADM) 1 and CADM2 Mediates the Spread between Neurons and Neuropathogenicity of Measles Virus with a Hyperfusogenic Fusion Protein.
Takemoto R, Hirai Y, Watanabe S, Harada H, Suzuki T, Hashiguchi T, Yanagi Y, Shirogane Y. J Virol. 2023 May 11:e0034023. doi: 10.1128/jvi.00340-23. Online ahead of print. PMID: 37166307

Women's knowledge of and attitudes towards group B streptococcus (GBS) testing in pregnancy: a qualitative study.
Constantinou G, Ayers S, Mitchell EJ, Walker KF, Daniels J, Moore S, Jones AM, Downe S. BMC Pregnancy Childbirth. 2023 May 11;23(1):339. doi: 10.1186/s12884-023-05651-0. PMID: 37170236

Botulinum neurotoxin injection in the deltoid muscle: application to cosmetic shoulder contouring.
Yi KH, Lee JH, Hu H, Park HJ, Lee HJ, Choi YJ, Kim HJ. Surg Radiol Anat. 2023 May 13. doi: 10.1007/s00276-023-03163-2. Online ahead of print. PMID: 37178218

Cost-effectiveness Analysis of Integrated Bite Case Management and Sustained Dog Vaccination for Rabies Control.
Taylor E, Prada JM, Del Rio Vilas V, Undurraga EA, Wallace R, Horton DL. Am J Trop Med Hyg. 2023 May 15:tpmd220308. doi: 10.4269/ajtmh.22-0308. Online ahead of print. PMID: 37188344

COVID-19 pandemic response in the Meuse-Rhine Euroregion: methods, participation and recommendations of a longitudinal cross-border study.
Stabourlos C, van Bilsen CJA, Brinkhues S, Moonen CPB, Demarest S, Hanssen DAT, van Loo IHM, Savelkoul PHM, Philippsen D, van der Zanden BAM, Dukers-Muijrers NHTM, Hoebe CJPA. Arch Public Health. 2023 May 13;81(1):91. doi: 10.1186/s13690-023-01102-6. PMID: 37179369

Transcriptional programming of CD4^{+} T_{RM} differentiation in viral infection balances effector- and memory-associated gene expression.
Nguyen QP, Takehara KK, Deng TZ, O'Shea S, Heeg M, Omilusik KD, Milner JJ, Quon S, Pipkin ME, Choi J, Crotty S, Goldrath AW. Sci Immunol. 2023 May 12;8(83):eabq7486. doi: 10.1126/sciimmunol.abq7486. Epub 2023 May 12. PMID: 37172104

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.
Cheung TH, Cheng SSY, Hsu D, Wing-Lei Wong Q, Pavelyev A, Sukarom I, Saxena K. Hum Vaccin Immunother. 2023 May 15:2184605. doi: 10.1080/21645515.2023.2184605. Online ahead of print. PMID: 37183965

Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
Panni UY, Chen MY, Zhang F, Cullinan DR, Li L, James CA, Zhang X, Rogers S, Alarcon A, Baer JM, Zhang D, Gao F, Miller CA, Gong Q, Lim KH, DeNardo DG, Goedegebuure SP, Gillanders WE, Hawkins WG. Cancer Immunol Immunother. 2023 May 13. doi: 10.1007/s00262-023-03463-x. Online ahead of print. PMID: 37179276

Side effects of COVID-19 vaccination and breast cancer.
Kleebayoon A, Wiwanitkit V. Clin Exp Med. 2023 May 15. doi: 10.1007/s10238-023-01086-1. Online ahead of print. PMID: 37184601

Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.
Zelek WM, Harrison RA. Immunobiology. 2023 May 11;228(3):152393. doi: 10.1016/j.imbio.2023.152393. Online ahead of print. PMID: 37187043

Diversity of cervicovaginal human papillomavirus (HPV) genotypes and naturally occurring E6/E7 DNA polymorphisms of HPV-16 in Ghana.
Kaba G, Stevenson A, Sakyi SA, Konney TO, Bhatia R, Titiloye NA, Oppong SA, Agyemang-Yeboah F, Cuschieri K, Graham SV. Tumour Virus Res. 2023 May 11:200261. doi: 10.1016/j.tvr.2023.200261. Online ahead of print. PMID: 37179021

Causes and risk factors of death among people who inject drugs in Indonesia, Ukraine and Vietnam: findings from HPTN 074 randomized trial.
Dumchev K, Guo X, Ha TV, Djoerban Z, Zeziulin O, Go VF, Sarasvita R, Metzger DS, Latkin CA, Rose SM, Piwowar-Manning E, Richardson P, Hanscom B, Lancaster KE, Miller WC, Hoffman IF. BMC Infect Dis. 2023 May 11;23(1):319. doi: 10.1186/s12879-023-08201-3. PMID: 37170118

Viral Genetic Determinants of Prolonged Respiratory Syncytial Virus Infection Among Infants in a Healthy Term Birth Cohort.
Lawless D, McKennan CG, Das SR, Junier T, Xu ZM, Anderson LJ, Gebretsadik T, Shilts MH, Larkin E, Rosas-Salazar C, Chappell JD, Fellay J, Hartert TV. J Infect Dis. 2023 May 12;227(10):1194-1202. doi: 10.1093/infdis/jiac442. PMID: 36375000

Socioeconomic and risk-related drivers of compliance with measures to prevent SARS-CoV-2 infection: evidence from the Munich-based KoCo19 study.
Pedron S, Laxy M, Radon K, Le Gleut R, Castelletti N, Noller JMG, Diefenbach MN, Hölscher M, Leidl R, Schwettmann L; KoCo19 collaboration group. BMC Public Health. 2023 May 11;23(1):860. doi: 10.1186/s12889-023-15759-9. PMID: 37170091

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.
Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, Kimura KT, Deguchi S, Wang L, Lytras S, Tamura T, Kida I, Nasser H, Shofa M, Begum MM, Tsuda M, Oda Y, Suzuki T, Sasaki J, Sasaki-Tabata K, Fujita S, Yoshimatsu K, Ito H, Nao N, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Kuramochi J, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A, Matsuno K, Takayama K, Hashiguchi T, Tanaka S, Fukuhara T, Ikeda T, Sato K. Nat Commun. 2023 May 11;14(1):2671. doi: 10.1038/s41467-023-38188-z. PMID: 37169744

Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study.
Schieppati F, Russo L, Gamba S, Galimberti E, Giaccherini C, Tartari CJ, Bolognini S, Verzeroli C, Ticozzi C, Barcella L, Marchetti M, Falanga A. Thromb Haemost. 2023 May 12. doi: 10.1055/s-0043-1768921. Online ahead of print. PMID: 37172940

Continuous positive airway pressure in COVID-19-associated respiratory failure: improving patient care with a proforma.
Moore D. Br J Nurs. 2023 May 11;32(9):412-419. doi: 10.12968/bjon.2023.32.9.412. PMID: 37173090

Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice.
Park BR, Bommireddy R, Chung DH, Kim KH, Subbiah J, Jung YJ, Bhatnagar N, Pack CD, Ramachandiran S, Reddy SJC, Selvaraj P, Kang SM. Immun Ageing. 2023 May 11;20(1):20. doi: 10.1186/s12979-023-00344-w. PMID: 37170231

Neonatal refractory Sweet syndrome triggered by Bacille Calmette-Guerin vaccination with extensive pulmonary involvement.
Zhang Z, Zhou W, Liang J, Wei R, Yao Z, Gu Y, Li H. J Eur Acad Dermatol Venereol. 2023 May 12. doi: 10.1111/jdv.19180. Online ahead of print. PMID: 37170965

Carriage of Neisseria meningitidis among travelers attending the Hajj pilgrimage, circulating serogroups, sequence types and antimicrobial susceptibility: A multinational longitudinal cohort study.
Yezli S, Yassin Y, Mushi A, Alabdullatif L, Alburayh M, Alotaibi BM, Khan A, Walsh L, Lekshmi A, Walker A, Lucidarme J, Borrow R. Travel Med Infect Dis. 2023 May 11:102581. doi: 10.1016/j.tmaid.2023.102581. Online ahead of print. PMID: 37178946

Food additive succinate exacerbates experimental autoimmune encephalomyelitis accompanied by increased IL-1β production.
Sugiyama Y, Takata K, Kinoshita M, Motooka D, Shiraishi N, Kihara K, Murata H, Beppu S, Koda T, Yamashita K, Namba A, Fujimoto K, Kumanogoh A, Okuno T, Mochizuki H. Biochem Biophys Res Commun. 2023 May 14;656:97-103. doi: 10.1016/j.bbrc.2023.03.041. Epub 2023 Mar 16. PMID: 36958260

Spontaneous resolution of inflammatory myopathy involving the masseter muscle following COVID-19 mRNA vaccination.
Tada T, Murao H, Shiratani R, Park J, Hideshima M, Kanki H, Ishikawa N, Shibahara T, Fujimoto J, Higa S. Mod Rheumatol Case Rep. 2023 May 11:rxad022. doi: 10.1093/mrcr/rxad022. Online ahead of print. PMID: 37178168

Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination.
[No authors listed] Open Forum Infect Dis. 2023 May 11;10(5):ofad251. doi: 10.1093/ofid/ofad251. eCollection 2023 May. PMID: 37180589

Predicting the spread of covid-19 and the impact of government measures at the early stage of the pandemic: The Dutch case-Stricter but short-term measures are better.
Tenhagen CJ, Topan E, Groothuis-Oudshoorn KCGM. PLoS One. 2023 May 12;18(5):e0283086. doi: 10.1371/journal.pone.0283086. eCollection 2023. PMID: 37172041

Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022.
Park SK, Choe YJ, Jang EJ, Kim RK, Lee SW, Kwon GY, Shin J, Choi SY, Jeong MJ, Park YJ. J Korean Med Sci. 2023 May 15;38(19):e143. doi: 10.3346/jkms.2023.38.e143. PMID: 37191847

No effects of COVID-19 on the development of type 1 diabetes autoimmunity and no evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed type 1 diabetes patients relative to healthy subjects.
Claudio T, Raffaella N, Valeria T, Tiziana F, Laura P, Francesca S, Valeria F, Monica M, Enrica M, Andrea L, Fabio M, Francesco C, Susanna M. Acta Diabetol. 2023 May 12:1-7. doi: 10.1007/s00592-023-02103-1. Online ahead of print. PMID: 37171699

On the optimal presence strategies for workplace during pandemics: A COVID-19 inspired probabilistic model.
Davoodi M, Senapati A, Mertel A, Schlechte-Welnicz W, M Calabrese J. PLoS One. 2023 May 12;18(5):e0285601. doi: 10.1371/journal.pone.0285601. eCollection 2023. PMID: 37172012

Anal Intraepithelial Neoplasia and Anal Squamous Cell Carcinoma: Updates From the Last 3 Years.
Albuquerque A. J Low Genit Tract Dis. 2023 May 11. doi: 10.1097/LGT.0000000000000749. Online ahead of print. PMID: 37166025

Why we should care about moral foundations when preparing for the next pandemic: Insights from Canada, the UK and the US.
Pizza L, Ronfard S, Coley JD, Kelemen D. PLoS One. 2023 May 12;18(5):e0285549. doi: 10.1371/journal.pone.0285549. eCollection 2023. PMID: 37172059

Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children.
Badano MN, Duarte A, Salamone G, Sabbione F, Pereson M, Chuit R, Baré P. Immunology. 2023 May 15. doi: 10.1111/imm.13656. Online ahead of print. PMID: 37188378

Farm management practices associated with influenza A virus contamination of people working in Midwestern United States swine farms.
Lopez-Moreno G, Culhane MR, Davies P, Corzo C, Allerson MW, Torremorell M. Porcine Health Manag. 2023 May 15;9(1):13. doi: 10.1186/s40813-023-00304-2. PMID: 37183258

The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.
Vesikari T, Langley JM, Spaans JN, Petrov I, Popovic V, Yassin-Rajkumar B, Anderson DE, Diaz-Mitoma F. Vaccine. 2023 May 11:S0264-410X(23)00528-5. doi: 10.1016/j.vaccine.2023.05.010. Online ahead of print. PMID: 37179167

Clinical evaluation of commercial SARS-CoV-2 serological assays in a malaria endemic setting.
Dabitao D, Shaw-Saliba K, Konate DS, Highbarger HC, Lallemand P, Sanogo I, Rehman T, Wague M, Coulibaly N, Kone B, Baya B, Diakite SAS, Samake S, Akpa E, Tounkara M, Laverdure S, Doumbia S, Lane HC, Diakite M, Dewar RL. J Immunol Methods. 2023 May 11:113488. doi: 10.1016/j.jim.2023.113488. Online ahead of print. PMID: 37179012

Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures.
Inagaki M, Abe N, Li Z, Nakashima Y, Acharyya S, Ogawa K, Kawaguchi D, Hiraoka H, Banno A, Meng Z, Tada M, Ishida T, Lyu P, Kokubo K, Murase H, Hashiya F, Kimura Y, Uchida S, Abe H. Nat Commun. 2023 May 11;14(1):2657. doi: 10.1038/s41467-023-38244-8. PMID: 37169757

Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID.
Scott NA, Pearmain L, Knight SB, Brand O, Morgan DJ, Jagger C, Harbach S, Khan S, Shuwa HA, Franklin M, Kästele V, Williams T, Prise I, McClure FA, Hackney P, Smith L, Menon M, Konkel JE, Lawless C, Wilson J, Mathioudakis AG, Stanel SC, Ustianowski A, Lindergard G, Brij S, Diar Bakerly N, Dark P, Brightling C, Rivera-Ortega P, Lord GM, Horsley A; CIRCO; Piper Hanley K, Felton T, Simpson A, Grainger JR, Hussell T, Mann ER. Eur Respir J. 2023 May 11;61(5):2202226. doi: 10.1183/13993003.02226-2022. Print 2023 May. PMID: 36922030

Development and validity assessment of ELISA test with recombinant chimeric protein of SARS-CoV-2.
Fernandez Z, de Arruda Rodrigues R, Torres JM, Marcon GB, de Castro Ferreira E, de Souza VF, Sarti EFB, Bertolli GF, Araujo D, Demarchi LHF, Lichs G, Zardin MU, Gonçalves CCM, Cuenca V, Favacho A, Guilhermino J, Dos Santos LR, de Araujo FR, Silva MR. J Immunol Methods. 2023 May 11:113489. doi: 10.1016/j.jim.2023.113489. Online ahead of print. PMID: 37179011

Can ChatGPT/GPT-4 Assist surgeons in confronting patients with Mpox and handling future epidemics?
He Y, Wu H, Chen Y, Wang D, Tang W, Moody MA, Ni G, Gu S. Int J Surg. 2023 May 11. doi: 10.1097/JS9.0000000000000453. Online ahead of print. PMID: 37161504

Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination.
Middleton BF, Danchin M, Cunliffe NA, Jones MA, Boniface K, Kirkwood CD, Gallagher S, Kirkham LA, Granland C, McNeal M, Donato C, Bogdanovic-Sakran N, Handley A, Bines JE, Snelling TL. Vaccine. 2023 May 11:S0264-410X(23)00525-X. doi: 10.1016/j.vaccine.2023.05.007. Online ahead of print. PMID: 37179162

Humoral Response After Five Successive Doses of SARS-CoV-2 mRNA Vaccine in Kidney Transplant Patients.
Cazorla JM, Villanego F, Aguilera A, Garcia T, Orellana C, Trujillo T, Gómez AM, Mazuecos A. Transplantation. 2023 May 12. doi: 10.1097/TP.0000000000004628. Online ahead of print. PMID: 37170412

Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy.
Ollila HM, Sharon E, Lin L, Sinnott-Armstrong N, Ambati A, Yogeshwar SM, Hillary RP, Jolanki O, Faraco J, Einen M, Luo G, Zhang J, Han F, Yan H, Dong XS, Li J, Zhang J, Hong SC, Kim TW, Dauvilliers Y, Barateau L, Lammers GJ, Fronczek R, Mayer G, Santamaria J, Arnulf I, Knudsen-Heier S, Bredahl MKL, Thorsby PM, Plazzi G, Pizza F, Moresco M, Crowe C, Van den Eeden SK, Lecendreux M, Bourgin P, Kanbayashi T, Martínez-Orozco FJ, Peraita-Adrados R, Benetó A, Montplaisir J, Desautels A, Huang YS; FinnGen; Jennum P, Nevsimalova S, Kemlink D, Iranzo A, Overeem S, Wierzbicka A, Geisler P, Sonka K, Honda M, Högl B, Stefani A, Coelho FM, Mantovani V, Feketeova E, Wadelius M, Eriksson N, Smedje H, Hallberg P, Hesla PE, Rye D, Pelin Z, Ferini-Strambi L, Bassetti CL, Mathis J, Khatami R, Aran A, Nampoothiri S, Olsson T, Kockum I, Partinen M, Perola M, Kornum BR, Rueger S, Winkelmann J, Miyagawa T, Toyoda H, Khor SS, Shimada M, Tokunaga K, Rivas M, Pritchard JK, Risch N, Kutalik Z, O'Hara R, Hallmayer J, Ye CJ, Mignot EJ. Nat Commun. 2023 May 15;14(1):2709. doi: 10.1038/s41467-023-36120-z. PMID: 37188663

The chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers.
Sherif AY, Harisa GI, Alanazi FK. Curr Drug Deliv. 2023 May 12. doi: 10.2174/1567201820666230512122825. Online ahead of print. PMID: 37183467

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
Havranek B, Lindsey GW, Higuchi Y, Itoh Y, Suzuki T, Okamoto T, Hoshino A, Procko E, Islam SM. Commun Biol. 2023 May 12;6(1):513. doi: 10.1038/s42003-023-04860-9. PMID: 37173421

Delayed cutaneous hypersensitivities to COVID-19 vaccination - Phenotypic distribution and tolerability of vaccine rechallenge.
De Luca JF, Awad A, Vogrin S, Waldron JL, McInnes K, Gibney G, Hall R, Douglas AP, Chua KY, Holmes NE, Trubiano JA. J Allergy Clin Immunol Pract. 2023 May 11:S2213-2198(23)00529-9. doi: 10.1016/j.jaip.2023.04.045. Online ahead of print. PMID: 37178767

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R,

Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Goldberg SV, Swindells S, Chaisson RE, Nahid P. Am J Respir Crit Care Med. 2023 May 15;207(10):1376-1382. doi: 10.1164/rccm.202206-1118OC. PMID: 36790881

COVID-19 in Morocco's region: Observational study of prevalence in symptomatic adults using the PANBIOS® rapid antigen test September 2021.
Haroun AE, Obtel M, El Hilali S, Zeghari Z, Oulachguer N, Idrissi KS, Razine R. Influenza Other Respir Viruses. 2023 May 11;17(5):e13142. doi: 10.1111/irv.13142. eCollection 2023 May. PMID: 37180839

Global economic burden per episode for multiple diseases caused by group A Streptococcus.
Lee JS, Kim S, Excler JL, Kim JH, Mogasale V. NPJ Vaccines. 2023 May 15;8(1):69. doi: 10.1038/s41541-023-00659-1. PMID: 37188693

Optimization of Vaccine Responses in Solid Organ Transplant Recipients.
Miller-Handley H, Huaman MA. Clin Pharmacol Ther. 2023 May 11. doi: 10.1002/cpt.2909. Online ahead of print. PMID: 37170690

Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination.
[No authors listed] Open Forum Infect Dis. 2023 May 11;10(5):ofad251. doi: 10.1093/ofid/ofad251. eCollection 2023 May. PMID: 37180589

Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir.
Nakamura K, Sugiyama M, Ishizuka H, Sasajima T, Minakawa Y, Sato H, Miyazawa M, Kitakawa K, Fujita S, Saito N, Kashiwabara N, Kohata H, Hara Y, Kanari Y, Shinka T, Kanemitsu K. J Infect Chemother. 2023 May 12:S1341-321X(23)00113-7. doi: 10.1016/j.jiac.2023.05.003. Online ahead of print. PMID: 37182841

A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy.
Li Q, Dong Z, Cao Z, Lei H, Wang C, Hao Y, Feng L, Liu Z. ACS Nano. 2023 May 15. doi: 10.1021/acsnano.3c01404. Online ahead of print. PMID: 37184402

Distinct association between chronic EBV infection and T cell compartments from pediatric heart, kidney, and liver transplant recipients.
Yamada M, Macedo C, Louis K, Shi T, Landsittel D, Nguyen C, Shinjoh M, Michaels MG, Feingold B, Mazariegos GV, Green M, Metes D. Am J Transplant. 2023 May 13:S1600-6135(23)00468-9. doi: 10.1016/j.ajt.2023.05.007. Online ahead of print. PMID: 37187296

Memory T cells possess an innate-like function in local protection from mucosal infection.
Arkatkar T, Davé V, Cruz Talavera I, Graham JB, Swarts JL, Hughes SM, Bell TA, Hock P, Farrington J, Shaw GD, Kirby A, Fialkow M, Huang ML, Jerome KR, Ferris MT, Hladik F, Schiffer JT, Prlic M, Lund JM. J Clin Invest. 2023 May 15;133(10):e162800. doi: 10.1172/JCI162800. PMID: 36951943

Raman spectra characterization of size-dependent aggregation and dispersion of polystyrene particles in aquatic environments.

Gao H, Liu C, Wang H, Shen H. Chemosphere. 2023 May 12:138939. doi: 10.1016/j.chemosphere.2023.138939. Online ahead of print. PMID: 37182713

'We do not rush to the hospital for ordinary wounds (suḷu tuvāla)': A qualitative study on the early clinical manifestations of cutaneous leishmaniasis and associated health behaviours in rural Sri Lanka.
Gunasekara SD, Wickramasinghe ND, Agampodi SB, Fernando MS, Weerakoon KG, Liyanage C, Dikomitis L, Agampodi TC. PLoS Negl Trop Dis. 2023 May 12;17(5):e0010939. doi: 10.1371/journal.pntd.0010939. Online ahead of print. PMID: 37172051

Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
Awasthi R, Maier HJ, Zhang J, Lim S. Hum Vaccin Immunother. 2023 May 15:2210046. doi: 10.1080/21645515.2023.2210046. Online ahead of print. PMID: 37185251

Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody.
Zhao T, Liang P, Ren J, Zhu J, Yang X, Bian H, Li J, Cui X, Fu C, Xing J, Wen C, Zeng J. Anal Chim Acta. 2023 May 15;1255:341102. doi: 10.1016/j.aca.2023.341102. Epub 2023 Mar 20. PMID: 37032051

Evaluation of Serial Testing After Exposure to COVID-19 in Early Care and Education Facilities, Illinois, March-May 2022.
Holman EJ, Winfield CM, Borkowf CB, Kauerauf J, Baur C, Ahmed S, Funk M, Pinsoneault A, Barnes A, Hutcherson H, Oberholtzer Z, Carter B, Ruth LJ, Thomas ES. Public Health Rep. 2023 May 13:333549231173014. doi: 10.1177/00333549231173014. Online ahead of print. PMID: 37178058

Investigating the epidemiological and economic effects of a third-party certification policy for restaurants with COVID-19 prevention measures.
Hirokawa K, Hirota J, Kawaguchi D, Masaki Y, Onita C. Sci Rep. 2023 May 11;13(1):7655. doi: 10.1038/s41598-023-34498-w. PMID: 37169796

Rapid detection of Nipah virus using the one-pot RPA-CRISPR/Cas13a assay.
Miao J, Zuo L, He D, Fang Z, Berthet N, Yu C, Wong G. Virus Res. 2023 May 11:199130. doi: 10.1016/j.virusres.2023.199130. Online ahead of print. PMID: 37178792

Use of sotrovimab in vaccinated versus unvaccinated COVID-19 patients in a resource-limited emergency department during the omicron surge.
Nene RV, Santodomingo MA, Balog B, Martinez H, Murillo E, Tomaszewski CA, LaFree A. J Am Coll Emerg Physicians Open. 2023 May 11;4(3):e12958. doi: 10.1002/emp2.12958. eCollection 2023 Jun. PMID: 37188260

Temporal reliability and stability of delay discounting: A 2-year repeated assessments study of the Monetary Choice Questionnaire.
Strickland JC, Gelino BW, Rabinowitz JA, Ford MR, Dayton L, Latkin C, Reed DD. Exp Clin Psychopharmacol. 2023 May 15. doi: 10.1037/pha0000651. Online ahead of print. PMID: 37184943

Standardizing Routine Vaccination of Dermatologists with Occupational Exposure to Human Papillomavirus in Clinical Settings.

Rypka KJ, Farah RS, Mansh M. J Am Acad Dermatol. 2023 May 13:S0190-9622(23)00757-0. doi: 10.1016/j.jaad.2023.04.053. Online ahead of print. PMID: 37187428

OMIP-91: A 27-color flow cytometry panel to evaluate the phenotype and function of human conventional and unconventional T-cells.
Anderson J, Jalali S, Licciardi PV, Pellicci DG. Cytometry A. 2023 May 14. doi: 10.1002/cyto.a.24738. Online ahead of print. PMID: 37183268

SUCCESSFUL REVACCINATION OF A CHILD WITH GIANOTTI-CROSTI SYNDROME FOLLOWING DIPHTHERIA TETANUS AND RABIES VACCINATIONS.
Yuksel Bulut H, Arslan H, Ertugrul A, Oz FN, Ulusoy Severcan E, Bostanci I. J Allergy Clin Immunol Pract. 2023 May 13:S2213-2198(23)00543-3. doi: 10.1016/j.jaip.2023.05.007. Online ahead of print. PMID: 37187240

Emergence of a novel genotype of class II New Castle Disease virus in North Eastern States of India.
Rajkhowa TK, Zodinpuii D, Bhutia LD, Islam SJ, Gogoi A, Hauhnar L, Kiran J, Choudhary OP. Gene. 2023 May 15;864:147315. doi: 10.1016/j.gene.2023.147315. Epub 2023 Feb 24. PMID: 36842725

Evaluation of the Immunological Response of Childhood Cancer Patients Treated with a Personalized Peptide Vaccine for Refractory Soft Tissue Tumor: A Four-Case Series.
Oda K, Ito Y, Yamada A, Yutani S, Itoh K, Ozono S. Kurume Med J. 2023 May 12. doi: 10.2739/kurumemedj.MS682012. Online ahead of print. PMID: 37183020

An Efficacy and Mechanism Driven Study on the Impact of Hypoxia on Lipid Nanoparticle Mediated mRNA Delivery.
Ma Y, Fenton OS. J Am Chem Soc. 2023 May 15. doi: 10.1021/jacs.3c02584. Online ahead of print. PMID: 37184377

SARS-CoV-2 Omicron BA.1.1 is Highly Resistant to Antibody Neutralization of Convalescent Serum from the Origin Strain.
Li J, Li X, Mao H, Huang C, Sun Y, Miao L, Li J, Song W, Zhang Y, Huang J, Chen K. Virus Res. 2023 May 11:199131. doi: 10.1016/j.virusres.2023.199131. Online ahead of print. PMID: 37178794

Correction to: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).
[No authors listed] J Natl Cancer Inst. 2023 May 13:djad076. doi: 10.1093/jnci/djad076. Online ahead of print. PMID: 37178175

Overall effect of a campaign with measles vaccine on the composite outcome mortality or hospital admission: a cluster-randomised trial among children aged 9-59 months in rural Guinea-Bissau.
Varma A, Thysen SM, Martins JSD, Nanque LM, Jensen AKG, Fisker AB. Int J Infect Dis. 2023 May 12:S1201-9712(23)00561-1. doi: 10.1016/j.ijid.2023.05.011. Online ahead of print. PMID: 37182547

Outcome and Morphofunctional Changes on Cardiac Magnetic Resonance in Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.
Ammirati E, Lupi L, Palazzini M, Ciabatti M, Rossi VA, Gentile P, Uribarri A, Vecchio CR, Nassiacos D, Cereda A, Conca C, Tumminello G, Piriou N, Lelarge C, Pedrotti P, Stucchi M, Peretto G, Galasso M,

Huang F, Ianni U, Procopio A, Saponara G, Cimaglia P, Tomasoni D, Moroni F, Turco A, Sala S, Di Tano G, Bollano E, Moro C, Abbate A, Della Bona R, Porto I, Carugo S, Campodonico J, Pontone G, Grosu A, Bolognese L, Salamanca J, Diez-Villanueva P, Ozieranski K, Tyminska A, Sardo Infirri L, Bromage D, Cannatà A, Hong KN, Adamo M, Quattrocchi G, Foà A, Potena L, Garascia A, Giannattasio C, Adler ED, Sinagra G, Ruschitzka F, Camici PG, Metra M, Pieroni M. Circ Heart Fail. 2023 May 15:e010315. doi: 10.1161/CIRCHEARTFAILURE.122.010315. Online ahead of print. PMID: 37183708

Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.
Karime C, Hashash JG, Farraye FA. Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00348-8. doi: 10.1016/j.cgh.2023.05.004. Online ahead of print. PMID: 37187325

The FLURESP European commission project: cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic?
Beresniak A, Napoli C, Oxford J, Daruich A, Niddam L, Duru G, Tozzi AE, Atti MCD, Dupont D, Rizzo C, Bremond-Gignac D. Cost Eff Resour Alloc. 2023 May 15;21(1):30. doi: 10.1186/s12962-023-00432-0. PMID: 37189126

Author Correction: Intradermal needle-free injection prevents African Swine Fever transmission, while intramuscular needle injection does not.
Salman M, Lin H, Suntisukwattana R, Watcharavongtip P, Jermsutjarit P, Tantituvanont A, Nilubol D. Sci Rep. 2023 May 15;13(1):7840. doi: 10.1038/s41598-023-34898-y. PMID: 37188851

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K, Kahlhöfer J, Dörge P, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, Wedemeyer H, Deterding K; HIDIT-2 Study Team. Liver Int. 2023 May 15. doi: 10.1111/liv.15602. Online ahead of print. PMID: 37183524

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230501:20230515 as the publication date 81 records*

1.WO/2023/070223SYNTHETIC GLYCOCONJUGATE VACCINE PROTOTYPE AGAINST STREPTOCOCCUS SUIS
WO - 04.05.2023
Clasificación Internacional C07H 15/04 Nº de solicitud PCT/CA2022/051600 Solicitante UNIVERSITÉ DE MONTRÉAL Inventor/a SEGURA, Mariela
The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapted for use against other serotypes of S. suis such as serotypes 1, 1/2, 3, 9, and 14. Also, the vaccine may be adapted for use in humans.

2.4174183FUSIONSGEN, REKOMBINANTER NEUARTIGER HOCHEFFIZIENTER CORONAVIRUS-IMMUN-DNA-IMPFSTOFF, HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON
EP - 03.05.2023
Clasificación Internacional C12N 15/62 Nº de solicitud 21894027 Solicitante AURORA GENEVAC BIOTECH CO LTD Inventor/a YU JIYUN
A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method and use thereof are provided. The immune DNA vaccine ZD-nCor19 provided herein uses RBD protein, residues 301-538 in the S2 subunit and residues 138-369 in the N protein of the novel coronavirus as target antigens, and has specific immune synergism molecules introduced at suitable positions, and thus can simultaneously efficiently induce humoral immunity and cellular immunity, and can avoid safety problems associated with ADE that may be generated by the full-length S protein and the full-length N protein, thereby achieving dual effects of prevention and treatment. The vaccine can be used as a safe, efficient and stable vaccine variety against novel coronavirus infection.

3.20230133364NOVEL CORONAVIRUS VACCINE BASED ON INFLUENZA VIRUS VECTOR AND PREPARATION METHOD THEREOF
US - 04.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 17770521 Solicitante GUANGZHOU N BIOMED LTD. Inventor/a Ling Chen
Disclosed are a novel coronavirus vaccine based on an influenza virus vector and a preparation method thereof. The vaccine can efficiently express two antigens, i.e., its own HA antigen and an exogenous SC2R1 antigen, enabling the vaccine to induce immune responses to the two antigens, thus achieving the purpose of preventing both influenza virus and novel coronavirus, thereby eliminating the impacts of the two major infectious diseases of influenza and novel coronavirus on social economy, etc. at one time. In addition, based on existing mature influenza platform techniques, the influenza vaccine can be prepared and produced on a large scale, and the use of influenza vaccines has a long history and good safety.

4.20230137174NOVEL SALMONELLA-BASED CORONAVIRUS VACCINE
US - 04.05.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17907619 Solicitante NEC ONCOIMMUNITY AS Inventor/a Heinz LUBENAU
The present invention relates to a DNA vaccine comprising a *Salmonella typhi* Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.

5.WO/2023/076180COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY
WO - 04.05.2023
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/US2022/047599 Solicitante GENVIVO, INC. Inventor/a FISCHER-LOUGHEED, Jacqueline
Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

6.4173635NEUARTIGES IMMUNSTIMULANS UND IMPFSTOFFZUSAMMENSETZUNG DAMIT
EP - 03.05.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 20942169 Solicitante REPUBLIC KOREA ANIMAL & PLANT QUARANTINE AGENCY Inventor/a LEE MINJA
The present inventors have found that innate immune response and T cell exhaustion pathway are more greatly over-expressed in pigs than cattle, such that the pigs are less likely to form adaptive and humoral

immune responses than cattle. It would be suggested herein an innovative strategy for improvement of abnormal immune responses in pigs by simultaneously inducing potent cellular and humoral immune responses and applying T cell agonists as a new vaccine adjuvant. This result may provide an important clue for understanding a difference in the immune response between the cattle and pigs, while suggesting a method for maximizing the immune response and vaccine efficacy, which are less expressed in pigs than cattle.

7.20230136960Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same
US - 04.05.2023
Clasificación Internacional C12N 15/88 Nº de solicitud 17912741 Solicitante Nature's Toolbox, Inc. Inventor/a Michael Humbert
The inventive technology includes a novel immunostimulatory RNA vaccine for the COVID-19 coronavirus. In one preferred aspect, the inventive technology includes a novel mRNA sequence encoding at least one antigenic peptide or protein comprising or consisting of a COVID-19 coronavirus protein or a fragment or variant thereof.

8.4171630PRÄERYTHROZYTÄRE MALARIAIMPFSTOFFE
EP - 03.05.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 20943397 Solicitante PATH Inventor/a KING C RICHTER
Pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaeneamide, or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant with enhanced specific immune response against antigens and good preservation stability and a malaria vaccine with biological activity allow for the provision of pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action.

9.WO/2023/072805A VACCINE FOR THE PROTECTION OF PIGLETS AGAINST SWINE INFLUENZA A VIRUS INFECTION
WO - 04.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/079532 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a NAGARAJ, Basav, Hangalapura
The present invention pertains to the use of a vaccine based on an alphavirus RNA replicon particle (αRP) vector encoding an antigen of an IAV-S for the passive vaccination of piglets against a pathogenic infection with swine influenza virus.

10.4171619BRUSTKREBSIMPFSTOFF
EP - 03.05.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21828216 Solicitante NAT BREAST CANCER COALITION Inventor/a KNUTSON KEITH L
The invention relates to vaccines for breast cancer therapy. The invention also relates to methods of preventing and treating breast cancer using a breast cancer vaccine.

11.WO/2023/076977NOROVIRUS VACCINE AND METHODS OF USE
WO - 04.05.2023
Clasificación Internacional A61K 39/125 Nº de solicitud PCT/US2022/078753 Solicitante THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor/a ATOCHINA-VASSERMAN, Elena

Provided is a Norovirus vaccine comprising mRNA molecules encoding Norovirus VP1 antigens and methods of use thereof to treat or prevent a disease or disorder associated with Norovirus infection.

12.4172897ADAPTIVE IMPFSTOFF-STOCKWERK
EP - 03.05.2023
Clasificación Internacional G06Q 10/06 Nº de solicitud 21745874 Solicitante SEQIRUS UK LTD Inventor/a BOLLANDS ALLEN
A method of selectively providing access to an inventory of pre-pandemic vaccines is disclosed. The method includes identifying at least two Influenza Viruses of Pandemic Potential (IVPP) to provide available vaccines; determining a stockpile requirement for vaccines against selected IVPPs among the at least two IVPPs; obtaining finished vaccines against each of the selected IVPPs; storing an inventory of finished vaccines against each of the selected IVPPs; providing the finished vaccines against at least one of the selected IVPPs in response to an access request; and periodically obtaining further finished vaccines against one or more of the selected IVPPs and adding the further finished vaccines to the inventory of finished vaccines. Additionally disclosed are methods of selecting the inventory of finished vaccines for an adaptive vaccine stockpile.

13.20230140549EXPRESSION SYSTEM FOR EXPRESSING HERPESVIRUS GLYCOPROTEIN COMPLEXES
US - 04.05.2023
Clasificación Internacional A61K 39/245 Nº de solicitud 17806157 Solicitante CITY OF HOPE Inventor/a Felix WUSSOW
An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. The expression system or the vector can be included in a vaccine composition. The vaccine composition can be used for preventing or treating herpesvirus infections.

14.20230133188MODIFIED MRNAS FOR VACCINE DEVELOPMENT
US - 04.05.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17912402 Solicitante BASECLICK GMBH Inventor/a Thomas FRISCHMUTH
A modified messenger RNA (mRNA) of the present invention encodes within its ORF an antigen such as a viral protein, an immunogenically active part of such viral protein, or an anticancer protein or epitope, and contains at least one of an alkyne- or azide-modification in at least one nucleotide. A preferred viral protein encoded by the inventive mRNA is a Corona vims protein, especially nucleoprotein N of SARS-CoV-2. The modified mRNA or a pharmaceutical composition containing such mRNA is especially useful in the context of a method for vaccination against viral infection and adding an adjuvant like a STING antagonist further enhances the immune response in an individual and accordingly the vaccination efficiency.

15.20230138274Body Fluids Sampling Device and Method of using the Same
US - 04.05.2023
Clasificación Internacional A61B 5/15 Nº de solicitud 17915497 Solicitante Preci Health SA Inventor/a Lucien Vouillamoz
A fluid sampling device and a method is provided for collecting body fluid samples such as blood without the intervention of medically trained personnel. The body fluid sampling device having a sample containment chamber made of a material having a thermal inertia permitting the maintenance of sample temperature over a known period of time. Optionally an isolating cover or sleeve may slide in place by a

mechanism triggered by thermal contraction of an element after the device has reached a sufficiently low temperature in a patients refrigerator. Associated methods are provided to ensure hermetic transport of the collected body fluid sample to an analysis lab. Also disclosed is a device and app combination for drug or vaccine injection, the app including means to allow for verification of the patient's ID and/or the particular device used. The device my be equipped with geo-localization and long-range communication capabilities.

16.301248MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF
IL - 01.05.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 301248 Solicitante JANSSEN PHARMACEUTICALS, INC Inventor/a

17.20230134033IMMUNOGENIC COMPLEX FOR ELICITING PROTECTIVE IMMUNITY AGAINST GROUP B STREPTOCOCCUS
US - 04.05.2023
Clasificación Internacional A61K 39/09 Nº de solicitud 18048148 Solicitante Minervax APS Inventor/a Per Bo PEDERSEN FISCHER
The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B *Streptococcus* surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B *Streptococcus*. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B *Streptococcus* infection, as well as a method of preventing or treating a group B *Streptococcus* infection.

18.20230139366BRARTEMICIN ANALOGUES
US - 04.05.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 18047708 Solicitante VICTORIA LINK LTD Inventor/a Amy Jane FOSTER
The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.

19.20230136745AN ANTITHROMBIC MOLECULE HAVING APAC ACTIVITY FOR THE PREVENTION AND/OR TREATMENT OF THROMBOCYTOPENIA
US - 04.05.2023
Clasificación Internacional A61K 47/64 Nº de solicitud 17918391 Solicitante Aplagon OY Inventor/a Riitta Lassila
The invention relates to an anti-thrombotic molecule having both anti-platelet and anti-coagulant (APAC) activity and, in particular, its use as a medicament to prevent and/or treat heparin-induced thrombocytopenia (HIT) type I or II; and/or heparin-induced thrombocytopenia and thrombosis (HITT); and/or heparin-independent thrombocytopenia autoimmune HIT (aHIT); and/or vaccine-induced thrombocytopenia and thrombosis (VITT). The invention has use in both the medical and veterinary industries.

20.301224ALPHA-SYNUCLEIN VACCINE FOR THE TREATMENT OF SYNUCLEINOPATHIES
IL - 01.05.2023
Clasificación Internacional A61K 38/00 Nº de solicitud 301224 Solicitante PROTHENA BIOSCIENCES LIMITED Inventor/a

21.WO/2023/070873METHOD FOR PREPARING SARS-COV-2 VIRUS-LIKE PARTICLES AND USE OF SARS-COV-2 VIRUS-LIKE PARTICLES

WO - 04.05.2023
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/CN2021/138037 Solicitante SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor/a DAI, Junbiao
A composition for preparing SARS-CoV-2 virus-like particles. The composition comprises a first plasmid containing a Stru ΔS fragment, and any one or two selected from a second plasmid containing an S fragment and a third plasmid containing a packaging signal fragment of the SARS-CoV-2 virus. The method for preparing the composition comprises: respectively splitting a Stru ΔS fragment, an S fragment and/or an ORF1ab packaging signal fragment into short DNA fragments having homologous sequences between adjacent fragments, and performing homologous recombination on the short DNA fragments and a linear plasmid vector in a yeast cell. The present invention further relates to a method for preparing SARS-CoV-2 virus-like particles using the composition, the obtained SARS-CoV-2 virus-like particles, and the use of the composition in the preparation of a vaccine for preventing or treating SARS-CoV-2 virus infections and in the in-vitro research on cells infected by the SARS-CoV-2 virus.

22.301262MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL - 01.05.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 301262 Solicitante OTHAIR PROTHENA LIMITED Inventor/a

23.4171514KALTFILTRATION VON ÖL-IN-WASSER-EMULSIONSADJUVANTIEN
EP - 03.05.2023
Clasificación Internacional A61K 9/107 Nº de solicitud 21752737 Solicitante SEQIRUS UK LTD Inventor/a HUNN STEPHEN
The present disclosure relates to the method of filtering emulsions at cold temperatures. Specifically, cold filtration of emulsion adjuvants for vaccine manufacture is discussed.

24.4171625KLEBSIELLA PNEUMONIAE O-ANTIGEN IMPFSTOFF
EP - 03.05.2023
Clasificación Internacional A61K 39/108 Nº de solicitud 21731535 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a CARRANZA SANDMEIER MARIA PAULA
The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to *Klebsiella pneumoniae* O-antigens, conjugates ccccomprising a *K. pneumoniae* O-antigen, host cells suitable for their production and immunogenic compositions or vaccines containing at least one *Klebsiella pneumoniae* O-antigen.

25.WO/2023/076539A SUBUNIT CRYPTOCOCCUS VACCINE
WO - 04.05.2023
Clasificación Internacional A61K 39/02 Nº de solicitud PCT/US2022/048142 Solicitante UNIVERSITY OF MASSACHUSETTS Inventor/a LEVITZ, Stuart
Provided herein are subunit vaccines against Cryptococcus.

26.4174074MULTIANTENNÄRE GLYCOLIPIDMIMETIKA
EP - 03.05.2023
Clasificación Internacional C07D 498/04 Nº de solicitud 21382980 Solicitante CONSEJO SUPERIOR INVESTIGACION Inventor/a GARCÍA FERNÁNDEZ JOSÉ MANUEL
The invention relates to a multiantennary glycolipid mimetics of formula I, wherein X, Y, Z and R^1 are defined in the description, or a pharmaceutical composition thereof and their use as a medicament, particularly, for the treatment and/or prevention of an immune disease cursed by Th1/Th2 imbalance. Further the invention relates to a vaccine which comprises a compound of formula I.

27.WO/2023/072816MULTIANTENNARY GLYCOLIPID MIMETICS
WO - 04.05.2023
Clasificación Internacional C07D 498/04 Nº de solicitud PCT/EP2022/079553 Solicitante CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) Inventor/a GARCÍA FERNÁNDEZ, José Manuel
The invention relates to a multiantennary glycolipid mimetics of formula (I), wherein X, Y, Z and R1 are defined in the description, or a pharmaceutical composition thereof and their use as a medicament, particularly, for the treatment and/or prevention of an immune disease cursed by Th1/Th2 imbalance. Further the invention relates to a vaccine which comprises a compound of formula (I).

28.4171628PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON COVID-19 UND VERWANDTEN ERKRANKUNGEN
EP - 03.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21734243 Solicitante UNTHREADT B V Inventor/a KHAN NISAR AHMED
The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b.identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a vaccine comprising one or more agents interacting with at least one region of at least 4 consecutive amino acids present in the SARS-CoV-2 proteome, not conserved between the SARS-CoV-2 proteome and the human proteome. Finally, the invention can provide a molecular and cellular explanation for the deviant infectivity, clinical behaviour, and pathology of emerging SARS-CoV-2 variants over time, to design vaccines to specifically prevent these complications, and to select peptides as therapeutic modality to treat these clinical manifestations and complications.

29.20230134571ENGINEERED ANTIBODIES TO HIV ENV
US - 04.05.2023
Clasificación Internacional C07K 16/10 Nº de solicitud 17772561 Solicitante International AIDS Vaccine Initiative Inventor/a Devin SOK
The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.

30.301223β-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL - 01.05.2023

Clasificación Internacional A61K 39/00 Nº de solicitud 301223 Solicitante OTHAIR PROTHENA LIMITED Inventor/a

31.301406VARIANT STAPHYLOCOCCUS AUREUS LUKA AND LUKB POLYPEPTIDES AND VACCINE COMPOSITIONS
IL - 01.05.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 301406 Solicitante JANSSEN PHARMACEUTICALS, INC Inventor/a

32.2023014004 71H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
US - 04.05.2023
Clasificación Internacional A61K 31/519 Nº de solicitud 18081558 Solicitante BRISTOL-MYERS SQUIBB COMPANY Inventor/a YAM B. POUDEL
Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7).
Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

33.4171627IMPFSTOFFKOMBINATION GEGEN RESPIRATORISCHE SYNZYTIALVIRUSINFEKTION
EP - 03.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21733702 Solicitante JANSSEN VACCINES & PREVENTION BV Inventor/a CALLENDRET BENOIT C S
Methods of safely inducing a protective immune response against respiratory syncytial virus (RSV) and methods of preventing infection and/or replication of RSV in human subjects are described. The methods include administering to the subjects (a) an effective amount of an adenoviral vector encoding a recombinant RSV F protein that is stabilized in a pre-fusion conformation, and (b) an effective amount of an RSV F protein that is stabilized in a pre-fusion conformation.

34.4172633VERFAHREN, ZUSAMMENSETZUNGEN UND SYSTEME ZUM NACHWEIS VON CORONAVIRUSNEUTRALISIERENDEN ANTIKÖRPERN
EP - 03.05.2023
Clasificación Internacional G01N 33/68 Nº de solicitud 21745569 Solicitante LABORATORY CORP AMERICA HOLDINGS Inventor/a PETROPOULOS CHRISTOS J
The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.

35.WO/2023/070317BIFUNCTIONAL NANOBODY BASED ON DC, AND CONSTRUCTION METHOD THEREFOR AND USE THEREOF
WO - 04.05.2023
Clasificación Internacional C07K 16/28 Nº de solicitud PCT/CN2021/126429 Solicitante JIANGSU ACADEMY OF AGRICULTURAL SCIENCES Inventor/a CHENG, Haiwei
Disclosed in the present invention are a bifunctional nanobody based on DC, and a construction method therefor and the use thereof. The bifunctional nanobody is a target protein, wherein a target protein specific nanobody based on DC is linked to a gene encoding a virus antigen specific nanobody with a particle size of 150 nm or less using a linker element to obtain a target gene fragment, and the obtained target protein is subjected to recombinant expression. According to the method of the present invention, specific nanobodies for different pathogens are screened, and a corresponding porcine DC targeted bifunctional nanobody is constructed and is used for preparing a vaccine for pigs.

36.4171626STABILISIERTE CORONAVIRUS-SPIKE (S)-PROTEINIMMUNOGENE UND VERWANDTE IMPFSTOFFE
EP - 03.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 20943768 Solicitante SCRIPPS RESEARCH INST Inventor/a HE LINLING
The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.

37.WO/2023/077147T-CELL VACCINES FOR PATIENTS WITH REDUCED HUMORAL IMMUNITY
WO - 04.05.2023
Clasificación Internacional A61K 39/145 Nº de solicitud PCT/US2022/079034 Solicitante PELLIS THERAPEUTICS, INC. Inventor/a KUPPER, Thomas S.
Administration of intact, non-replicating or replication-deficient poxvirus, in combination with a T cell antigen, to disrupted epithelial tissue induces antigen-specific T cell mediated immunity in a subject with reduced humoral immunity such as those undergoing B cell depletion therapies. Compositions and methods for inducing T cell mediated immune responses to antigen in epithelial tissues of a subject are provided. The methods include administering to disrupted epithelial tissue intact, non-replicating or replication-impaired poxvirus including one or more T cell antigens. The epithelial tissue may be mechanically disrupted by a device such as a scarification needle or an abrader device prior to, at the same time, or immediately after the administration of the vaccine composition.

38.WO/2023/076907MALARIA VACCINE FORMULATIONS
WO - 04.05.2023
Clasificación Internacional A61K 39/015 Nº de solicitud PCT/US2022/078665 Solicitante NOVAVAX AB Inventor/a REIMER, Jenny M.
Disclosed herein are immunogenic compositions comprising an antigen of a Plasmodium parasite. Methods of administering the aforementioned compositions are also disclosed.

39.202301404301H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US - 04.05.2023
Clasificación Internacional C07D 519/00 Nº de solicitud 17792887 Solicitante BRISTOL-MYERS SQUIBB COMPANY Inventor/a Matthew COX
Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

40.4171243ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEREITSTELLUNG VON GESUNDHEITSVORTEILEN BEI EINEM TIER
EP - 03.05.2023
Clasificación Internacional A23C 9/20 Nº de solicitud 21758162 Solicitante NESTLE SA Inventor/a YU PING
A method of enhancing vaccine efficacy, treating or preventing an allergy, or treating or preventing an autoimmune disease in an animal can comprise administering to the animal a composition comprising colostrum.

41.WO/2023/073672THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-COV-2
WO - 04.05.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/IB2022/060499 Solicitante GENEONE LIFE SCIENCE, INC. Inventor/a MUTHUMANI, Kar
Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.

1.20230142894VACCINE FOR PREVENTION OF NECROTIC ENTERITIS IN POULTRY
US - 11.05.2023
Clasificación Internacional A61K 39/08 Nº de solicitud 18089056 Solicitante ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor/a Kenneth ROLAND
In certain embodiments, the present invention provides a poultry vaccine comprising an antigenic protein comprising a PlcC protein unit that is operably linked to a peptide linker that is operably linked to a NetB protein unit, where the vaccine is effective in stimulating a protective cellular and/or humoral immune response to C. perfringens. Methods are also provided for making the vaccine and for vaccinating poultry by administering such a vaccine.
2.20230145774TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION
US - 11.05.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17907013 Solicitante BIONTECH SE Inventor/a Ugur SAHIN
The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immunostimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.
3.WO/2023/080501METHOD OF PROVIDING INFORMATION FOR PREDICTING IMMUNE RESPONSE TO SARS-COV-2 VACCINE THROUGH GUT MICROBIOTA AND FUNCTIONAL BIOMARKER PROFILES, AND METHOD OF PROVIDING SUBJECT-CUSTOMIZED VACCINE INFORMATION
WO - 11.05.2023
Clasificación Internacional C12Q 1/6883 Nº de solicitud PCT/KR2022/016100 Solicitante KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION Inventor/a SEONG, Hye
The present invention relates to a method of providing information for predicting immune response to SARS-CoV-2 vaccination and a method of providing customized vaccine information, and more specifically, the present invention verifies that the taxonomic composition of a gut microbiota, metabolites produced thereby, and functional profiles thereof are significantly correlated with the immune response after vaccination, and thus can be used to predict the immune response to SARS-CoV-2 vaccination or provide subject-customized vaccine information. According to the present invention, by identifying the taxonomic composition and functional biomarkers of a subject's gut microbiota prior to vaccination, the subject's humoral immune response level after vaccination can be predicted and information can be provided for vaccine administration that would induce an effective immune response and fewer side effects in the subject.

4.20230146516PRECISION-BASED IMMUNO-MOLECULAR AUGMENTATION (PBIMA) COMPUTERIZED SYSTEM, METHOD, AND THERAPEUTIC VACCINE
US - 11.05.2023
Clasificación Internacional G16H 10/60 Nº de solicitud 17944335 Solicitante Neo7Logix, LLC Inventor/a Shamsuddin Sultan Khan
As disclosed herein a precision based immunomolecular augmentation (PBIMA) high specificity patient profiling networked computer system, rapid therapeutic vaccine design method, and personalized vaccine, which utilizes immuno-molecular biopathway HLA affinity mapping and selection prediction ranking tools. This PBIMA approach comprises: Strategic-Selection, Molecular-Mapping, Antigen-Alignment, Receptor-Recognition, and Tactical Technology (SMART). The platform obtains data from a patient's genes and proteins as input. NGS data, including WES, WGS, ctDNA and cfDNA, RNAseq uses as input. PBIMA comprises a gene-protein-cell Cloud-based sequence editing interface to select the high confidence peptides. The PBIMA vaccine is a solution-based multi-purpose vaccine design strategy. PBIMA technology can produce therapeutic vaccines for cancer, autoimmune, neurodegenerative, inflammation-driven disease, and novel pathogen infection treatment. PBIMA therapeutic design is multi-mechanistic and broad-spectrum.
5.WO/2023/077395VESICULAR STOMATITIS VIRUS-BASED EBV VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 11.05.2023
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/CN2021/128848 Solicitante SUN YAT-SEN UNIVERSITY CANCER CENTER (SYSUCC) Inventor/a ZENG, Musheng
A vesicular stomatitis virus-based EBV vaccine, a preparation method therefor, and a use thereof. For the first time, the key EBV glycoproteins gB and gHgL are displayed on the VSV surface, and the modified VSV is used for animal immunization. A new type of EBV vaccine is provided and is expected to induce bodies to generate sufficiently strong immune responses to prevent EBV from infecting host cells, thereby reducing the incidence of EBV-related tumor and non-tumor diseases. It is found that the modified VSV can produce significant specific antibodies against EBV surface glycoproteins gB and gHgL. Moreover, it is proved that the specific antibodies produced can inhibit EBV from infecting epithelial cells and B lymphocytes. It is also shown that a VSV-based EBV vaccine can be used for preventing EBV infections and related tumor and non-tumor diseases among people with good immune effects.
6.WO/2023/080408PRIMER SET, COMPOSITION AND KIT FOR DETECTING VACCINIA VIRUS AND ANALYSIS METHOD USING SAME
WO - 11.05.2023
Clasificación Internacional C12Q 1/70 Nº de solicitud PCT/KR2022/012714 Solicitante KOLON INDUSTRIES, INC. Inventor/a CHOI, Heon Sik
The present invention relates to a primer set, a composition and a kit for detecting vaccinia virus to detect and quantify vaccinia virus, and an analysis method using same. The primer set for detecting vaccinia virus has a short analysis period and excellent sensitivity and specificity compared to conventional virus quantification methods, and thus, when real-time PCR using such a primer set is performed, vaccinia virus can be detected and quantified more rapidly and accurately in real time.
7.20230146932MULTI-EPITOPE PAN-CORONAVIRUS VACCINE COMPOSITIONS
US - 11.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 18046862 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a Lbachir BenMohamed
Multi-epitope, pan-coronavirus recombinant vaccine compositions featuring a combination of highly conserved B cell epitopes, highly conserved CD4+ T cell epitopes, and highly conserved CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The present invention uses several

immuno-informatics and sequence alignment approaches and multiple immunological assays in vitro using human blood and saliva samples from COVID patients and healthy patients to identify several human B cells, CD4+ and CD8+ T cell epitopes that are highly conserved and antigenic in vitro. The Invention also used an in vivo unique mouse model of ACE2/HLA-A0201/HLA-DR triple transgenic mouse model to test the immunogenicity and the protective efficacy against SARS-CoV-2 infection and COVID-Like symptoms, of the identified B and T cell epitopes and of the resulting multi-epitope-pan-Coronavirus vaccine candidates. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of Coronaviruses mutations.

8.WO/2023/080718VACCINE COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-CORONAVIRUS-2 INFECTION

WO - 11.05.2023

Clasificación Internacional A61K 39/215 Nº de solicitud PCT/KR2022/017256 Solicitante SK BIOSCIENCE CO., LTD. Inventor/a HONG, Seung-Hye

The present invention relates to a vaccine composition for prevention or treatment of SARS-Coronavirus-2 infection, comprising: RBD nanoparticles comprising a trimer and a pentamer, the trimer being formed by assembling three first polypeptide monomers comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% identity thereto, and the pentamer being formed by assembling five second polypeptide monomers comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 75% identity thereto; and an adjuvant. The vaccine composition, according to the present invention, exhibits excellent immunogenicity when inoculated, and thus the vaccine composition of the present invention may be usefully employed for the purpose of preventing SARS-Coronavirus-2 infection or alleviating symptoms when infected therewith.

9.20230144060MERS-CoV VACCINE

US - 11.05.2023

Clasificación Internacional A61K 39/215 Nº de solicitud 17918244 Solicitante Sumagen Canada Inc. Inventor/a Chil-Yong KANG

A recombinant vesicular stomatitis vims (rVSV) carrying at least one gene that encodes for a MERS-CoV structural protein or modifications thereof. Vaccines or immunogenic compositions against MERS-CoV, and prime boost immunization platforms a prime boost immunization combination against MERS-CoV including: (a) a prime vaccine or immunogenic composition comprising a rVSV carrying at least one gene that encodes for a MERS-CoV structural protein or modifications thereof, and (b) a boost vaccine or immunogenic composition comprising a rVSV carrying the same at least one gene that encodes for a MERS-CoV structural protein or modifications thereof. The at least one gene can be genetically modified to encode a modified MERS-CoV structural protein that elevates glycoprotein synthesis and trigger efficient humoral immune response.

10.WO/2023/079507RESPIRATORY SYNCYTIAL VIRUS RNA VACCINE

WO - 11.05.2023

Clasificación Internacional A61K 39/12 Nº de solicitud PCT/IB2022/060639 Solicitante SANOFI Inventor/a CASIMIRO, Danilo

The present disclosure provides a respiratory syncytial virus (RSV) vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding an RSV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

11.WO/2023/081471HUMAN BROADLY CROSSREACTIVE INFLUENZA MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF

WO - 11.05.2023

Clasificación Internacional C07K 16/10 Nº de solicitud PCT/US2022/049142 Solicitante DANA-FARBER CANCER INSTITUTE, INC. Inventor/a MARASCO, Wayne A.

The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.

12.20230147269METHOD FOR PRODUCING INACTIVATED INFLUENZA VACCINE AND VACCINE COMPOSITION THEREOF

US - 11.05.2023

Clasificación Internacional A61K 39/145 Nº de solicitud 17905040 Solicitante DENKA COMPANY LIMITED Inventor/a Ryotaro MITSUMATA

An inactivated influenza vaccine may have high immunogenicity and may be produced by method including performing inactivation treatment using formaldehyde including treating a virus solution containing an influenza virus collected from a host with β-propiolactone in advance. The inactivation treatment using formaldehyde may be performed by adding formalin to the virus solution at a final concentration of 0.005 to 0.015 vol %.

13.WO/2023/080328VACCINE ADJUVANT COMPOSITION COMPRISING AGRIMONIA PILOSA EXTRACT AND GALLA RHOIS EXTRACT

WO - 11.05.2023

Clasificación Internacional A61K 39/39 Nº de solicitud PCT/KR2021/018808 Solicitante APRG CO., LTD. Inventor/a KANG, Se Chan

The present invention relates to a vaccine adjuvant composition comprising an Agrimonia pilosa extract and a Galla rhois extract, wherein the vaccine adjuvant composition can increase the effect of virus vaccines and can thus be effectively used as an adjuvant for increasing the immune response of various vaccines, such as SARS-CoV-2 virus and influenza virus vaccines.

14.WO/2023/077206GENETICALLY MODIFIED EPITOPES AND MULTIEPITOPE PROTEINS, IMMUNOGENIC COMPOSITIONS AND USE THEREOF

WO - 11.05.2023

Clasificación Internacional C07K 14/44 Nº de solicitud PCT/BR2022/050425 Solicitante UNIVERSIDADE FEDERAL DO RIO DE JANEIRO - UFRJ Inventor/a ALINE, Aline Silva Barreto

This invention consists of genetically modified epitopes and multiepitope proteins composed of these genetically modified epitopes to avoid the formation of neoepitopes. The multiAAA protein is composed of genetically modified epitopes by addition of three alanine residues. The multiGPGPG protein is composed of genetically modified epitopes by addition of glycine-proline-glycine-proline-glycine residues. Both proteins are formulated as immunogenic compositions. This invention aims at optimising the vaccinal efficacy and immunological potency of a vaccine against leishmaniasis through the use of its more potent and promiscuous epitopes, having a wider world population coverage, and further aims at solving the problem of the absence of a vaccine against human visceral leishmaniasis, a lethal disease that is spreading in Brazil and the world.

15.WO/2023/078279IMMUNOGENIC COMPOSITION AND USE THEREOF

WO - 11.05.2023

Clasificación Internacional C07K 14/195 Nº de solicitud PCT/CN2022/129153 Solicitante FECULA BIOTECH CO., LTD. Inventor/a CHEN, Chih-Ming

Provided are an immunogenic composition and the use thereof. Provided is an immunogenic composition comprising a glycosylated chaperonin 60 derived from Lactobacillus reuteri and an immunogen, an oral vaccine comprising the immunogenic composition, and the anti-cancer use of the oral vaccine.

16.20230145860METHODS TO GENERATE VACCINE COMPOSITIONS THAT PRIME HUMAN LEUKOCYTE ANTIGEN CLASS I RESTRICTED CD8 T-CELL RESPONSES AGAINST VIRAL NON-VIRION-INTEGRAL DERIVED EPITOPES
US - 11.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 17907532 Solicitante Genovie AB Inventor/a Reagan Micheal Jarvis
Method for providing a vaccine composition capable of effectively inducing a systemic immune response and/or a localised immune response upon administration, wherein the composition comprises human leukocyte antigen class I (HLAI)-restricted epitopes selected from viral pathogen non-virion-integral proteins (non-VIP) and thus prime a CD8 T-cell response specifically directed against virally infected cells.
17.WO/2023/080246BETACORONAVIRUS ATTENUATED STRAIN
WO - 11.05.2023
Clasificación Internacional C12N 7/01 Nº de solicitud PCT/JP2022/041445 Solicitante THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY Inventor/a TAKEKAWA, Shiro
The purpose of the present invention is to provide a strain that is useful as a new betacoronavirus vaccine. A novel betacoronavirus, according to the present invention, having, in combination, a prescribed substitution mutation relating to temperature sensitivity, and a prescribed deletion mutation relating to attenuation, is found to be useful as a betacoronavirus vaccine strain having excellent attenuated characteristics.
18.20230145957A VACCINE TO PROTECT AGAINST MYCOPLASMA HYOPNEUMONIAE
US - 11.05.2023
Clasificación Internacional A61K 39/295 Nº de solicitud 17917987 Solicitante Intervet Inc. Inventor/a Johanna Jacoba Elisabeth Bijlsma
A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.
19.20230143494METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES
US - 11.05.2023
Clasificación Internacional A01N 37/20 Nº de solicitud 17975645 Solicitante BAYER HEALTHCARE LLC Inventor/a SHENGJIANG LIU
This disclosure relates to methods for use in inactivating viruses. The methods of inactivating viruses with N-methylglucamides is applicable to the purification process of biologically-active drugs such as protein subunits, proteins (enzymes, factors, etc.), recombinant proteins, antibodies, vaccine or gene therapeutic products. The detergents used in this method are based on multiple N-methylglucamide homologs, consisting of a hydrophilic glucose moiety and hydrophobic fatty acid tail, linked by an amide bond. Additionally, these sugar-based detergents are nonionic by nature, which do not disrupt the drug protein, plasma biologics, non-enveloped viral vaccine or adeno associated viral particles.
A method of purifying a biological product solution of interest having an unidentified enveloped virus contaminant, including incubating a biological product solution of interest with a standard solution, inactivating any potential enveloped virus contaminant present in the biological product solution of step (a), measuring the inactivated virus present in the final solution of step (b), incubating a separate biological product solution of interest with a N-methylglucamide solution, measuring the inactivated virus present in the final solution of step (d), and comparing the results of the final solutions of step (c) and step (e).
20.WO/2023/081798MULTIVALENT INFLUENZA VACCINES COMPRISING RECOMBINANT HEMAGGLUTININ AND NEURAMINIDASE AND METHODS OF USING THE SAME
WO - 11.05.2023

Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/079274 Solicitante SANOFI PASTEUR INC. Inventor/a ALEFANTIS, Timothy
Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.
21.WO/2023/079113HYBRID MULTIVALENT INFLUENZA VACCINES COMPRISING HEMAGGLUTININ AND NEURAMINIDASE AND METHODS OF USING THE SAME
WO - 11.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/080875 Solicitante SANOFI Inventor/a ALEFANTIS, Timothy
Disclosed herein are hybrid multivalent vaccine or immunogenic compositions comprising (i) one or more influenza virus proteins selected from one or more influenza virus hemagglutinin (HA) proteins, one or more influenza virus neuraminidase (NA) proteins, or a combination thereof; and (ii) one or more ribonucleic acid molecules encoding one or more influenza virus proteins selected from one or more influenza virus HA proteins, one or more influenza virus NA proteins, or a combination thereof. Also disclosed are methods of using the vaccine or immunogenic compositions.
22.20230145817Neoepitope vaccine and immune stimulant combinations and methods
US - 11.05.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18150136 Solicitante NantCell, Inc. Inventor/a Shahrooz Rabizadeh
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
23.WO/2023/078946LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY
WO - 11.05.2023
Clasificación Internacional A61K 9/51 Nº de solicitud PCT/EP2022/080576 Solicitante ZIPHIUS VACCINES NV Inventor/a VALEMBOIS, Sophie
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula (I) and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
24.20230148332VACCINE ADJUVANTS
US - 11.05.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 17918249 Solicitante VIROVAX LLC Inventor/a Sunil Abraham David
A compound comprising a structure of Compound 1, or prodrug thereof, salt thereof, or tautomer, polymorph, solvate, or combination thereof, can be used as an adjuvant in vaccines. The Compound 1 can be used in: methods of performing a vaccination; methods of agonizing a TLR 7 and/or TLR 8; and/or methods of activating an immune system.
25.WO/2023/079529RE-FOCUSING PROTEIN BOOSTER IMMUNIZATION COMPOSITIONS AND METHODS OF USE THEREOF
WO - 11.05.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/IB2022/060700 Solicitante KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor/a RUEPING, Magnus Albert
Booster immunization compositions and methods of use thereof, are provided. The disclosed compositions use adjuvanted proteins as a booster vaccine targeting functionally relevant pathogen B and

T cell epitopes to re-focus a patient's adaptive antibody and cytotoxic T-cell response. The pharmaceutically active ingredient of the re-focusing boost vaccines include of one or several recombinant protein molecules in a full-length or truncated yet functional (meaning the overall antigenic tertiary structure is retained) version of disease-related protein or protein domain, a smaller subunit or specific or modified epitope or combination of shorter epitopes derived from that initial prime antigen sequence. Methods for re-focusing an immune response in a subject, to augment an existing (not sufficiently protective immune response) and effectively neutralize a pathogen of interest in a mammalian host organism include administering to a subject whose immune system has been primed by a previous infection/ vaccination against the pathogen.

26.WO/2023/077924VACCINE AGAINST PANCREATIC CANCER, AND MEDICAL USE THEREOF

WO - 11.05.2023

Clasificación Internacional A61K 47/64 Nº de solicitud PCT/CN2022/114956 Solicitante YUANBEN (ZHUHAI HENGQIN) BIOTECHNOLOGY CO., LTD. Inventor/a CAI, Jiong

An anti-tumor fusion protein, wherein the fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein has broad application prospects for the prevention and/or treatment of pancreatic cancer.

27.WO/2023/079472MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE

WO - 11.05.2023

Clasificación Internacional C12N 15/85 Nº de solicitud PCT/IB2022/060586 Solicitante KASHIV BIOSCIENCES, LLC Inventor/a GUPTA, Sudharti

The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants.

28.WO/2023/081936SARS-COV-2 VACCINES

WO - 11.05.2023

Clasificación Internacional C12N 15/86 Nº de solicitud PCT/US2022/079510 Solicitante GRITSTONE BIO, INC. Inventor/a GITLIN, Leonid

Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

29.WO/2023/081861ENHANCED EXPRESSION VIA AUTOTRANSPORTERS

WO - 11.05.2023

Clasificación Internacional C07K 19/00 Nº de solicitud PCT/US2022/079351 Solicitante UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor/a ZEICHNER, Steven, L.

Provided are expression cassettes that include coding sequences encoding at least one polar amino acid or at least one expression enhancement peptide that includes one or more polar amino acids, a polypeptide of interest, and a bacterial autotransporter β-barrel polypeptide. In some embodiments, the coding sequences are in frame with each other such that transcription and translation of the expression cassette in a host cell produces a fusion protein with the polar amino acid and/or the expression enhancement peptide, the polypeptide of interest, and the bacterial autotransporter β-barrel polypeptide expressed on the surface of the host cell. Also provided are expression vectors and host cells that include the expression cassettes, vaccine compositions based on the presently disclosed compositions, and methods for inducing immune responses, enhancing expression of the polypeptides of interest, for preventing or treating viral infections such as but not limited to coronavirus infections.

30.WO/2023/078954LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY

WO - 11.05.2023
Clasificación Internacional A61K 9/51 Nº de solicitud PCT/EP2022/080590 Solicitante ZIPHIUS VACCINES NV Inventor/a VALEMBOIS, Sophie
The current invention relates to ionizable lipid-like compounds according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula (I) and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
31.20230141404BFS INJECTION AND CONNECTION ASSEMBLIES
US - 11.05.2023
Clasificación Internacional A61M 5/178 Nº de solicitud 18055103 Solicitante Koska Family Limited Inventor/a Jeff Price
A pre-filled medical delivery system assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) bottle to a patient utilizing one or more BFS injection or connection assemblies.
32.20230142621EXOSOMAL NUCLEIC ACID VACCINE MODULARLY CONFIGURED TO HARNESS MULTIPLE ANTIGEN PRESENTATION MECHANISMS
US - 11.05.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 17909610 Solicitante The Johns Hopkins University Inventor/a Stephen John Gould
The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.
33.WO/2023/077925DRUG FOR TREATING AND/OR PREVENTING CANCER AND USE THEREOF
WO - 11.05.2023
Clasificación Internacional A61K 39/395 Nº de solicitud PCT/CN2022/114957 Solicitante YUANBEN (ZHUHAI HENGQIN) BIOTECHNOLOGY CO., LTD. Inventor/a CAI, Jiong
The present invention provides a drug for treating and/or preventing cancer and a use thereof. The drug in the present invention comprises a recombinant MBP-MUC1-N fusion protein vaccine, a PD-1 antibody and/or oxaliplatin, and the drug can enhance an MUC1-specific anti-tumor immune response.
34.WO/2023/078950LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY
WO - 11.05.2023
Clasificación Internacional A61K 9/51 Nº de solicitud PCT/EP2022/080581 Solicitante ZIPHIUS VACCINES NV Inventor/a HAQUE, AKM, Ashiqul
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula (I) and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
35.202301448241H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US - 11.05.2023
Clasificación Internacional C07D 487/04 Nº de solicitud 17793248 Solicitante BRISTOL-MYERS SQUIBB COMPANY Inventor/a Liqi HE

Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

36.WO/2023/078574A PHARMACEUTICAL KIT FOR ONCOLYTIC VIROTHERAPY OF BREAST CANCER, ITS PREPARATION AND USE

WO - 11.05.2023

Clasificación Internacional A61P 35/00 Nº de solicitud PCT/EP2021/080992 Solicitante SVEUCILISTE U ZAGREBU Inventor/a HALASSY, Beata

The present invention discloses a pharmaceutical kit consisting of composition I and composition II. Composition I comprises a viable Measles virus (MeV), Edmonston Zagreb vaccine strain with one or more pharmaceutical excipients. Composition II comprises a viable, Vesicular stomatitis virus (VSV) Indiana strain according to ATCC, with one or more pharmaceutical excipients. The final dosage forms are a suspension or a lyophilized powder for reconstitution of injectable suspension. The compositions I and II from the said kit are administered by a specific dosage regimen as a therapy complementing surgical excision. The dosage regimen in combination with surgery enables effective therapeutical treatment of carcinomas, in particularly the treatment of early-stage breast cancers, including locally recurrent breast cancer.

37.20230148369NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS

US - 11.05.2023

Clasificación Internacional C07K 14/47 Nº de solicitud 17820821 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

38.WO/2023/079528COMPOSITIONS SUITABLE FOR USE IN A METHOD FOR ELICITING CROSS-PROTECTIVE IMMUNITY AGAINST CORONAVIRUSES

WO - 11.05.2023

Clasificación Internacional A61K 39/215 Nº de solicitud PCT/IB2022/060699 Solicitante KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor/a CHAHAL, Jasdave

Immunogenic compositions and methods of use thereof, for eliciting an immune response against multiple coronaviruses, using a single vaccine composition are described. The compositions include an antigen from more than one pathogen, for example, more than one member of the β-coronavirus family, for example, SARS-CoV and MERS-CoV. Exemplary antigens include the receptor binding domain (RBD) of the coronavirus spike protein or a fragment thereof. The disclosed compositions are administered to a subject in need therefore, to generate an immune response against more than one pathogen, represented by the source of the antigens in the construct.

39.20230142780USE OF VIRAL VECTORS FOR CORONAVIRUS VACCINE PRODUCTION

US - 11.05.2023

Clasificación Internacional A61K 39/215 Nº de solicitud 17918000 Solicitante 4MVac LLC Inventor/a Hansell Hall Stedman

Provided herein are compositions that includes AAVs and AAV vectors that include a sequence encoding a SARS-CoV-2 polypeptide or a fragment thereof. Also provided herein are methods and materials for making and using AAVs and AAV vectors to generate immunity to a coronavirus in a subject.
40.20230145121NEOANTIGEN VACCINES FOR TRIPLE NEGATIVE BREAST CANCER
US - 11.05.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17823937 Solicitante Washington University Inventor/a William Gillanders
The present disclosure is directed to compositions and methods of treating Triple Negative Breast Cancer (TNBC) in a human subject. A method of treating TNBC in a human subject includes administering a therapeutically effective amount of a neoantigen vaccine composition comprising a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, or a nucleic acid molecule encoding such a protein.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES